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Abstract 
 
Stanniocalcin-1 (STC-1) is a 56kDa disulphide-linked homodimeric glycoprotein in 
vertebrates, with the capacity to regulate the extracellular ionised calcium (Ca2+) 
concentration. Specifically, in fish, Stanniocalcin (STC) is released into bloodstream 
in response to rising serum calcium levels by acting on calcium sensitive receptors on 
both gill and intestine epithelial cells to reduce the calcium uptake. Initially, STC was 
identified as a secreted hormone having an inhibitory effect on whole body Ca2+ 
influx that prevents hypercalcemia. However the function of this protein in mammals 
is still unclear.  
During angiogenesis, essential angiogenic factors such as Vascular Endothelial 
Growth Factor (VEGF) and Platelet-derived Growth Factor (PDGF), initiate cellular 
responses, intracellular signaling events that drive proliferation, migration and 
survival of vascular endothelial and smooth muscle cells (SMCs), respectively. Thus, 
it is important to understand the physiology of the molecular mechanism through 
which VEGF and/or PDGF exerts its biological activities as well as its role in 
malignancies in order to develop anti-angiogenic strategies for therapeutic 
intervention.  
In the first part of this thesis, the role of STC-1 in endothelial cell function was 
characteristed using varirous approaches. Analysis of VEGF-stimulated migration 
showed that STC-1 can modulate endothelial cell motility but has no effect on 
endothelial cell signalling. 
Here, I identified for the first time that PDGF-BB but not PDGF-AA, strongly 
upregulates expression of STC-1 in vascular smooth muscle cells. PDGF-BB-induced 
STC-1 expression is at least partially mediated via PDGFR and possibly PDGFR/ 
heterodimers, but there appears to be compensation between the two receptors. 
However, the partial inhibition of STC-1 expression by siRNA-mediated knockdown 
of both PDGFRs raises the possibility that an unconventional pathway is also 
involved not mediated by known PDGFRs, or by a non-Receptor Tyrosine Kinase 
(RTK) pathway. 
Furthermore, a novel synergistic effect of STC-1 and PDGF-BB in SMCs on 
phosphorylation of Akt/PBK protein that leads to GSK3 inhibition was observed. As 
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a PDGF-induced protein, STC-1 is implicated in modulating PDGF-mediated cell 
motility, and is a potential modulator of PI3K-Akt pathway activation.  Akt enhanced 
phosphorylation might indicate a role for STC-1 in regulating SMC survival.  
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Chapter 1  
 
 
1 Introduction  
 
 
 
Stanniocalcin (STC) is a glycosylated homodimeric protein so called because it is 
produced by the Corpuscles of Stannius (CS) in teleostean and holostean fish (bony 
fish). The CS are fish-specific endocrine glands associated with the kidney, which were 
first described by Professor H. Stannius (assuming that they were fish adrenals 
(Stannius, 1839; Wagner, Hampong, Park, & Copp, 1986). Originally, STC was 
described as a regulatory hormone involved in calcium and phosphate regulation and 
homeostasis, positively regulated by extracellular ionised calcium (Ca2+) from the 
aquatic environment (Hanssen, Aarden, van der Venne, Pang, & Wendelaar Bonga, 
1991). In response to a rise in serum calcium levels, CS cells undergo a stepwise 
increase in STC secretion with each successive rise in calcium concentration. Upon 
release, STC acts on calcium sensitive receptors on both gill and gut epithelial cells to 
reduce calcium uptake. Subsequently, STC has an inhibitory effect on whole body 
calcium influx that prevents hypercalcemia and also stimulates phosphate (Pi) 
reabsorption by the kidneys (Chang, Jellinek, & Reddel, 2003). Inhibition of the uptake 
of calcium through the gills and intestines by STC, together with stimulation of 
inorganic phosphate reabsorption has been widely confirmed (Filvaroff et al., 2002; 
Sterba, Wagner, Schroedter, & Friesen, 1993; Wagner, Fargher, Milliken, McKeown, & 
Copp, 1993; Wagner, Jaworski, & Haddad, 1998) and its function in bony fish has been 
established as a calcium and phosphate regulatory hormone.  
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1.1  Stanniocalcin  
 
As mentioned previously, Stanniocalcin or as initially called teleocalcin, was first 
identified as a secreted homodimeric protein from CS. It took more than a century, 
however for the functional importance of these specialised glands for gill calcium 
transport to be established by the demonstration that surgical removal of CS glands 
caused hypercalcemia (Fontaine, 1964). Removal of the CS also reduces plasma Na+ 
and Cl- concentrations and decreases aortic blood pressure (Butler & Alia Cadinouche, 
1995; B. H. Yeung, Law, & Wong, 2012). Further studies showed that CS extracts 
inhibited gill calcium transport (Fenwick & So, 1974).  Subsequently, it was found that 
CS glands produced a 56 kDa glycoprotein that inhibited Ca2+ influx from the water 
without affecting Ca2+ efflux, thus promoting hypocalcemia (Flik et al., 1990; Lafeber, 
Flik, Wendelaar Bonga, & Perry, 1988; Wagner, De Niu, Jaworski, Radman, & Chiarot, 
1997; Wagner et al., 1993; Wagner et al., 1986). It was suggested that the inhibition of 
Ca2+ influx could be the result of a specific modulation of the Ca2+ uptake mechanism in 
the gill by reducing whole body Ca2+ uptake (Lafeber et al., 1988). Furthermore, 
consistent with a role of STC in fish calcium homeostasis in response to hypercalcemic 
stimuli, increased serum Ca2+ stimulates STC release by the CS, an effect mediated via 
calcium-sensing receptors (CaSR) identified on the surface of cultured CS cells. STC 
mRNA stability is also effected from elevated plasma Ca2+ concentration, indicating 
that Ca2+ levels as the primary stimulus, control storage and synthesis rate of STC in CS 
cells (Ellis & Wagner, 1995; Greenwood, Flik, Wagner, & Balment, 2009; Radman, 
McCudden, James, Nemeth, & Wagner, 2002). It is now well established that STC 
functions in fish to regulate Ca2+ levels primarily by inhibiting Ca2+ movement through 
the gills (Fig. 1.1).  
It seems likely that evolutionary conservation of a role for the CS and STC in regulating 
Ca2+ homeostasis is closely linked to the aquatic environment of fish and the oviparous 
nature of fish development in which embryos are surrounded by water with widely 
differing calcium concentrations. It is generally accepted that STC plays a major role in 
mineral homeostasis in both marine and freshwater fish, with, for example, little 
difference between freshwater and marine salmon in the blood level and sensitivity of 
STC to calcium levels. Indeed, in seawater, where the Ca2+ concentrations are 10 times 
higher than that of extracellular fluid, in the absence of STC, Ca2+ ions will penetrate by 
 21 
diffusion across the gills, skin and intestines as calcium moves along an electrochemical 
gradient, causing hypercalcemia in these organs.  
 
 
 
Figure 1.1: Physiological action of STC in fish 
This diagram represents the possible mechanism by which CS gland-derived STC acts on 
epithelial Ca2+ channels to inhibit calcium movement by preventing hypercalcemia in the fish. 
STC is thought to bind to CaSCs and potentially promotes complex formation that leads to 
inhibition of CaSCs resulting in Ca2+ influx homeostasis.  
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However the precise mechanism by which STC prevents hypercalcemia in fish remains 
unclear, and one of the main obstacles to defining the mechanism has been the inability 
to identify the STC receptor on its target cells. The effect of STC may partly be 
mediated via reduced mRNA expression of epithelial Ca2+ channels, as has been shown 
in Zebrafish (Tseng et al., 2009). STC-mediated Ca2+ channel inhibition in gill epithelial 
cells may also involve the activation of the cyclicAMP- Protein kinase A (PKC) 
pathway (Lu, Wagner, & Renfro, 1994). Salmon-derived STC has a concentration-
dependent stimulatory effect on renal inorganic phosphate (Pi) reabsorption by flounder 
renal proximal tubule cells (PTCs) whereas Ca2+ transport is unaffected (Lu et al., 
1994). Furthermore, STC increased cAMP levels, and transeptithelial STC-induced 
luminal-to-peritubular Pi flux was prevented by pre-incubation with H-89, a protein 
kinase A inhibitor. Thus, the authors concluded that the effect of STC on Pi transport by 
flounder PTCs is mediated through the cAMP-PKA pathway. The increased renal Pi 
retention might also elevate plasma Pi, thereby promoting Ca2+ and Pi deposition into 
bone and scales. Previous work also supported these findings by suggesting that STC 
not only reduces Ca2+ entry but actively promotes the efflux of intracellular Ca2+ load, 
an action that is consistent with the antihypercalcemic role of STC (Fenwick & 
Brasseur, 1991).  
STC production in fish is not confined to the CS glands and, in fact, the stc gene is 
variably expressed at lower levels in most organs. For example, in the rainbow trout, the 
highest levels of expression outside the CS glands are in the male and female gonads 
and the anterior region of the kidney (Richards, Fenton, Syed, & Wagner, 2012), 
whereas in flounder, Platichthys flesus, STC is highly expressed in the caudal 
neurosecretory system.  (Greenwood et al., 2009; Tseng et al., 2009).  
Apparently, the gene product in these other tissues does not necessarily perform the 
same biological functions as that in CS gland-derived STC. For instance a more heavily 
glycosylated variant is produced by the ovaries in female rainbow trout that may have a 
role in reproduction (McCudden, Kogon, DiMattia, & Wagner, 2001). It has further 
been proposed that stc expression in different tissues may have variable physiological 
effects on development and/or homeostasis as either autocrine or paracrine factors 
(Richards et al., 2012). 
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1.1.1 Stanniocalcin in mammals 
 
Normal physiological processes such as muscle contraction, nerve signal transmission 
and cellular metabolism constantly require regulatory homeostatic mechanisms that 
ensure an effective control of extracellular calcium levels. Aquatic vertebrates are 
surrounded by water, which acts as a continuous and abundant source of calcium; 
whereas terrestrial vertebrates are dependent on a dietary supply of calcium. Therefore, 
these two different environments, land and water, might be expected to have profound 
functional and evolutionary implications for calcium-regulating homeostatic 
mechanisms. 
In terrestrial vertebrates there are two main hormones important for calcium 
homeostasis: the hypercalcemic factor, parathyroid hormone (PTH), produced by the 
parathyroid glands and the hypocalcemic factor, calcitonin (CT). Both hormones act via 
specific receptors localized in the gut, bone and kidney. A third important factor is 
vitamin D, in particular its metabolite 1, 25-dihydroxyvitamin D3 which acts as a total 
body calcium-regulating hormone. Therefore, the presence in terrestrial vertebrates of 
STC homologs as antihypercalcemic hormones was originally doubted, as they were 
considered functionally redundant, particularly since terrestrial animals do not face the 
threat of hypercalcemia that fish are exposed to. Moreover, no homologous organs for 
CS have been identified in higher vertebrates. However, several studies showed that fish 
STC had PTH-like biological activity in mammalian cells (Lafeber, Herrmann-Erlee, 
Flik, & Wendelaar Bonga, 1989; Yoshiko, Kosugi, & Koide, 1996), and subsequently 
two independent laboratories discovered a mammalian ortholog of fish STC, renamed 
STC-1. STC-1 was identified by mRNA differential display of genes involved in the 
control of cellular proliferation and by a random sequencing screen of a human fetal 
lung cDNA library (Chang et al., 1995; Olsen, Cepeda, Zhang, Rosen, & Vozzolo, 
1996). Further immunological and biological assays revealed that a similar protein 
product to fish STC was expressed in human and rat kidney.  
A second human and mouse STC gene and protein, STC-2 was subsequently identified 
during a search in expressed sequence tag (EST) databases (Chang & Reddel, 1998), 
and more recently, a second fish STC has also been identified (Luo, Pisarska, & Hsueh, 
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2005).  
The STC-1 protein sequence has approximately 80% amino acid similarity with fish 
STC. This similarity between the two proteins indicates that the role of STC-1 as an 
anti-hypercalcemic factor may be conserved from fish to mammals (Chang, Dunham, 
Jeffrey, & Reddel, 1996). STC-2 protein seems quite different from STC-1 sharing only 
34% identity. Indeed, mammalian STC-1 is more closely related to fish STC-1 than to 
mammalian STC-2. Like fish STC, mammalian STC-1 and STC-2 are secreted as 
disulfide-linked homodimeric proteins with a conserved N-linked glycosylation site 
[Asn-X-Thr (Ser)] and conserved cysteine residues (see Figure 1.2). There are 11 
cysteine residues present in STC-1 monomers, forming five intramonomeric disulphide 
bonds and one intermonomeric disulphide bond. In contrast, STC-2 has 15 cysteine 
residues, albeit with the same spacing as fish STC and STC-1. In addition, mammalian 
STC-2 has 15 histidine residues clustered towards the C-terminus that are not present in 
either STC-1 or the fish STC-2 sequence (Luo et al., 2005). This might indicate a 
possible role of mammalian STC-2 in interaction with transition metals (DiMattia, 
Varghese, & Wagner, 1998; Moore et al., 1999).  
1.1.2 Structure of STC-1 gene 
1.1.2.1 Fish STC 
The fish stc gene from F. rubripes contains five exons spanning about 3 kb. Based on 
the comparison of stc1 gene structures, exons 3 and 4 of F. rubripes stc1 could be 
derived from a single exon with an intron insertion during evolution. Overall, the 
conservation of exon-intron boundaries among all stc1 and stc2 genes suggests that they 
originated from a common ancestral gene before the divergence of fish and mammals 
(Luo et al., 2005; McCudden, Kogon, et al., 2001).  
Four stanniocalcin genes have been identified and their products were isolated and 
characterized in T. nigroviridis and other teleost fishes. The isolated Tetraodon stc 
transcripts contain the pro-peptide and the entire mature peptide-coding region and they 
share high sequence similarity and conserved sequence motifs such as the N-terminal 
glycosylation domain and cysteine residues with the teleost and tetrapod homologues. A 
duplication of the stc1 and stc2 genes in the teleost lineage presumably gave rise to the 
 25 
four Tetraodon stcs and their presence in a variety of fish tissues is in agreement with 
their proposed paracrine, autocrine and intracrine roles in fish species (Schein et al., 
2012).  
In teleosts, the physiological role of STC-1-A is well established and a rise in 
extracellular Ca2+ levels above the physiological level activates its expression and 
promotes STC secretion by CS. Unlike stc1-a, the other stc genes exhibited low 
expression levels and no significant changes in response to increased environmental 
calcium in any of the tissues (CS, gills, and kidney) analysed (Schein et al., 2012). 
1.1.2.2  Mammalian STC-1 gene 
 
The gene encoding human stc-1 is located on the short arm of chromosome 8 (8p11.2-
p21). The Stc1 gene contains four exons spanning about 13kb with 91% nucleotide 
sequence identity with mouse stc-1 gene in coding regions (GenBank accession number 
AF512563) with a highly conserved long 3'- untranslated region (UTR) sequence 
(Chang et al., 1995; Varghese, Wong, Deol, Wagner, & DiMattia, 1998; Yoshiko & 
Aubin, 2004). The 5'- UTR of Stc1 gene but not of Stc2, is rich in the noncontiguous 
trinucleotide repeat, CAG, with 19 such repeats clustered within 102 nucleotides of the 
proximal transcription start site. In stc-1, four blocks of trinucleotide repeats consist of 
three to six CAG repeats, which are separated by 6-15 nucleotides (Chang et al., 1998). 
These repeats are found in the promoters of many genes and constitute regions that can 
affect DNA structure and modulate gene expression. Interestingly, length 
polymorphisms such as CAG repeats or other trinucleotide repeats (CGG and GAA) are 
sometimes associated with the pathogenesis of diseases, as documented in Huntington's 
disease. However, the significance of CAG repeats in the stc-1 gene is presently still 
unknown (Ishibashi & Imai, 2002). 
1.2 Mammalian STC-1  
 
The mammalian stc-1 gene is expressed as a predominant 4 kb transcript and an 
additional 2 kb transcript with significant expression of STC-1 seen in the heart, kidney, 
prostate, brain, bone, and thyroid gland, and the highest expression of STC-1 mRNA 
and protein in the ovary (McCudden, Tam, & Wagner, 2001; Paciga, Watson, DiMattia, 
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& Wagner, 2002). Indeed, STC-1 appears to circulate in the bloodstream during 
pregnancy and lactation, implying a possible role in reproductive biology (Chakraborty 
et al., 2007; Deol, Varghese, Wagner, & Dimattia, 2000; Li, Luo, & Wang, 2003; 
Tremblay et al., 2009).  
 
1.2.1 Human STC-1 protein 
 
With the exception of pregnancy and lactation, measurements of mammalian STC-1 in 
serum have shown low, even undetectable hormone levels. This is in contrast to fish in 
which STC circulates continuously for the maintenance of serum Ca2+ levels. The wide 
tissue distribution of endogenous STC-1 in mammals suggests that STC-1 might 
function as an autocrine/paracrine factor, intended for local-cellular signalling and 
regulation of cell function rather than acting as a classic endocrine hormone (Chang et 
al., 2003; Madsen et al., 1998; Wagner, Guiraudon, Milliken, & Copp, 1995). 
This notion is now, however, in dispute, since (James, Seitelbach, McCudden, & 
Wagner, 2005) have shown that mammalian red blood cells have significant carrying 
capacity for the hormone STC-1. They also described an additional STC-1 binding 
activity in glomerular filtrate suggestive of the existence of a soluble STC-binding 
protein. Together, these findings suggest that red blood cells and/or STC-1 binding 
protein may have specific roles in the transport of STC-1 to tissues that would otherwise 
have no access to the hormone, or a possible role in sequestering the hormone from the 
circulation (James et al., 2005).  
The mammalian STC-1 cDNA sequence predicts a protein of 247 amino acid residues 
with a single N-linked glycosylation consensus site. Immunoblotting analysis of human 
tissue-derived and recombinant STC-1 has revealed that STC-1 is a disulphide-linked 
homodimer of 25-kDa monomeric subunits and has a molecular mass of approximately 
50 kDa under nonreducing conditions (J. Zhang et al., 1998). However, western blot 
analysis under non-reducing conditions demonstrates that STC-1 secreted from bovine 
thecal/interstial cells consisted of three higher molecular weight proteins of 84, 112, and 
135 kDa. These STC-1 variant forms appear to not be warranted to different 
glycosylated forms, could be due to the combination of oligomerisation (Chang et al., 
2003; Paciga et al., 2002).  
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Figure 1.2: A comparison of fish STCs with human STC-1 and STC-2 
The sequence alignment of amino acid sequences of STC-1s from zebrafish (Danio 
rerio(Brachydanio rerio); GenBank accession #Q6PHV3), and Australian eel (Anguilla 
australis; accession #P18301) with human STC-1(accession #P52823) and STC-2 (accession 
#O76061) was performed by the clustalw program. The shaded amino acids indicate 100% 
identity. The putative N-linked glycosylation site is highlighted in red and the ten conserved 
cysteine residues are highlighted in green.  
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 All three proteins were preferentially associated with cholesterol lipid droplets, 
suggesting a regulatory effect on the steroidogenic pathway (Paciga et al., 2002). There 
is very little knowledge on the structure of STC-1 variants so far.  
An analysis of the human STC-1 amino acid sequence using online Prosite software 
revealed the presence of a consensus protein kinase ATP-binding domain near the N-
terminus of the protein (see Figure 1.2), a domain found in kinases, heat shock proteins 
and ATP-binding transporters. The possibility that STC-1 might have a kinase activity 
seems unlikely as it lacks a catalytic domain. It has been demonstrated however, that  
ATP is able to bind to STC-1 thereby antagonising STC-1 binding to its mitochondrial 
receptors (see section 1.2.2) (Ellard et al., 2007). Jellinek et al., (2000) showed that the 
human fibrosarcoma cell line, HT1080, secretes both STC-1 and STC-2 as 
phosphorylated proteins and indicated that STC-1 is phosphorylated exclusively on 
serine residue(s). However, the mechanism of STC-1 phosphorylation in HT1080 cells 
was not clearly demonstrated (Jellinek et al., 2000). 
 
Based on structural similarities between fish STC and STC-1, it is possible that STC-1 
is conserved through evolution from fish to mammals. Some important insights into the 
evolutionary conservation between these proteins have been yielded by analysis of the 
essential role of human STC-1 in calcium regulation in mammals. Olsen et al (1996) 
demonstrated the ability of human recombinant STC-1 (hrSTC-1) to inhibit the 
transport of calcium through fish gills (Olsen et al., 1996) and injection of hrSTC-1 into 
rats reduced renal phosphate excretion (Wagner et al., 1997). Furthermore, hrSTC-1 
decreases intestinal calcium uptake and simultaneously increases phosphate 
reabsorption in in vitro studies with pig and rat cells (Madsen et al., 1998). Published 
data also suggest a role for STC-1 in the control of intracellular Ca2+ in rat 
cardiomyocytes (Sheikh-Hamad et al., 2003) and neurons (Serlachius, Zhang, & 
Andersson, 2004). These findings suggest that mammalian STC-1 might contribute as a 
regulator of mineral homeostasis, with an effect on Ca2+ metabolism (reviewed in 
(Yoshiko & Aubin, 2004).  
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1.2.2 STC-1 receptors 
 
As mentioned above, elucidation of the mechanisms of action of STC in fish has been 
hampered by the inability so far to identify STC receptors on its target cells. Similarly, 
no receptors for mammalian STC have been molecularly cloned, identified or 
characterized. However, a number of studies have suggested the existence of various 
putative STC-1 receptors or high affinity binding sites. Using an STC-alkaline 
phosphatase (AP) fusion protein, receptor-binding assays on mammalian liver and 
kidney revealed the presence of STC-1 receptors on mitochondria and plasma 
membranes (McCudden, James, Hasilo, & Wagner, 2002). These receptors had 
saturable, high-affinity (0.25–0.8 nM), and displaceable binding sites for STC-1 in cells 
of the kidney, liver, breast, and ovaries (McCudden et al., 2002; McCudden, Majewski, 
Chakrabarti, & Wagner, 2004; Sheikh-Hamad, 2010). Analysis of membrane and 
mitochondrial receptors revealed that they have similar binding affinities, indicating that 
they are similar but regulated at different cell-proportions, with 90% at mitochondrial 
binding site, while 10% are located at the plasma membrane. The identity of the 
mitochondrial STC receptor(s) is yet to be established. 
Secreted STC-1 is thought to be an autocrine/paracrine hormone, that targets 
neighbouring cells, where it binds to cell surface receptors, and is subsequently 
sequestered into mitochondria. Sazonova et al (2008) proposed two different models, 
which involve the trafficking of STC-1 from the cell surface to the mitochondria 
(Sazonova et al., 2008). 
The first model proposes that the membrane receptor acts as a facilitator of STC-1 entry 
only, as opposed to a chaperone that accompanies STC-1 to the mitochondria, and 
consistent with model it was shown that no apparent receptor downregulation occurred 
after either short or long term exposure of Madin-Darby Canine Kidney Epithelial 
(MDCK) cells to high ligand concentrations. The second model implies that the 
membrane receptors do in fact serve as a chaperone to facilitate translocation of STC-1 
to the mitochondria and consistent with this model, Wang, et al. (2009) also reported a 
rapid internalization of recombinant STC-1 by freshly isolated murine peritoneal 
macrophages and localization to the mitochondria within 10 min (Y. Wang et al., 2009). 
Although STC-1 receptor levels do not seem to be reduced by excessive STC-1 
concentrations, when calcium-rich medium is used to inhibit STC-1 secretion, a 
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significant upregulation of STC-1 binding sites is observed, indicating a calcium-
dependent STC-1 effect on receptor recycling and/or expression (Sazonova et al., 2008; 
Sheikh-Hamad, 2010). 
 
As in mammals, (Richards et al., 2012) reported the localization of fish STC-1 
receptors, using freshwater rainbow trout as a model system. The fish receptor was 
found to be present on both microsomal membranes and mitochondria. The receptors 
had high affinity binding sites (3.2–3.7  nM),  similar  to  those  reported  in  mammals,  and  
in line with the concentrations of circulating STC-1 (0.1–5.0  nM)   in   fish   serum.  
However, in fish as well as in mammals, ligand sequestration occurs in a mitochondrial 
compartment.  In situ ligand binding studies revealed the presence of specific, STC-1 
binding sites in most fish tissues and/or organs, including brain, cartilage, adipocytes, 
skeletal, cardiac and visceral smooth muscle, liver, kidney, gastrointestinal tract, the 
eye, and the teeth (Richards et al., 2012). Red blood cells exhibited the strongest 
binding activity, followed by cardiac myocytes, and to a lesser extent in liver 
hepatocytes (Richards et al., 2012). Nephron epithelial cells were generally receptor-
positive in both the anterior and posterior portions of the kidney, whereas newly 
developing nephron segments were receptor-negative. Thus it appears that STC-1 
receptor expression might be developmentally regulated. Unexpectedly, there was low 
binding activity in STC-1 producing cells from the CS of both salmon and trout, 
whereas a sub-set of CS cells displayed a higher level of binding, indicating that 
secreted STC-1 may feed back on its cells of origin. 
 
Despite the accumulating evidence of STC-1 binding sites, the STC-1 receptor has not 
yet been purified or cloned or molecularly characterised. Furthermore, its downstream 
signalling pathways are essentially unknown. One study, in flounder proximal tubules, 
has suggested that the receptor may be G-protein coupled (Lu et al 1994), the evidence 
for this being that the effects of STC-1 on apical phosphate transport are PKA-
dependent (blocked by H-89 and mimicked by forskolin) and accompanied by increased 
cAMP production (Lu et al., 1994; Richards et al., 2012). Nevertheless, the definitive 
characterization of STC receptors in fish and mammals remains an important but 
elusive goal essential for determining STC function. 
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1.3 Role of STC-1 in development 
 
Transgenic mice over-expressing hSTC-1 have been generated by two independent 
laboratories using different promoters (Filvaroff et al., 2002; Varghese et al., 2002). 
Filvaroff et al (2002) inserted the gene for human STC-1 (hSTC-1) downstream of the 
rat muscle specific myosin light chain 2 promoter sequence to achieve efficient 
expression of hSTC-1 in muscle (mainly skeletal) but no other tissues. Overexpression 
of STC-1 in these mice resulted in growth retardation with distinct changes in the 
musculoskeletal system and osteoclast activity (see Table 1). Additionally, transgenic 
lines revealed significantly higher levels of serum ionized calcium but normal serum 
phosphate levels compared with wild-type mice. Furthermore, measurements of baseline 
vascular density strongly suggested that STC-1 transgenic mice had significantly higher 
capillary density in organs like heart and kidney and tissues like muscle and bone, 
compared with age-matched littermates. These changes could be due to direct effects of 
STC-1 on endothelial cells and their environment, consistent with previous studies 
showing up-regulation of STC-1 upon endothelial cell differentiation (Kahn et al., 
2000). STC-1 could also affect muscle mass, function, bone size, and structure 
(Filvaroff et al., 2002). Varghese et al analysed transgenic mice overexpressing STC-1 
using the metallothionein I minimal promoter. These mice had a growth retardation and 
reproduction phenotype. The highest levels of expression of STC-1 protein were 
detected in liver, heart, mammary glands and brain. Interestingly transgenic mRNA 
levels in heart and liver were consistently 2- and 5-fold higher in females, respectively, 
than those in males (Filvaroff et al., 2002; Varghese et al., 2002). In both studies, 
transgenic expression of hSTC-1 affected growth and reproduction, as manifested by 
dwarfism and reduced litter size, with elevated calcium levels in at least some lines of 
transgenic mice, in spite of their different hSTC-1 tissue expression profiles. In addition 
to dwarfism, muscle-specific transgenic mice had an energy wasting phenotype indicated 
by higher food and oxygen consumption rates and mitochondrial hypertrophy at the sites of 
transgene expression, suggesting the involvement of STC-1 in cellular metabolism and 
possibly a developmental phenotype (Ellard et al., 2007; Filvaroff et al., 2002). 
In contrast, Stc1−/− knockout mice did not exhibit gross morphological or behavioural 
abnormalities compared to wild-type mice (Chang, Cha, Koentgen, & Reddel, 2005). 
Histological  
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examination of the lung, heart, liver, kidney, brain, spleen, stomach, small intestine, 
colon, ovary, uterus, and testis did not reveal any overt differences (Chang et al., 2005). 
Parallel findings from a double knock out study suggested that the absence of mouse 
Stc1 and/or Stc2 genes has no effect on serum calcium and phosphate levels (Chang et 
al., 2008). It is therefore unlikely that mammalian STC-1 or STC-2 play a critical role in 
the prevention of systemic hypercalcaemia under normal physiological conditions. This 
conclusion is also largely consistent with results obtained with overexpression of STC-1 
in transgenic mice. Therefore, it seems reasonable to assume that the role of mammalian 
STC-1 is not restricted to the anti-hypercalcemic effects attributed to fish STC-1; its role in 
mineral homeostasis under normal conditions requires more investigation. 
 
1.4 Physiological roles of STC-1 
 
The physiological role of mammalian STC-1 is only beginning to be elucidated. 
Although the study of the biological activity of STC-1 has increased in the past decade, 
many questions regarding its role in the systems where it is expressed and various signals 
that trigger STC-1 secretion remained unanswered. In contrast to fish STC-1 which is 
largely regulated by elevated Ca2+ levels, mammalian STC-1 appears to be regulated in 
numerous physiological and pathophysiological processes such as angiogenesis (Bell et 
al., 2001; Holmes & Zachary, 2008; D. Liu, Jia, Holmes, Stannard, & Zachary, 2003; S. 
Yang et al., 2002) bone and muscle development (Filvaroff et al., 2002; Yoshiko, Aubin, 
& Maeda, 2002), inflammation (Huang et al., 2009; Y. Wang et al., 2009), hypoxia (H. 
Y. Yeung et al., 2005; Zhang et al., 2000), differentiation (K. Z. Zhang et al., 1998), 
neuroprotection, cellular stress response (Nguyen, Chang, & Reddel, 2009) and 
carcinogenesis (Chang et al., 2003; Neri & Bicknell, 2005). 
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Table 1.1 Murine phenotypes of STC-1 and STC-2  
 Protein +/+++   -/- Phenotype References 
Transgenic 
overexpression STC-1 
Viable   
Dwarfism and skeletal abnormalities 
High capillary density 
 
(Filvaroff et al., 2002; Varghese et al., 
2002) 
Transgenic 
overexpression STC-2 
Viable   
Substantial postnatal growth 
retardation. Intrauterine growth-
restrictive phenotype.  
 
(Gagliardi, Kuo, Raulic, Wagner, & 
DiMattia, 2005) 
STC-1   Viable 
No observed phenotype 
 
(Chang et al., 2005) 
STC-1/STC-2  Viable 
Increased body weight 
 
(Chang et al., 2008) 
STC-2   Viable Increased body weight (Chang et al., 2008) 
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Several studies have suggested that based on expression profiles, STC-1 may have a 
potential role in angiogenesis (Kahn et al., 2000), wound healing (Iyer et al., 1999) and 
capillary morphogenesis (Bell et al 2001), because it is highly induced by factors that 
may directly or indirectly be linked to angiogenic pathways (Zlot et al., 2003). For example, 
the observation that STC-1 is highly upregulated in endothelial cells treated with VEGF 
suggested a distinctive role for STC-1 in angiogenesis or the tumour vasculature in vivo 
(Fujiwara et al., 2000; Gerritsen et al., 2002; Holmes & Zachary, 2008; Neri & Bicknell, 
2005). Additionally, it has been reported that HGF alone, and synergistically in 
combination with VEGF, induced vascular morphogenesis in vitro and angiogenesis in 
vivo. The analysis of the gene expression profile of endothelial cells undergoing HGF- 
and VEGF-stimulated morphogenesis identified STC-1, as one of the most highly 
upregulated genes in the in vitro model (Zlot et al., 2003). Hypoxia can also increase 
STC-1 gene expression in several cancerous tissues and cell-lines (H. Y. Yeung et al., 
2005). In addition, there is evidence that hSTC-1 is a Hypoxia Inducible Factor-1 (HIF-
1) target gene, and strongly supports the involvement of STC-1 in hypoxic tumor 
angiogenesis (Law, Ching, Lai, & Wong, 2010).  
In situ hybridization has shown a clear upregulation of STC-1 expression in tumour 
blood vessels, which suggests that STC-1 could be a tumour vascular marker (Gerritsen 
et al., 2002).  
1.4.1 Protection from oxidative stress 
STC-1 has been implicated in the regulation of a key pathway involved in the response 
to oxidative stress, energy metabolism, governing cellular survival and proliferation. 
The involvement of STC-1 in cellular energy metabolism was initially investigated by 
McCudden et al. (2002). Analysis of MDCK cells transfected with a mouse soluble 
STC-AP fusion protein indicated that STC-1 localizes to the inner mitochondrial 
membrane and enhances NADH disappearance. The receptor binding assays also 
revealed the presence of a class of high affinity STC receptors in nephron epithelial 
cells and liver hepatocytes which were present on both the plasma membrane and 
mitochondria. More significantly perhaps, this study identified STC as a putative 
regulator of mitochondrial metabolism, as STC-1 had dose-dependent stimulatory 
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effects on electron transport in bovine sub-mitochondrial particles within the nanomolar 
range (Ellard et al., 2007; McCudden et al., 2002). 
Muscle-specific transgenic mice studies (Filvaroff et al., 2002; Varghese et al., 2002) as 
previously mentioned, showed an association between mitochondrial hypertrophy and 
energy wasting phenotypes with excessive STC-1 mitochondrial expression. These 
findings pointed to energy-related functions of STC-1 and also suggested that STC-1 
might be a stimulator of electron transport chain activity (ETC). Using intact functional 
mitochondria as well as whole cells, STC-1 was found to substantially increase state III 
oxygen consumption rate and uncouple oxidative phosphorylation as indicated by 
reduced ADP to oxygen ratios (Ellard et al., 2007). 
 
In addition, Wang et al (2009) further examined the respiratory effects of STC-1 on 
macrophage function and survival.  In freshly isolated peritoneal macrophages and 
cultured murine macrophages, addition of rhSTC1 to the medium had a dose and time–
dependent effect on ATP reduction. In contrast, using total cell lysates, no differences 
were observed in the activities of complex I, complex II, complex I + III, complex II + 
III, and complex IV in rhSTC1-treated cells compared with vehicle-treated controls. It 
is unlikely therefore that STC-1 directly inhibiting mitochondrial respiratory chain 
complexes is the cause for the decline in intracellular ATP levels (Y. Wang et al., 
2009). 
As a result of the uncoupling of mitochondrial oxidative phosphorylation, STC-1 was 
also expected to decrease the generation of reactive oxygen species (ROS). The first 
direct evidence of a protective role of STC-1 against ROS was demonstrated using 
dihydroethidium (DHE) staining as an indicator of superoxide (O2·−) generation. 
Incubation with rhSTC-1 for 24 hours led to a 40% reduction of superoxide generation 
in wild-type macrophages, whereas no effect was observed in macrophages from 
uncoupling protein 2 (UCP2)-/- mice. In addition, there was a cumulative reduction in 
mitochondrial membrane potential after a 24 hour treatment, sufficient for an 
attenuation of superoxide generation (Y. Wang et al., 2009) 
In contrast to these findings, STC-null mouse embryo fibroblasts (MEFs) appear to be 
resistant to oxidative stress induced by H2O2 treatment due to increased MEK and 
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ERK1/2 kinase activation. These data suggest that STC-1 expression could act to 
decrease survival of MEFs in response to oxidative stress by downregulating MEK and 
ERK1/2 activation (Nguyen et al., 2009). 
1.4.1.1 Induction of UCP2 
 
UCPs are important mitochondrial anion carriers that localize at the inner mitochondrial 
membrane and facilitate H+ leakage from the mitochondrial intermembrane space to the 
matrix (Huang et al., 2009; Sheikh-Hamad, 2010; Y. Wang et al., 2009). UCPs regulate 
the mitochondrial membrane potential through dissipation of the proton gradient across 
the inner mitochondrial membrane, without ATP generation. Whereas UCP1 expression 
is restricted to brown adipose tissue, UCP2 is more ubiquitously expressed, with 
expression also occurring in several phagocytic cell types (D. Park et al., 2011). 
The mechanism by which STC-1 reduces superoxide generation and enhances cell 
survival in macrophages is unknown, but appears to be mitochondrial uncoupling 
dependent, through increased UCP2 expression, and attenuation of ROS generation, 
resulting in a modest depolarisation of the mitochondrial membrane potential (MMP) 
(Huang et al., 2009; Y. Wang et al., 2009). Wang et al (2009) examined the effect of 
hrSTC-1 on UCP2 expression in cultured murine magrophages. An increase in UCP2 
was observed within the first hour of rhSTC-1 treatment. Given the suppression of 
superoxide generation by STC-1 in macrophages, the authors suggested that STC-1-
mediated superoxide reduction is not NADPH oxidase dependent (Sheikh-Hamad, 
2010; Y. Wang et al., 2009). 
 
1.4.2 Cell survival 
 
A possible role of STC-1 as an anti-apoptotic factor is supported by the finding that 
STC-1 is able to promote tolerance of mouse brains and hearts against ischemia 
(Westberg, Serlachius, Lankila, & Andersson, 2007). Their data provide an insight into 
the possible role of STC-1 in cell survival under hypoxic conditions. In agreement with 
these findings, Block et al (2008) also demonstrated that STC-1 reduced the number of 
apoptotic lung cancer epithelial cells following hypoxia. A number of recent studies 
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have implicated STC-1 in a possible role in tumor progression, showing that STC-1 
expression is regulated by p53 and NFB in apoptotic nasopharyngeal and colon cancer 
cells. In addition STC-1 expression is induced in hypoxic tumor microenvironments 
(Lai et al., 2007; Law et al., 2010).  
Similarly, serum-starved STC-1-treated macrophages exhibit lower cellular ATP levels 
in a dose and time-dependent manner, which might be followed by apoptosis. However, 
despite the decline in ATP levels, STC-1 actually appears to enhance cell viability, 
suggesting a role for STC-1 in cellular protection. This may be due to cell cycle arrest in 
the G1 phase (Y. Wang et al., 2009). Ohkouchi et al. (2012) reported that H2O2-treated 
A549 lung carcinoma cells exhibited improved cell survival when co-cultured with 
mesenchymal stromal cells (MSCs) than when grown alone. This increased cell survival 
was attributed to STC-1 since STC-1 blocking antibodies prevented this effect. 
Furthermore, it was found that the STC-1 secreted by MSCs upregulated UCP2 
expression in A549 cells, thus making them resistant to ROS and enhancing anaerobic 
glycolysis, the latter phenomenon being a feature of many cancer cells known as the 
Warburg effect. Similarly, Ohkouchi et al (2012) showed that rSTC1 decreased ROS 
levels and the MMP of A549 cells, as well as increasing lactate production. All of these 
effects were shown to be dependent on UCP2 upregulation. This study raises the 
possibility of using antibodies or antagonists to STC-1 as an anti-cancer therapy 
(Ohkouchi et al., 2012).  
Data regarding the regulation of STC-1 by hypoxia and its role in reduction in ROS 
generation in macrophages further suggests a possible important role of STC-1 in 
promoting cell survival, although there is controversy as to whether STC-1 is pro-survival 
or pro-apoptotic. For example, in contrast to the previous studies, Law et al (2008) 
demonstrated that trichostatin A (TSA) induced apoptotic cell death in human colon 
adenoma cells (HT29), accompanied by a time and dose-dependent induction of STC-1 
levels. TSA is a histone deacetylase (HDAC) inhibitor that is known to promote histone 
and non-histone protein acetylation, an essential post-translational process in regulating 
chromatin topology, gene transcription and intracellular signalling. Treatment of tumor 
cells with HDAC inhibitors has been shown to induce transcriptional activation of genes 
that are essential for the inhibition of cell growth, metastasis, and angiogenesis but also 
induce apoptosis. The treatment of HT29 cells with 500 nM of TSA significantly 
stimulated STC-1 gene expression at 4 h of treatment, and this was shown to be 
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mediated by NFB acetylation. The induction of STC-1 expression by TSA suggests a 
role for STC-1 in the cellular apoptotic process in human carcinogenesis (Law et al., 
2010; Law, Lai, Lui, Wan, & Wong, 2008). 
1.5 STC-1, cancer and angiogenesis 
1.5.1 STC in cancer  
STC-1 was originally cloned as part of a search for cancer-related genes (Chang et al., 
1995) and since then STC-1 has been shown to be highly expressed in many different 
human tumours suggesting that the elevation of this protein might be involved in 
remodulation of tumorigenic microenvironment (Chang et al 2003;Yeung et al 2012). 
Increased STC-1 expression has been reported in the following human neoplasms: non-
small cell lung cancer (Du, Gu, Li, & Gao, 2011), colorectal cancers and hepatocelluar 
carcinomas (Fujiwara et al., 2000; Tamura et al., 2011), breast carcinoma (McCudden et 
al., 2004; Wascher et al., 2003), ovarian cancer (G. Liu et al., 2010), and leukemia 
(Tohmiya et al., 2004). In breast cancer, the levels of both STC-1 and STC-2 were 
reported to correlate with the expression of estrogen receptor (ER). The importance of 
STCs for cancer progression or tumour growth is at present unclear, but some studies 
report that STC-1 may promote tumour cell growth by enhancing the expression of an 
important vascular growth factor, VEGF in gastric cancer cells. Thus, the role of STC-1 
is thought to be mediated through the alteration of microenvironment, which in turn 
induces neovascularisation of tumors without direct effect on proliferation of cancer 
cells (He et al., 2011; G. Liu et al., 2010).  
1.5.2 STC and angiogenesis 
 
One way in which STCs could affect the tumour microenvironment is through 
regulation of angiogenesis. Since mice deficient in either STC-1 or STC-2 or both 
STCs, are viable and exhibit no gross or overt defects in development (see Table 1 
above), it is unlikely that STCs play essential or important roles in vasculogenesis or 
embryonic angiogenesis or early development of the cardiovascular system. However, 
this does not preclude an important role of STCs in angiogenesis in adult organisms, 
particularly that associated with disease or disease-related processes. In this context, it 
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is relevant to note, as mentioned above, that mice transgenically over-expressing STC-1 
had significantly higher capillary density in several tissues including heart, kidney, 
muscle and bone (Table 1). It is therefore of interest that in several genome array 
profiling studies of gene regulation in models of angiogenesis (blood vessel formation; 
discussed below) and in response to the essential angiogenic factor, VEGF, upregulation 
of STC-1 has been a common observation array profiling studies of both VEGF-A165-
regulated gene expression and gene expression in in vitro models of capillary 
angiogenesis (Bell et al., 2001; Gerritsen et al., 2002; Glienke et al., 2000; Holmes & 
Zachary, 2008; Kahn et al., 2000; D. Liu et al., 2003; S. Yang et al., 2002). It is clear from 
these studies that STC-1 mRNA expression is upregulated in angiogenesis in in vitro 
models, and is upregulated in human endothelial cells in response to VEGF. At the time 
that I began work on this thesis, it was unknown how STC-1 regulated angiogenesis, or 
whether it might play a significant role in this process. Zlot et al (2003) reported that 
recombinant STC-1 inhibited Hepatocyte Growth Factor (HGF)-induced endothelial 
cell migration and morphogenesis in vitro, but had no detectable effect on responses to 
Vascular Endothelial Growth Factor (VEGF or VEGF-A) or Fibroblast Growth Factor-2 
(FGF-2). Nevertheless, given that VEGF-A strongly upregulated STC-1 expression at 
the level of mRNA and protein expression (Holmes & Zachary, 2008) it remained 
possible that STC-1 might regulate VEGF responses in endothelial cells, and one of the 
aims of this thesis was to explore that possibility. 
 
1.6 Vascular development  
 
In large multicellular organisms in all vertebrates, the vasculature is an internal 
transport system that delivers oxygen and nutrients to peripheral tissues, carries 
metabolites and macromolecules generated by one tissue to other tissues, and removes 
waste products. This network initially starts to form during embryonic development in a 
process termed vasculogenesis.  
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1.6.1 Vasculogenesis 
 
Vasculogenesis involves the differentiation of endothelial precursors or angioblasts and 
their assembly into a primitive vascular network, comprising the primary capillary 
plexuses and the major primordial vessels, principally (in mice, for example) the dorsal 
aorta and cardinal vein. The haemangioblasts are multipotent precursor cells that form 
blood islands in the yolk sac, where they differentiate into haematopoietic and 
endothelial cells. Vascular growth factor receptor-2 (VEGFR-2, also called Flk-1 and 
KDR in mice and humans, respectively) is known to be a haemangioblast cell surface 
marker, since embryos lacking VEGFR-2 show defects in both haematopoietic and 
endothelial lineages (Risau, 1997). During their differentiation, haematopoietic 
progenitor cells lose VEGFR-2 expression whereas the transcription factor Scl/tal-1 
expression is induced. Endothelial progenitors maintain VEGFR-2 expression, which 
plays a key role in delineating their fate as endothelial cells. Subsequently this newly 
formed, primitive vessel structure, termed the primary vascular plexus, successively 
expands, while other angioblasts aggregate directly to form the dorsal aorta and cardinal 
vein; further growth and remodelling of these embryonic structures, involving 
angiogenesis, vessel morphogenesis and pruning, and recruitment of mural cells or 
pericytes and vascular smooth muscle cells, results in the formation of a more organised 
complex mature vascular network (Carmeliet & Jain, 2011). 
1.6.2 Angiogenesis 
Angiogenesis is the predominant mechanism of blood vessel formation in later stages of 
embryonic development and in adulthood physiologically and in disease. During 
angiogenesis, endothelial cells undergo proliferation, differentiation, migration and 
morphogenesis in a series of events tightly coordinated by the actions of a variety of 
growth factors and cell-adhesion molecules. Under the influence of the key angiogenic 
factor, VEGF (specifically VEGF-A), trans-endothelial permeability of parental vessels 
increases plasma proteins (like fibronectin, fibrinogen etc) extravasate and provide a 
provisional structure for ECs to migrate on. VEGF-A is also essential for selection of 
the endothelial tip cells, which form at the tips of new advancing angiogenic sprouts 
(see Figure 1.3). Signalling via the Delta-like ligand 4 (Dll4)/Notch receptor pathway 
also plays a key role in regulating VEGF-mediated tip cell selection by suppressing the 
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tip cell phenotype in neighbouring cells and determining formation of stalk cells, in 
order to ensure organised rather than chaotic vessel sprouting (Phng & Gerhardt, 2009). 
Subsequent migration of endothelial tip cells from their resident site followed by 
endothelial stalk cells, is also facilitated by increased expression and secretion of matrix 
proteases such as matrix metalloproteinases (MMPs) disrupting and remodelling 
surrounding extracellular matrix (ECM) and loosening inter-endothelial contacts. 
Matrix-bound angiogenic factors such as VEGF, TGF-beta and FGF are released and 
proteolytically activated. Thus, the activities of MMPs inhibitors such as Tissue 
Inhibitors of Metalloproteinases (TIMPs) play a critical role in vessel growth and 
maintenance. TIMPs tightly control the basement membrane deposition during vessel 
maturation and the generation of anti-angiogenic fragments such as tumstatin and 
angiostatin1. Chemotactic migration of endothelial tip cells, exhibiting many extended 
filopodia, is then followed by the assembly of endothelial tip and stalk cells into solid 
cords which later leads to formation of vessels with a central lumen (Fig. 1.3).  
VEGF guides in a co-ordinated manner the tip cell migration, regulation of lumen 
formation and vessel size, by production of a VEGF gradient. Once the endothelial 
channels, protected by the surrounding pro-survival factors, are formed into lumens they 
require a more stable, durable and functional structural support. This stabilisation of 
nude nascent vessels is established with the recruitment of mural cells and leads to 
endothelium quiescence, differentiation, survival and haemostatic regulation. Mural 
cells such as vascular smooth muscle cells (VSMC) and pericytes play an important role 
in providing vessel stability and integrity through interstitial matrix deposition and 
direct interaction with the endothelium. VSMC contribute more in larger vessels like 
arteries and veins, whereas pericytes directly interact with the endothelial layer in 
smaller distal vessels such as capillaries, venules and arterioles. 
In contrast to sprouting vessel formation, non-sprouting angiogenesis, as initially 
described in lung development (Short, Bennett, & et al., 1950), involves the splitting of 
pre-existing vessels by transcapillary pillars or posts of extracellular matrix (Risau, 
1997).
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Figure 1.3: Main stages and processes in angiogenic sprouting (from Carmeliet & Jain 
2011)  
Schematic diagrams illustrating the main stages, cellular processes and angiogenic factors and 
their receptors involved in sprouting angiogenesis. See text and Carmeliet & Jain (2011) for 
further details. 
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During this process, there is no requirement for immediate endothelial cell proliferation, 
but rather the rearrangement and remodelling of the existing endothelium. Moreover, 
critical processes such as proteolytic degradation of basement membrane or invasion of 
surrounding tissues may not occur. Despite strong morphological evidence that supports 
a role for this process in various tissues, little is known about the physiological role and 
molecular regulation of non-sprouting angiogenesis (intussusception) (reviewed in 
Carmeliet & Jain 2011). Vessels, particularly in diseases such as cancer, may also form 
via other mechanisms such as vasculogenesis from tissue or bone marrow-derived 
progenitors, vessel co-option, vascular mimicry and direct tumour to endothelial cell 
differentiation (reviewed in Carmeliet & Jain 2011). 
1.6.2.1 The endothelium 
 
The endothelium was originally defined by the Swiss anatomist Wilhelm His in 1865, 
as the cell lining of blood vessels, lymphatics, and mesothelial-lined cavities. This 
definition would be restricted later on, to include only the inner cell layer of blood and 
lymphatics vessels.  
This inner cellular flat layer of endothelial cells, one cell thick, forms the tunica intima 
layer of blood vessels. In many physiological functions, endothelial cells play an 
important role as a microenvironment sensor, vasomotor toner, blood cell trafficker, 
hemostatic balancer, and regulator of permeability and survival, and control of innate 
and adaptive immunity.  
1.6.3 Vascular-derived angiogenic factors and signalling 
 
Vascular cells secrete and produce a variety of growth factors that are capable, either 
alone or in concert with other growth factors, of promoting angiogenesis. The most 
extensively studied factors that have been implicated in the regulation of angiogenesis 
include VEGF, bFGF, PDGF, angiopoietins (Ang)-1 and -2 and their receptors, the 
Ties, Ephs/ephrins, as well as Notch and its ligands (eg. Dll4). Indeed their potential 
effects on facilitation of any stage of angiogenesis are critical in determining the fate of 
the mature vasculature. 
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1.6.3.1 VEGF 
VEGF, so named due to its apparent specificity for endothelial cells, is a potent mitogen 
that was first isolated from medium conditioned by bovine pituitary follicular cells 
(Ferrara & Henzel, 1989) and subsequently purified and cloned (Keck et al., 1989; 
Leung, Cachianes, Kuang, Goeddel, & Ferrara, 1989).  
VEGF was actually initially described as vascular permeability factor (VPF) due to its 
ability to induce vascular fluid leakage in the guinea-pig skin (Keck et al., 1989; Senger 
et al., 1983). Since these early reports it has been shown that VEGF promotes 
angiogenesis in three-dimensional in vitro models, as well as in vivo models. A critical 
role for VEGF in blood vessel development has been shown by many investigators 
highlighting the pro- angiogenic effects like the ability to induce survival, migration and 
vascular permeability in endothelial cells (Connolly et al., 1989). The angiogenic 
properties of VEGF make it an attractive area of interest for possible therapeutic usage 
and/or modulation in various pathological conditions. In addition there are several 
indications that point to VEGF as a crucial mediator of neovascularization of aggressive 
tumours (Aiello et al., 1994; Kim et al., 1993). 
1.6.3.2 The VEGF family  
The VEGF family of growth factors consists of five heparin-binding homodimeric 
glycoproteins of 45 kDa, VEGF-A, -B, -C, -D and placental growth factor (PlGF); in 
addition there is a virus-encoded factor, VEGF-E, and VEGF-F which is found in 
viperinae snake venom (reviewed in (Holmes & Zachary, 2005) .  
The VEGF-A gene is located on chromosome 6p21.9 in the human genome and is 
arranged into eight exons separated by seven introns (Houck et al., 1991). In humans, 
cDNA sequence analysis has revealed four different isoforms of VEGF-A, that are 
generated by alternate splicing of exons 6 and 7 consisting of 121, 165, 189 and 206 
amino acids long, (29). The presence or the absence of exons 6 or 7 that encode for the 
heparin-binding domain is the main characteristic feature that determines the relative 
diffusibility of these isoforms. Thus the smaller acidic isoform, VEGF-A121, does not 
bind heparin and is freely diffusible. In contrast, VEGF-189 and VEGF-206 have 
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regions rich in basic residues due to the inclusion of exon 6, and are almost completely 
sequestered in the ECM having a high affinity for heparin (Robinson & Stringer, 2001). 
It has been reported that a lack of heparin binding affinity results in a reduction in the 
mitogenic activity of VEGF suggesting that the heparin (or ECM) binding domain is an 
essential stimulatory cue for initiation of correct vascular formation (Ruhrberg et al., 
2002). ECM sequestered VEGF can be released from the bound form by heparinase or 
by plasmin cleavage at the C-terminus generating a soluble bioactive fragment (J. E. 
Park, Keller, & Ferrara, 1993). In addition exons 7 and 8 also encode the domains 
responsible for binding to the VEGF co-receptor, Neuropilin-1 (NRP-1) (Guo, Jia, 
Song, Warren, & Donner, 1995; Jia et al., 2004; Soker, Takashima, Miao, Neufeld, & 
Klagsbrun, 1998). Together, differential binding to heparin and NRP-1 are thought to 
largely explain the varying angiogenic potential of the splice variants. 
VEGF-A165 is regarded as the most biologically active isoform in terms of endothelial 
biology and angiogenesis. As a result it has been the most intensively studied and best 
characterized isoform. As may be expected, VEGF-A165 has intermediate properties 
whereby a significant fraction, but not all, remains bound to the cell surface and ECM.  
VEGF-A is able to induce proliferation, migration and survival of endothelial cells in 
vitro and blood vessel permeabilisation in vivo (Neufeld, Cohen, Gengrinovitch, & 
Poltorak, 1999). Moreover, VEGF-A165 gene expression is regulated by oxygen 
availability (Shweiki, Itin, Soffer, & Keshet, 1992), and its production in response to 
hypoxia is an important regulator of abnormal angiogenesis in several diseases such as 
diabetic retinopathy (Adamis et al., 1994), psoriasis (Detmar et al., 1994) and cancer 
(Shweiki, Neeman, Itin, & Keshet, 1995). Gene targetting in mice has further confirmed 
a pivotal role for VEGF-A in angiogeneic processes, with the absence of only one 
VEGF-A allele causing severe and lethal disruption to the developing vasculature 
(Carmeliet et al., 1996; Ferrara, 1996). 
VEGF-B is a pro-angiogenic growth factor, which can form heterodimers with VEGF-A 
(Silvestre et al., 2003). Gene disruption studies observed that VEGF- B knockout mice 
are viable and fertile (Aase et al., 2001; Bellomo et al., 2000; Silvestre et al., 2003).  
Bellomo et al (2000) reported that VEGF-B-/- mice have smaller hearts than wild type 
mice, suggesting a role of VEGF-B in cardiac development, while Aase et al (2001) 
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found that atrial conduction was impaired, indicating that VEGF-B could also be 
important in adult heart function (Aase et al., 2001). Recent studies have also suggested 
that VEGF-B can promote neuronal survival and induce endothelial fatty acid uptake 
(Fischer et al., 2008; Hagberg et al., 2010). 
Both VEGF-C and VEGF-D bind to VEGFR2 and VEGFR3, though proteolytic 
cleavage of the N- and C-terminal domains of the full-length proteins enhances their 
affinity for VEGFR2 (Koch, Tugues, Li, Gualandi, & Claesson-Welsh, 2011); Figure 
1.4). However, whereas VEGF-C knockout mice die at E15.5-17.5 with severe oedema 
and abnormal lymphatic vessel formation (M. J. Karkkainen et al., 2004), VEGF-D -/- 
mice are viable and healthy, showing no vascular or lymphatic abnormalities (Baldwin 
et al., 2005). Thus VEGF-C is required for lymphatic angiogenesis whereas VEGF-D 
does not appear to have a developmental role. Nevertheless, studies have shown that 
VEGF-D does not stimulate endothelial cell proliferation in vitro, but can promote 
angiogenesis in adult animal models (Anisimov et al., 2009; Jia et al., 2004; A. M. 
Karkkainen et al., 2009). 
Originally discovered as a VEGF homologue, Placenta growth factor (PlGF) primarily 
binds to VEGFR1, has little or no direct mitogenic activity and does not appear to have 
a particular role in development (Carmeliet et al., 2001; J. E. Park, Chen, Winer, Houck, 
& Ferrara, 1994). Studies have indicated that PlGF may regulate angiogenesis by direct 
or indirect mechanisms. For example PlGF can form heterodimers with VEGF-A and 
these are poor inducers of angiogenic pathways compared with VEGF-A homodimers. 
Conversely, PlGF homodimers out compete VEGF-A for binding to VEGFR1, thereby 
enhancing VEGF-A binding to VEGFR2 in endothelial cells (Cao et al 2009). Given its 
potential effect on enhancement of VEGF responses, anti-PlGF antibodies have been 
used to inhibit the growth of tumours in transplantable tumour models with mixed 
results (Carmeliet & Jain, 2011). In preclinical models, PlGF protein or gene delivery 
increases the revascularization of ischaemic tissues (Carmeliet & Jain, 2011). However, 
the effectiveness of PlGF as either a therapeutic agent or target remains unclear.  
1.6.3.3 Regulation of VEGF gene expression 
 
The regulation of VEGF gene expression plays a major role in blood vessel growth. 
VEGF mRNA expression is rapidly upregulated by exposure to low cellular oxygen 
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concentrations (hypoxia) in a variety of cultured cells. Hypoxia-induced VEGF 
expression is a result of a heterodimer transcription factor complex, Hypoxia inducible 
factor-1 (HIF-1)  and  binding to hypoxia response element (HRE) in the VEGF 
promoter. Under normoxic conditions HIF-1 hydroxylated on key proline residues by 
the oxygen-dependent enzyme, prolyl hydroxylase (PH); hydroxylated HIF-1 is 
ubiquitinylated and is recognized by the von Hippel-Lindau gene product protein, which 
is essential for HIF-1 proteasomal degradation. During hypoxia, however, PH is 
inhibited, non-hydroxylated HIF-1 accumulates and forms a complex with HIF-1, 
which then translocates to the nucleus. This translocation leads to the HIF-1 complex 
and other transcriptional co-activators inducing VEGF transcription (Ferrara & Kerbel, 
2005).  In addition, VEGF mRNA expression has been shown to be induced by several 
cytokines or growth factors, such as PDGF-BB, TGF-b and FGF-2 in cells and during 
neovascuralization and/or tumorigenesis (Ferrara & Kerbel, 2005; Stavri, Hong, et al., 
1995; Stavri, Zachary, Baskerville, Martin, & Erusalimsky, 1995). 
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1.6.4  VEGF receptors  
 
Three cell surface tyrosine kinases (RTK) have been identified as VEGF receptors 
(VEGFRs): VEGFR1 / Flt-1, VEGFR2 / KDR (mouse fetal liver kinase-1, Flk-1) and 
VEGFR3 / Flt-4 (Neufeld et al., 1999). In addition some VEGF isoforms bind to the co-
receptors, NRP1 and 2 (Pellet-Many et al., 2011; Pellet-Many, Frankel, Jia, & Zachary, 
2008; Soker et al., 1998). The three VEGFRs share a similar structural composition 
with an N-terminal extracellular domain of seven immunoglobulin (Ig)-like domains 
(VEGFR3 has six, domain five is replaced by a disulphide bond), a single 
transmembrane region and a consensus cytoplasmic tyrosine kinase catalytic region, 
which is divided into two parts by an insert sequence. Figure 1.4 shows the VEGF 
receptors and summarises their interaction with different VEGF isoforms. 
VEGFR1 has a 10-fold higher affinity for the main VEGF isoform, VEGF- A165, than 
VEGFR2 (Petrova, Makinen, & Alitalo, 1999). Nevertheless, the VEGFR1 undergoes 
little detectable phosphorylation when bound to VEGF-A165, whereas, VEGF-A165 
binding to VEGFR2 results in autophosphorylation on several major sites and is 
followed by the activation of downstream signalling (Zachary, 2003). 
 
1.6.4.1 VEGFR1 & VEGFR2 
 
VEGFR1 has a molecular weight of about 210 kDa, but can also be secreted as a soluble 
form, lacking the seventh Ig-like domain (transmembrane sequence). Soluble VEGFR1 
acts as a physiological negative regulator of VEGF action by sequestering VEGF-A and 
preventing VEGFR-2 signalling (Kendall & Thomas, 1993; Olsson, Dimberg, Kreuger, 
& Claesson-Welsh, 2006).  
In situ hybridization studies have shown that VEGFR1 is highly expressed in 
endothelial cells during embryonic development, then downregulated in adult vascular 
endothelium (Millauer et al., 1993). VEGFR1-knockout mice are embryonic lethal with 
apparent vascular defects. Endothelial cell differentiation was unaffected but their 
assembly into functional channels was severely impaired, implying an essential role for 
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VEGFR1 in vascular organisation (Fong, Rossant, Gertsenstein, & Breitman, 1995).  In 
comparison to VEGFR2, VEGFR1 has weak tyrosine kinase autophosphorylation 
activity following stimulation by VEGF with no direct mitogenic signalling observed 
(Seetharam et al., 1995). In response to VEGF-A, six residues in the C-terminal tail of 
VEGFR1 including tyrosines 1169, 1213, 1242, 1309, 1327, and 1333 have been 
identified as phosphorylation sites, although the extent of phosphorylation of some of 
these residues appears to be minimal. 
 
 
 
 
 
Figure 1.4: Binding specificities of five VEGFs (VEGFA, VEGFB, VEGFC, VEGFD and PlGF) to 
three VEGFRs.  
Proteolytic processing of VEGFC and VEGFD enhances affinity for VEGFR2. VEGFR Ig-like 
domains involved in VEGF binding are hatched circles. VEGFRs 1 and 2 are also expressed as 
soluble forms (sVEGFR1 and sVEGFR2) comprising the extracellular domain lacking the 
seventh Ig-like domain. Key: JMD, juxtamembrane domain; KID, kinase insert domain; TMD, 
transmembrane domain; TKD1, ATP-binding domain; TKD2, phosphotransferase domain. 
Figure from Koch et al 2011. 
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PlGF has also been reported to play a role in crosstalk between Flt1 and Flk1 (Autiero, 
Luttun, Tjwa, & Carmeliet, 2003). Furthermore VEGFR1 may be differentially 
activated by different ligands like VEGF-A and PIGF, possibly due to ligand-specific 
phosphorylation, which results in distinct biological effects (Autiero et al., 2003; 
Roskoski, 2007). In addition, genetic deletion of the intracellular tyrosine kinase 
domain of VEGFR1 in mice showed that this domain is not required for vascular 
development, indicating that VEGF-A-induced stimulation through VEGFR1 tyrosine 
kinase may not be required for early vessel development (Hiratsuka et al 1998). 
Nevertheless further studies with these mice have shown that the tyrosine kinase 
activity of this receptor does appear to play a role in pathogenic angiogenesis, 
particularly in tumours where high levels of VEGFR1-specific ligands, such as PlGF, 
are produced (Hiratsuka et al., 2001; Hiratsuka, Minowa, Kuno, Noda, & Shibuya, 
1998). In addition, activation of VEGFR1 is implicated in the increased expression of 
MMPs and in the paracrine release of growth factors from endothelial cells (Shibuya, 
2006). 
VEGFR2 binds to the different isoforms of VEGF-A (110–165 amino acid residues), 
and the fully processed forms of VEGF-C, VEGF-D and VEGF-E (Fig. 1.4). VEGFR2 
is the key mediator of the mitogenic, angiogenic, chemotactic and vascular 
permeability-enhancing effect of VEGF-A. Although VEGFR2 has lower affinity for 
VEGF than VEGFR1, VEGFR2 is responsible for most of VEGF signal transduction in 
ECs (Zachary, 2003). 
VEGFR2 was thought to be specific for endothelial cells and bone marrow progenitor 
cells, but some studies have also demonstrated the existence of VEGFR2 expression in 
neuronal progenitor cells (Quinn, Peters, De Vries, Ferrara, & Williams, 1993; X. Yang 
& Cepko, 1996). VEGFR2-deficient mice die in utero between E8.5-9.5 due to lack of 
vasculogenesis and blood island formation (Shalaby et al., 1995). In knockout embryos, 
severe early defects in the development of haematopoietic and endothelial cells as well 
as disorganized blood vessels were observed and indicate that VEGFR2 is essential for 
blood vessel formation and vasculogenesis. 
Multiple tyrosine phosphorylation sites in VEGFR2 have been shown to be 
phosphorylated in response to VEGF and are potentially involved in essential signalling 
pathways stimulating endothelial cell proliferation and migration, indicating that 
VEGFR2 is the key signalling receptor for mediating VEGF activity in endothelial cells 
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(Waltenberger, Claesson-Welsh, Siegbahn, Shibuya, & Heldin, 1994). There are at least 
six tyrosine residues in the cytoplasmic domain of VEGFR2 that become 
phosphorylated after VEGF binding: Y951 and Y996 (in the kinase domain), Y1054 
and Y1059 (in the catalytic domain) and Y1175 and Y1214 (in the c-terminus). Residue 
Y1175 has been shown to be a critical mediator of VEGFR2 signalling, with several 
studies indicating that phosphorylated Y1175 acts as a docking site for various 
signalling proteins. For example, Y1175 phosphorylation results in binding and 
activation of phospholipase C1 (PLC1), which then activates the PKC signalling 
pathway (Takahashi & Shibuya, 2001). Y1175 also recruits the Shb adaptor protein, 
which subsequently activates the phosphoinositide-3’   kinase   (PI3K)   pathway  
(Holmqvist et al., 2004) and another adaptor protein, Sck (Igarashi, Shigeta, Isohara, 
Yamano, & Uno, 1998; Ratcliffe et al., 2002; Warner, Lopez-Dee, Knight, Feramisco, 
& Prigent, 2000). Knock-in mice that have Y1173 (which is the murine equivalent to 
Y1175) mutated to phenylalanine die during early embyogenesis with similar vascular 
defects to VEGFR2 knock-out mice (Sakurai, Ohgimoto, Kataoka, Yoshida, & Shibuya, 
2005). Mutation of Y951 to phenylalanine inhibits VEGF-induced stress fibre formation 
and endothelial migration. This residue has also been found to associate with VRAP 
(VEGFR2 associated protein), which interacts with src (Matsumoto et al., 2004; Wu et 
al., 2000). However, src activation is primarily thought to occur via Y1057 (the murine 
equivalent of Y1059) and association with c-Cbl (Meyer, Sacks, & Rahimi, 2008). 
Furthermore, activated src has a regulatory role in Y1175 phsophorylation since 
phosphorylation of this residue was inhibited when Y1057 was mutated (Meyer et al., 
2008). Y1054 and Y1059 may also regulate VEGFR2 internalization since mutation of 
theses sites reduced VEGF-mediated endocytosis of the receptor (Dougher et al 1999). 
Y1214 is reported to be involved in NCK binding leading to activation of the small 
GTPase, cdc42, and further downstream, p38MAPK (Lamalice, Houle, & Huot, 2006; 
Lamalice, Houle, Jourdan, & Huot, 2004). However, mice with a mutation of the 
murine residue equivalent to Y1214 (Y1212F) were viable and fertile, without any 
obvious phenotype (Sakurai et al., 2005). 
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1.6.4.2 VEGFR3 
VEGFR3 plays a key role in remodelling the primary capillary plexus in the embryo 
and contributes to angiogenesis and lymphatic blood vessel development in the adult 
(Dumont et al., 1998). VEGFR3 is expressed during embryonic vascular development 
after which its expression declines and is subsequently restricted to lymphatic vessels 
(Kaipainen et al., 1995).  VEGFR3 binds VEGF-C and VEGF-D but not VEGF-A. 
VEGFR3 is the only VEGF receptor that has a distinct extracellular rearrangement of its 
Ig-like domains. Proteolytic cleavage in the sixth Ig domain of the receptor causes a 
disulphide linkage between the two components of the original chain (Pajusola et al., 
1992).   
1.6.4.3 Neuropilin-1 & -2  
Based upon chemical cross-linking studies, Soker et al identified a VEGF receptor in 
HUVEC samples that differed from VEGFR1 and VEGFR2 (Soker, Fidder, Neufeld, & 
Klagsbrun, 1996). These investigators purified this receptor from human MDA-MB-231 
breast cancer cells and showed that it is identical to neuropilin-1 (NRP1), a surprising 
result at the time owing to its initial characterization as a neuronal recognition molecule 
and a neuronal cell adhesion molecule (Soker et al., 1998). Subsequent work by Chen et 
al (2000) led to the discovery of the related neuropilin-2 (NRP2). NRPs are non-protein 
tyrosine kinase co-receptors for various members of VEGF family (reviewed in (Pellet-
Many et al., 2008). In neurons, they also act as co-receptors for the class 3 semaphorins, 
which are secreted glycoproteins that serve as chemorepulsive axon guidance molecules 
capable of collapsing axonal growth cones and repelling axons of ganglia during 
neurogenesis. NRP1 binds to some isoforms of VEGF-A, VEGF-B and PlGF2, whereas 
NRP2 binds to VEGF-A145, VEGF-A165, VEGF-C and -D (Gluzman-Poltorak, Cohen, 
Herzog, & Neufeld, 2000; Mamluk et al., 2002) (see 1.8.4.1 and Fig. 1.4). In addition, 
soluble forms of NRPs composed of most of the extracellular portion are generated by 
alternative splicing, and are secreted by various tissues. sNRPs maintain their ability to 
bind semaphorins and VEGF and may therefore act as decoy receptors and preventing 
ligand binding to cell surface receptors (Cackowski, Xu, Hu, & Cheng, 2004; Gagnon et 
al., 2000). 
  53 
NRPs are transmembrane receptors containing a large extracellular region, a 
transmembrane  segment,  and  a  short  (≈40  amino  acid  residue)  intracellular  portion  that  
contains a PDZ domain-binding motif (Fig. 1.5). The b1 and b2 domains in the 
extracellular domain are essential for VEGF binding. NRP-1 and NRP-2, act as co-
receptors with VEGFR1, VEGFR2, and VEGFR3 that transduce VEGF signalling, 
though their precise role in VEGF signalling is unclear (Pellet-Many et al., 2008).  
The critical role of NRP1 in vascular development is shown in gene-targeting studies, in 
which NRP1 knockout mice died at embryonic age (E)10-14 with multiple vascular and 
neuronal defects (Kawasaki et al., 1999). Moreover generation of endothelial-specific 
NRP1-null mice showed that NRP1 deficient mice also died at E12.5 with major cardiac 
defects and abnormal arterial branching (Gu et al., 2003). In contrast a knock-in mutant 
NRP1 that binds VEGF but not semaphorin did not result in death until the neonatal 
stage, with the mice showing impaired sensory neuronal pathfinding. Although NRP2 
shares 44% homology with NRP1 and is expressed in many of the same cells as NRP1 
it cannot compensate for the loss of NRP1 in knockout models. Indeed, NRP2 knockout 
studies indicate NRP2 has a restricted role in lymphangiogenesis and sensory guidance 
(H. Chen et al., 2000; Yuan et al., 2002). 
Complex formation between NRP1 and VEGFR2 in endothelial cells have been shown 
to increase VEGF-stimulated migration possibly by enhancing VEGFR2 cell signalling 
by stabilising and prolonging ligand binding. Indeed there is evidence that the 
cytoplasmic domain of NRP1 participates in complex formation, since VEGFR2-NRP1 
association is decreased if the PDZ binding domain is deleted (Prahst et al., 2008). 
Nevertheless, overexpression of a mutant NRP1 lacking the cytoplasmic domain 
(Nrp1∆C)   does not impact on ligand induced VEGFR2 phosphorylation (at tyrosine 
residue 1175) as opposed to NRP1 knockdown by siRNA which significantly reduces 
phosphorylation at this residue (Evans et al., 2011). Although the cytoplasmic tail of 
NRPs has no known transductional signalling role, some studies have indicated that it 
serves as a docking site for downstream signaling molecules, alone or in conjunction 
with co-receptors. Indeed, the PDZ binding domain of NRP1 can interact with synectin 
(also known as GIPC1) in a yeast two-hybrid screen (Cai & Reed, 1999). Further 
studies demonstrated that NRP1 associated with synectin in endothelial cells and 
synectin knockdown reduced VEGF-induced migration (L. Wang, Mukhopadhyay, & 
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Xu, 2006). Synectin regulates G-protein-coupled receptor signalling and interacts with 
proteins involved in cytoskeletal scaffolds (Abramow-Newerly, Roy, Nunn, & Chidiac, 
2006; M. Liu & Horowitz, 2006). Synectin may also be involved in NRP1-mediated cell 
attachment since Synectin-NRP1 binding induces 51 integrin internalisation 
(Valdembri et al., 2009).  
 
 
 
Figure 1.5: Neuropilins, their ligands and co-receptors.  
A. Class 3 Semaphorins bind NRP1 and NRP2 with differing specificities. Plexins A1 and A2 
are the major signalling receptors for Semaphorins, and complex with NRPs and Semaphorins 
to form a complex essential for growth cone collapse and axonal guidance in neurogenesis. The 
plexin cytoplasmic domain contains two regions of homology found in GTPase activating 
proteins. Key: IPT, immunoglobulin-like domains shared by plexins and transcription factors; 
MRS, Met-related sequences. B. Some isoforms of members of the VEGF family bind to NRP1 
and NRP2 as indicated. The VEGF-A121 isoform binds to NRP1 but does not promote 
NRP1/VEGFR2 complexation. NRP1 may also associate with VEGFR1/Flt1, and NRP2 is 
reported to complex with the receptor for VEGF-C and VEGF-D, VEGFR3. Key: Ig-like, 
immunoglobulin-like. Figure adapted from Pellet-Many et al 2008. 
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Although synectin knockout in zebrafish phenocopies zebrafish NRP1 knockouts 
(Chittenden et al., 2006; L. Wang et al., 2006), this is not the case with mice 
(Chittenden et al., 2006). Synectin knockout mice are viable, although they are smaller 
than wild type mice and exhibit microvascular arterial defects (Chittenden et al., 2006). 
It is clear therefore that synectin alone does not mediate intracellular NRP1 function.  
1.7  Vascular Smooth Muscle Cell physiology 
 
Larger blood vessels (arterioles, arteries, venules and veins) consist of a single layer of 
endothelial cells surrounding the vessel lumen, and the vessel wall, primarily composed 
of a continuous layer of vascular smooth muscle cells (SMC), and an outer adventitial 
layer containing fibroblasts, connective tissue, nerves and in large vessels a 
microvasculture called the vasa vasorum (see Figure 1.6). During development, smooth 
muscle cells and pericytes play major roles in the formation, remodelling, stabilisation, 
maturation and function of the vascular network. The primary roles of SMC in the 
mature vasculature are contraction, regulation of blood vessel tone, blood pressure, and 
blood flow distribution (Owens, 1995).  
Fully mature SMC are multifunctional mesenchymal cells which display a marked 
phenotypic plasticity. Thus, changes in the local environment can result in profound and 
reversible changes in their differentiated phenotype. Depending on specific local 
conditions, which could be a result of cell interactions, alteration of extracellular matrix, 
or in response to cytokines, SMC will undergo adaptive changes often resulting in 
remodelling of the vessel wall. Thus, SMC within adult animals retain remarkable 
phenotypic diversity and plasticity during normal development, during repair of 
vascular injury, and in disease states including arteriosclerosis and tumour angiogenesis. 
These  phenotypic  alterations  commonly  termed  “dedifferentiation”,  are  modulations  of  
the differentiated state involving reversible interconversions between phenotypes with 
an impact on the normal structure or function of the differentiated SMC. The spectrum 
of phenotypes expressed by SMC emphasizes their transition between and within two 
polar distinct well-described states: contractile and synthetic (reviewed in (Gomez & 
Owens, 2012; Owens, Kumar, & Wamhoff, 2004). 
The synthetic phenotype is predominant during vascular development or regeneration, 
where SMC play a key role in morphogenesis of the blood vessels, simultaneously 
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participating in vessel growth and remodelling. At the early stages of vasculogenesis, 
SMC are highly proliferative, migratory and synthetic, producing extracellular matrix 
components such as collagen, elastin, cadherens, integrins and proteoglycans that 
constitute a major portion of the blood vessel wall while at the same time acquiring 
contractile capacities. In this synthetic state, SMC possess abundant gap junctions with 
endothelial cells and communicate directly through connexon-containing gap junctions 
(Owens et al., 2004). The process of recruitment of SMC or pericytes is critical for the 
establishment of a physiologically remodelled and mature vessel. 
In contrast, contractile SMC exist mainly within established adult blood vessels, 
proliferate at an extremely low rate, are largely non-migratory, and exhibit very low 
biosynthetic activity. In this state 80-90% of the cell volume is occupied by contractile 
apparatus, whereas organelles such as endoplasmic reticulum, Golgi and free ribosomes 
are few in number and located in the perinuclear region. Mature fully differentiated 
SMC perform their contractile function by expressing a unique repertoire of contractile 
proteins, such as myosin, tropomyosin, actin, ion channels, and signalling molecules. 
These proteins are required for contractile properties that are distinct from terminally 
differentiated skeletal or cardiac muscles cells. In vivo observations have shown that the 
SMC responsible for the neointimal thickening in the rat carotid artery balloon injury 
model appear to switch into a reversible phenotypic modulation in response to the 
insult. Under these complicated local conditions, SMC undergo a change from their 
normal function of contraction and maintenance of vessel wall tone to one of repair of 
the wound by migration, synthesis of matrix and/or cell replication (Gomez & Owens, 
2012). These SMC exhibit an ability to proliferate, and express PDGF-BB mRNA but 
low levels of PDGFR, similar to that seen as in SMC in neonatal rat (Majesky, 
Benditt, & Schwartz, 1988; Majesky, Giachelli, Reidy, & Schwartz, 1992).  
However, the origin of the SMCs, which form the neointimal thickening, remains 
controversial. Once wound healing is complete, the cells appear to return to their 
previous phenotype and function (Campbell, Campbell, Manderson, Horrigan, & 
Rennick, 1988). 
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Figure 1.6: Anatomic view of a multilayered arterial vessel wall 
This is a schematic diagram showing the cross-sectional view of an arterial wall and its wall 
components in the mature cardiovascular system.  
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There is strong evidence that phenotypic modulation of SMC plays a major role in a 
number of major diseases in humans including atherosclerosis, cancer, and hypertension 
(Owens et al., 2004). Indeed, the complexity of different phenotypes that may be 
manifested by SMC is evident within atherosclerotic lesions. These are characterised by 
an increase in troponin, myosin, -actin and the vimentin to desmin protein ratio (Skalli, 
Bloom, Ropraz, Azzarone, & Gabbiani, 1986; Valente et al., 1988). 
 
1.7.1  SMC in disease 
 
Atherosclerosis is an inflammatory pathology, which is thought to result from damage 
involving oxidative stress to the vascular endothelium lining the artery. Endothelial 
injury results in the migration of inflammatory cells such as macrophages and T-
lymphocytes into the arterial wall. The macrophages develop into foam cells resulting in 
the accumulation of lipid, followed by proliferation and migration of SMC from the 
media into the intima. The occurrence of proliferation and subsequent accumulation of 
SMC results in further intimal expansion. Accumulation of SMC in the tunica intima 
(neointima formation) plays a crucial role in the pathogenesis of atherosclerosis, and is 
also implicated in restenosis following angioplasty or stenting (Ross, 1995, 1999). In 
the neointima, growth factors and proteolytic agents induce SMC proliferation and 
migration. During this process, SMC undergo phenotypic modulation, from a contractile 
to a synthetic phenotype, resulting in reduced expression of typical SMC contractile 
proteins and an enhanced response to growth and chemotactic factors (Orlandi & 
Bennett, 2010). 
 
There is very clear evidence that the morphological, biochemical, physiological and 
molecular properties of SMC vary at different stages of atherosclerosis, and also within 
different lesion types and between different regions within a given lesion. For example, 
in early lesion development SMC phenotypic change plays a maladaptive role, whereas 
it may have a beneficial adaptive role in stabilization of plaques in mature lesions. 
However, at the later stages of atherosclerosis, it contributes to plaque destabilization 
through VSMC apoptosis and /or activation of various protease cascades. It is not yet 
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known whether atherosclerosis plays a role in initiating SMC phenotypic switching or if 
it is the SMC modulation that participates in the development and progression of 
atherosclerotic lesions (Ross, 1999). 
 
1.7.2  Platelet Derived Growth Factors  
 
Platelet-derived growth factor (PDGF) was initially characterised as a serum growth 
factor for fibroblast, smooth muscle cells and glia cells (Ross, Glomset, Kariya, & 
Harker, 1974). PDGFs are a family of closely related growth factors with an 
approximate molecular weight of 30 kDa. There are five disulphide-linked homo- and 
heterodimers of homologous isoforms (Fig. 6): the A and the B polypeptide chains, 
which give rise to three dimeric bioactive ligands, AA, BB and AB, and the recently 
identified PDGF-C and PDGF-D chains (Fredriksson, Li, & Eriksson, 2004; Stroobant 
& Waterfield, 1984). The heterodimer PDGF-AB is currently believed to be the only 
heterodimer form in human platelets with somewhat different signaling properties from 
the homodimers (Ekman, Thuresson, Heldin, & Ronnstrand, 1999), and its 
physiological role still remains to be established. Since these findings substantial 
experimental evidence has shown that PDGF through its receptors plays an important 
role in embryonic development. Increased PDGF activity has also been linked with 
several pathological conditions and diseases such as cancer. This has led to increased 
interest in PDGFs as a therapeutic target, and PDGF/PDGFRs inhibitors are currently 
being tested in both pre-clinical models as well as human clinical trials. 
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Figure 1.7: Proteolytic processing of PDGF family 
This picture is a representation of the proteolytic processing of PDGF precursor 
polypeptides and their domains. PDGF isoforms are close structurally related growth 
factors that are produced as precursor molecules and undergo proteolytic processing in 
their N terminal pro-peptides and in C terminal as in the case of B-chain. Soluble 
inactive forms of PDGF- C and PDGF-D include their characteristic CUB domain, 
which is proteolytic removed extracellulally ready to bind to the PDGF receptors.
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1.7.2.1 PDGF family 
 
Mammalian PDGF family members carry a growth factor core domain containing a 
conserved set of cysteine residues, the so-called cysteine knot motif (Fredriksson et al., 
2004). The cysteine knot is an eight-cysteine residue ring with three intramolecular and 
one intermolecular disulphide bond per monomer. The core domain is necessary and 
sufficient for the stability of the ligand dimeric structure to bind and functionally 
activate its receptors (Andrae, Gallini, & Betsholtz, 2008). Other related growth factors 
such as VEGFs share a similar structure. 
The crystal structure of PDGF-BB (Oefner, D'Arcy, Winkler, Eggimann, & Hosang, 
1992) revealed that each monomeric molecule has two long highly twisted antiparrallel 
-strands and the two subunits are associated in a head-tail conformation, which is also 
found in VEGF . 
The A and B chains of PDGF are 60% similar in their amino acid sequences, while the 
C and D chains display approximately 50% identity (Fredriksson et al., 2004; Heldin & 
Westermark, 1990). PDGFs are all expressed and assembled as inactive dimeric 
precursors and terminal proteolytic processing is necessary for their biological activity 
(Fig. 1.6). PDGF-A and PDGF-B have short N-terminal extensions upstream of the 
growth factor domain, that undergoes intracellular proteolytic processing by furin or 
related proprotein convertases. PDGF-B also requires C-terminal processing, which is 
suggested to be essential to acquire receptor-binding ability (Fredriksson et al., 2004; 
Siegfried, Khatib, Benjannet, Chretien, & Seidah, 2003). In contrast, PDGF-C and 
PDGF-D chains display a distinct protein domain, the so-called CUB domain, as part of 
their N-terminal extensions. Both PDGF-C and PDGF-D are secreted as latent ligands, 
requiring activation by limited extracellular proteolysis to release the growth factor 
domains from the CUB domains by plasmin and/or other serum proteases. The 
proteolytic processing of PDGF polypeptides is shown in figure 1.7. 
Additionally, in their C-termini, both PDGF-C and PDGF-D lack amino acid sequence 
extensions referred to as the retention motif, while PDGF-A and B have mainly basic 
amino acid sequences involved in binding to extracellular matrix. However, CUB 
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domains are implicated in protein–protein and protein-carbohydrate interactions that 
might regulate the extracellular distribution of latent C and D chains.  
The genes encoding for the A and B chains are located on human chromosomes 7 and 
22, while C and D genes are located on chromosomes 4 and 11, respectively 
(Fredriksson et al., 2004). The genes are structurally related with similar exon/intron 
organizations, and they have apparently arisen by gene duplication and evolutionary 
divergence. In addition, alternative splicing of exon 6 in the PDGFA gene leads to the 
formation of multiple PDGF-A secreted polypeptides, with or without the retention 
motif, (Bonthron, Collins, Grzeschik, van Roy, & Speleman, 1992; Rorsman & 
Betsholtz, 1992). 
PDGFs are primarily characterised as paracrine growth factors which are released from 
cells and bind to their extracellular receptors, and may also be engaged in autocrine 
loops in tumours, similar to those recently described for VEGF-A required for 
endothelial survival and vascular maintenance (Lee et al., 2007). 
In general, PDGFs are expressed in discrete populations of cells and act locally as 
paracrine growth factors to drive different cellular responses (for review, see (Betsholtz, 
2004; Hoch & Soriano, 2003). PDGF expression is highly regulated in vivo during 
development and in certain physiological hypertrophic responses, whereas in cells, 
expression is responsive to a variety of stimuli, including hypoxia, thrombin, cytokines, 
and growth factors, including PDGF itself (for review, see (Heldin & Westermark, 
1999). 
The PDGF-BB homodimer is the predominant and most intensively studied isoform. It 
is produced by activated platelets and lesion macrophages and stimulates SMC 
proliferation, migration and survival. It also induces rapid downregulation of selective 
contractile markers in cultured SMC (Dandre & Owens, 2004). It is physiologically 
important in intercellular crosstalk between endothelial cells secreting PDGF-BB and 
SMC expressing PDGF-BB receptors. Furthermore, both VSMC and endothelial cells 
secrete PDGF-BB (Jacot & Wong, 2008). 
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Figure 1.8: PDGF–PDGFR interactions in cultured cells.  
Each chain of the PDGF family member binds and activates homo- and heterodimeric 
complexes of PDGFR-α   and   PDGFR-β,   indicated   by   solid   arrows,   whereas   hached   arrows  
indicate weak bindings. Upon ligand activication, receptor dimerisation and 
autophosphorylation determine its mitogenic responses.  
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1.7.3  PDGF Receptors 
 
PDGF family members bind to two different cell surface receptors, PDGFR- and 
PDGFR- (Fig. 1.8). PDGFR- binds all three isoforms (PDGF-AA, -AB, -BB) with 
high and similar affinity. In contrast, PDGFR- was found to bind to PDGF-BB with 
high affinity, but with approximately 10-fold lower affinity to PDGF-AB, and does not 
bind at all to PDGF-AA. 
In humans and other mammals, two structurally and functionally related PDGFRs 
(PDGF receptor tyrosine kinases) have been identified, namely  PDGFRα  and  PDGFRβ  
(Fig. 1.8). The PDGFRs are plasma membrane spanning receptors with a similar 
organization with an extracellular ligand-binding domain composed of five 
immunoglobulin-like loops, a single transmembrane domain, a regulatory 
juxtamembrane domain, a split tyrosine kinase domain and a C-terminal tail. The gene 
encoding  PDGFRα  is  located  in  chromosome  4q11-4q12 and is transcribed as a 6.5 kb 
messenger  RNA,  while  PDGFRβ  gene  is  positioned  in  chromosome  5q33  producing a 
5.5kb mRNA (Claesson-Welsh, Eriksson, Westermark, & Heldin, 1989). After 
proteolytic processing of their signal peptides each precursor protein is modified into N-
linked and O-linked   glycosylated   mature   form   of   170   kDa   PDGFRα   and   190   kDa  
PDGFRβ and the size of their glycosylation varies among different cell types (Claesson-
Welsh, 1994). 
There is an overall pattern of PDGFR expression in fibroblasts and SMC of different 
species,   though   there   are   reports   of   exclusive   expression   of   PDGFRα   in   platelets  
(Vassbotn, Havnen, Heldin, & Holmsen, 1994) and  PDGFRβ  in  pericytes  and  myoblasts  
(Sundberg, Ljungstrom, Lindmark, Gerdin, & Rubin, 1993)  However, in development 
PDGFRs specific functions totally depend on cell type and context-specific expression. 
Binding of PDGF to the N-terminal part of the extracellular domain of the receptor 
causes dimerization of receptors to form homo- or heterodimers, which is an essential 
and key event for receptor activation. Dimeric PDGF isoforms bind simultaneously to 
the receptor, such that the ligand forms a bridge between two receptors, resulting in 
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receptor dimerisation. Receptor dimerization occurs in a dose-dependent manner and is 
accompanied by changes in the intracellular domain conformation. The conformational 
changes in turn enable autophosphorylation of multiple tyrosine residues on the receptor 
dimeric intracellular domains by ATP binding. Specific downstream signal molecules 
bind to these phosphorylated tyrosines via SH2 (Src homology 2) or PTB (Phospho 
Tyrosine binding) motifs involving protein-protein interactions, which initiate a cascade 
of signal transduction.  
According to a common model of how a tyrosine kinase receptor autophosphorylates 
itself, a basal kinase activity or "unlocking" trigger to phosphorylate a particular 
tyrosine residue serves as a substrate for full enzymatic activity directed toward other 
tyrosine residues in the receptor molecules as well as other substrates for the kinase. 
However, analysis of site-directed mutations in PDGFRs has begun to shed light on in 
vivo functions of specific phosphorylation sites. 
PDGFR- and - homodimers as well as heterodimeric receptors, transduce potent 
overlapping, but not identical, mitogenic signals (Heldin & Westermark, 1999). It is 
notable that no heterodimers involving PDGF-C and PDGF-D chains have been 
described so far (Fredriksson et al., 2004).  
VSMC, fibroblasts and many other cells types express both receptor isoforms, PDGFR-
 is the major isoform expressed by pericytes (Sundberg et al., 1993) whereas PDGFR-
 is expressed by other cell types such as platelets (Vassbotn et al., 1994). 
  
1.7.4  PDGFRs signal transduction 
 
As mentioned previously, PDGF-ligand binding and receptor dimerisation results in 
conformational changes that lead to autophosphorylation of specific tyrosine residues in 
the intracellular domain. This initiates a cascade of downstream mitogenic signals 
involving multiple SH2-domain-containing proteins that bind directly to the 
phosphorylated tyrosine residues of the activated receptors. 
Receptor tyrosine phosphorylation sites induced by ligand binding serve two purposes: 
firstly, to regulate the state of activity within kinase domain and phosphatase 
disactivation. Secondly, to create docking sites for downstream signal transduction 
molecules, which leads in kinase-substrates interaction through SH2 domains.  
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Mutation of Tyr 857 into phenylalanine in second part of the tyrosine kinase domain of 
PDGFRβ   and   Tyr   849   for   PDGFRα   showed   that   phosphorylation   of   this   tyrosine  
residue has an important role in positive regulation of kinase activity (Kazlauskas and 
Kovalenko, 2004). Binding to tyrosine phosphorylation sites involves recruitment of 
many signal transduction molecules containing also SH3 domains that activate other 
downstream molecules, via binding to proline-rich stretches and "pleckstrin homology" 
domains such as Sos 1, or other GTP-binding proteins. A range of signalling molecules 
associate with PDGFR phosphorylation sites in vitro.  
1.7.4.1 Downstream signal transduction molecules 
 
Src family tyrosine kinases: Two tyrosine residues in the juxtamembrane domain, Tyr 
579 and Tyr 581 are involved in binding and activation of members of the Src family of 
cytoplasmic kinases, Src, Fyn, and Yes, resulting in increase of kinase activity (Gould 
& Hunter, 1988). Despite the fact that Src is known to be involved in stimulation of cell 
cycle  progression,  binding  of  Src  to  PDGFRα  was  shown  to  not  be  so  important  for  its  
mitogenic response (DeMali & Kazlauskas, 1998). Although PDGFRα  phosphorylation 
results   in   an   initial   increase   in  Src   kinase   activity,   PDGFRα  mutated  on   two   tyrosine  
residues Tyr 572 and Tyr 574 responsible for Src binding was not be able to induce 
PDGF-AA-mediated Src activation but did not prevent DNA synthesis when the 
receptors were expressed in pig aortic endothelial cells, indicating that  initial burst of 
Src activity might be only required for efficient tyrosine phosphorylation of selected 
signaling molecules in an activated cell but not in a later event as cell proliferation 
(Gelderloos, Rosenkranz, Bazenet, & Kazlauskas, 1998; Hooshmand-Rad, Yokote, 
Heldin, & Claesson-Welsh, 1998). 
Phosphatidylinositol 3-kinase (PI3K): is a family of proteins, which generates 
intracellular pool of phosphoatidylinositol 3,4,5 –triphosphoate (PIP3). PDGFRs 
interact and tyrosine phosphorylate p85 subunit of PI3K but not of p110 by association 
of its two SH2 domains and one SH3 domain with two phosphorylated tyrosine 
residues,  Tyr  740  and  751,  in  the  PDGFRβ  kinase  insert  (Fantl et al., 1992; Kashishian, 
Kazlauskas, & Cooper, 1992; Klippel, Escobedo, Fantl, & Williams, 1992). The 
PDGFRβ   contains   two   optimized   binding   sites   for   SH2   domains   of   p85,   PI3K   for  
binding to their respective phospho-tyrosine   residues,  whereas  PLCγ  binding   site  Tyr  
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1021 could be a competitive site for PI3K as well (Songyang et al., 1993). The p85 
phosphorylation by PDGFRs promotes directed cell migration, actin reorganization and 
cell survival through activation of downstream effectors, most importantly the 
serine/threonine kinase Akt/PKB.  
PLC   (phospholipase   C)   γ: This enzyme hydrolyses PIP2 to generate the second 
messengers, inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG), in turn 
leading, respectively to mobilization of Ca2+ from intracellular stores, and activation of 
certain members of the PKC family. In vivo studies have shown that Tyr 1009 and Tyr 
1021 in the C-terminal region of PDGFRs bind   and   activate   PLCγ   possibly   by  
interactions with both of two SH2-containing domains in PLC (Ronnstrand et al., 
1992). PDGFR-mediated  PLCγ  activation  is important for cell mitogenesis and motility 
(Kundra, Soker, & Zetter, 1994). 
The ERK cascade: Furthermore, PDGF receptors also recruit and associate with 
several additional signalling molecules, adaptors such as Grb2 and Shc that bind 
through its SH3 domains to the Ras guanine nucleotide exchange factors mSos1 and 
mSos2 which accelerate Ras GTPase activity that is particular important in coupling 
PDGF receptors to downstream MAPK signalling pathways involved in the control of 
cell proliferation and differentiation. Ras protein in turn undergoes a conformational 
change that serves as a switch for its activation cycle between an inactive GDP-bound 
form and a biologically active GTP-bound state. Consequently, active Ras GTP binds 
and activates other downstream targets like Raf-1 protein-serine/threonine kinase which 
leads to the activation of mitogenic ERK cascade (Andrae et al., 2008; van der Geer, 
Henkemeyer, Jacks, & Pawson, 1997). PDGFs are also able to activate other MAPK 
pathways, such as p38 kinase. 
Excessive or uncontrolled PDGFR signaling may be dangerous, so that a stringent 
feedback control mechanism exits by which PDGFR tyrosine phosphorylation is tightly 
regulated by endocytotic internalization and degradation of ligand-receptor complex, 
and/or by dephosphorylation of PDGFRs and its substrates through SH2-domain PTPs 
(protein tyrosine phosphatases). Ligand bound PDGF receptors are dephosphorylated by 
tyrosine phosphatase SHP-2 that is also able to dephosphorylate Src protein (Stokoe and 
McCormick 1997). 
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1.7.4.2 The  differences  in  PDGFRα  and  PDGFRβ  cellular  signalling 
 
After PDGFRs activation a number of signaling cascades are triggered that leads to 
multiple cellular and developmental responses. Although there are many similarities 
between PDGFRα   and   PDGFRβ   signal transduction, comparison of downstream 
cellular regulation and developmental signal demonstrates that there are also a number 
of  differences.  For  instance,  in  contrast  to  PDGFRβ  signalling,  disruption  of  PDGFRα-
mediated PI3K activation is important in normal skeletal development.  
As  mention   above,   even   though  both   receptors   recruit   and   interact  with  PI3K,  PLCγ, 
SHP-2, only PDGFRβ   stably   associates   with   GTPase-activating protein, instead 
different binding site exist for SHP2 phosphatase, SHP-2 binds to the kinase insert of 
the  PDGFRα,   but   to   the   tail   of   the   PDGFRβ   (Heidaran, Pierce, Jensen, Matsui, & 
Aaronson, 1990). 
Differences in signalling mechanisms of the α   and   β   receptors   are   also   observed   in  
disease state SMC, for example in the genetically hypertensive rat strain used as a 
model for human hypertension. In this study, PDGF-AA and PDGF-BB had different 
effects on DNA and protein synthesis. Therefore, in this cell type, it was suggested that 
PDGFRα,   which   was   abnormally   expressed,   could   cause   cellular   hypertrophy   during  
hypertension  whereas  PDGFRβ  elicits  a  mitogenic  response  (Inui, Kitami, Tani, Kondo, 
& Inagami, 1994).  
In addition, while PDGF-AA is known to stimulate DNA synthesis and proliferation in 
normal SMC from a variety of species, PDGF-BB is both a potent mitogen for SMC 
and also a potent chemoattractant, whereas several studies indicate that PDGF-AA has 
either no chemotactic activity in SMC or negatively regulates the chemotactic response 
to PDGF-BB (Koyama, Hart, & Clowes, 1994; Koyama, Morisaki, Saito, & Yoshida, 
1992; Siegbahn, Hammacher, Westermark, & Heldin, 1990). 
 
The restricted expression patterns of PDGF receptors as well as their cell interaction 
sites are considered to be important and specific for their functional and developmental 
effects. Gene targeting studies have identified some specific characteristic receptor 
regulation by showing that PDGFRβ signaling can fully recompense for loss of 
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PDGFRα-specific signaling and can direct certain cellular functions that α cannot 
(Klinghoffer, Mueting-Nelsen, Faerman, Shani, & Soriano, 2001). Distinct PDGFRβ 
signals are required to promote optimal function of specific cell types such as SMCs 
whereas PDGFRα   signals   are   important   for   tissue   derived   from nonneuronal cranial 
neural crest cells (Klinghoffer et al., 2001; Soriano, 1997). 
1.7.5  Role of PDGF in development 
 
Distinct biological functions of the PDGF isoforms during development are largely 
studied by targeted disruption of gene encoding the PDGF-AA and PDGF-BB or 
PDGFRs in mice. PDGF-A deficient embryos survived only around three weeks of age 
with severe lung alveoli malfunctions, leading to alveolar myofibroblast 
undifferentiated phenotype (Bostrom et al., 1996). 
Loss of function of PDGF-BB chain resulted in abnormally developed kidney 
glomeruli, a dilated heart and vasculature hemorrhages, causing perinatal death. The 
disruption of PDGF-BB reflects its primary importance in angiogenesis as a major 
mediator of pericyte recruitment to newly sprouting capillaries, and as a major mitogen 
and chemoattractant for SMC. Targeted disruption of the PDGF β  receptor  gene  is  lethal  
at or just before birth, and the mutants mice are anemic, suffer from haemorrhage and 
have reduced platelet counts (thrombocytopenic); these mice also exhibit defects in 
kidney glomerulus maturation probably secondary to a loss of kidney mesangial cells 
(Soriano 1994). 
No   obvious   abnormalities   were   observed   in   central   nerve   system   of   the   β   receptor  
mutant. Both PDGF-BB   chain   and   β   receptor   mutants   show   a   similar   phenotype  
important in kidney and vascular wall development, supporting the idea that PDGF-BB 
and   β   receptor   signalling   are   crucial   of   these   tissues   during   development   (Soriano, 
1994).  
Mutant   α   receptor mice die during early embryonic stages and exhibit incomplete 
cephalic closure, severe dermal defects and significant defects in skull and skeleton. 
Disruption   of   PDGFRα   signalling   seems   to   be   mainly   important   for   non-neuronal 
cardiac crest development similar with defects observed in PDGF-A/C double 
knockouts (Morrison-Graham, Schatteman, Bork, Bowen-Pope, & Weston, 1992; 
Soriano, 1997).   
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1.8  Aims of this thesis 
 
At the outset of this thesis it was known that STC-1 expression was upregulated in 
models of angiogenesis and in cultured endothelial cells in response to VEGF. 
However, very little was known regarding the role of STCs in either endothelial cell 
function or in angiogenesis. Various lines of evidence did indicate that STC-1 might 
regulate different aspects of mammalian cell function, though neither the mechanisms 
mediating these cellular effects, nor their physiological or pathological significance 
were understood. It was also largely unknown at this time whether STCs were 
expressed or were regulated in SMC. Therefore the overall goals of this thesis is to 
increase our understanding of STC-1 function in vasculature, specifically to:  
 
 
 Examine the role of STC-1 in endothelial cell function, and in angiogenesis in cell 
culture models using a variety of approaches, including treatment with 
recombinant STC-1 protein (which had recently become commercially available), 
inhibition of endogenous STC-1 expression using specifically targeted small 
interfering RNA (siRNA), and over-expression of STC-1 using an adenovirus 
encoding STC-1 to allow for efficient transduction of primary endothelial cells. 
Some pilot work had been performed in this laboratory immediately prior to the 
commencement of my PhD work, which had generated STC-1-encoding 
adenoviruses, and suggested that STC-1 did not regulate endothelial cell 
proliferation in response to VEGF, that STC-1 over-expression could negatively 
regulate VEGF-induced endothelial cell migration. However, these data were 
preliminary and I therefore aimed to reproduce these data, and to further examine 
the role of STC-1 in VEGF functions. 
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Since VSMC are an important component of the vasculature, I also hypothesised that 
STC upregulated in endothelial cells might have implications for regulation of VSMC 
function. VSMC in culture are also highly synthetic cells, and I therefore also 
hypothesised that STCs might be expressed in VSMC, and that their expression might 
be regulated in VSMC.  
 Examine STC-1 expression in VSMC, and to assess whether STC-1 expression 
was regulated by growth factors for VSMC, particularly PDGFs.  
 Analyse the role of STC-1 in the regulatory functions of VSMC that might be 
relevant for their role in development or disease, such as cell migration, survival 
or proliferation.  
  Investigate possible mechanisms through which STC could act in either 
endothelial cells or VSMC. 
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Chapter 2 
 
2 Material and Methods 
Each experimental technique used in this thesis is described below. Supporting 
information, which explains the key principle for each method was extracted from 
Wilson and Walker (2005, 6th edition) and/or product literature as appropriate. 
 
2.1  General materials 
Endothelial cell basal medium (EBM) and endothelial growth supplements 
(Singlequots) were purchased from Lonza and fetal bovine serum (FBS) from Life 
Technologies Ltd. Smooth muscle cells (SMC), SMC basal media and SMC growth 
supplements were obtained from TCS CellWorks Ltd. 
Recombinant human PDGF-BB (disulfide-linked homodimer of two B chains) and 
PDGF-AA (homodimer of A chain) were purchased from Peprotech EC Ltd. Human 
recombinant VEGF-A165  (mature secreted 165 amino acid (aa) form) was from R&D 
Systems. Primary antibody suppliers and dilutions are given in Table 2.1.  
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siRNAs were from either Life Technologies Ltd, ThermoFisher Scientific or Qiagen as 
indicated in Table 2.2. Lipofectamine® RNAiMAX siRNA Transfection Reagent was 
provided from Life Technologies Ltd. DuoSet ELISA Development kit for the detection 
of STC-1 was obtained from R&D Systems.  Complete™  Protease  inhibitor  cocktail  was  
from Roche Diagnostics Ltd  and Phosphatase inhibitors were from Sigma. All other 
chemicals or reagents were from standard suppliers or as listed in the text.  
2.2  Human Cell culture  
All cells were grown in cell cultureware (BD Biosciences) under sterile conditions in a 
37°C, 95% air/5% CO2 incubator. 
2.2.1 Smooth Muscle Cells 
Human Coronary Artery Smooth Muscle Cells (HCASMCs, TCS CellWorks) or Human 
Aortic Smooth Muscle Cells (HAoSMCs, TCS CellWorks) were grown in Smooth 
muscle cell (SMC) growth medium comprising SMC basal medium plus SMC growth 
supplement   (containing   gentamycin   (25μg/ml)   amphotericin   B   (50   µg/ml)   and   2.5 % 
v/v FBS.  
Experiments used confluent SMCs at passages 3-7 and those used for signalling studies 
were starved overnight in serum free SMC medium. Cells were then washed in serum-
free medium and incubated in serum-free medium with or without the addition of 
growth factors for the indicated times. For some studies, cells were pre-incubated with 
pharmacological inhibitors or 100 ng/ml recombinant human Stanniocalcin-1 protein 
(rhSTC-1, MyBioSource) for 30 mins prior to the addition of other growth factors, for 
example, 30ng/ml recombinant human PDGF-BB for a further 10 mins.  
2.2.2 Endothelial Cells 
 
Human Umbilical Vein Endothelial Cells (HUVEC, TCS CellWorks) were grown on 
gelatin-coated cultureware in endothelial growth medium (EGM; consisting of EBM 
supplemented with 10% v/v FBS,  and Singlequots; containing 10 ng/ml recombinant 
human epidermal growth factor, 12 μg/ml   bovine brain extract and 50 μg/ml  
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gentamicin-ampicillin). Experiments utilized confluent HUVECs at passage 3 or 4 that 
were rendered quiescent by overnight incubation in EBM containing 0.3% FBS 
prepared as a dilution. Prior to the addition of factors and other treatments, the quiescent 
cells were washed twice in serum-free EBM and then incubated with or without the 
addition of factors for 24 hours.  
 
2.2.3 Human dermal fibroblasts 
Human dermal fibroblasts (HDF) were grown in M106 medium (Life Technologies Ltd) 
supplemented with Low Serum Growth Supplement (Life Technologies Ltd; containing 
2%  v⁄∕v  FBS,  1  µg⁄∕ml  hydrocortisone,  10  ng⁄∕ml  human  epidermal  growth  factor,  3  ng⁄∕ml  
basic  fibroblast  growth  factor  and  10  µg⁄∕ml  heparin). 
 
2.3 SDS-PAGE and Western blotting  
2.3.1 Principle 
 
Eletrophoresis is a separation technique based on the movement of charged 
macromolecules under the influence of an electrical field. Sodium dodecyl sulphate 
(SDS) polyacrylamide gel electrophoresis (PAGE) is the most widely used protein 
separation technique. SDS-PAGE separates denatured proteins migrating through a gel 
according to their polypeptide size.  
The protein samples are diluted and denatured in buffer containing the ionic detergent 
SDS, forming an imposed negatively charged complex and DTT which cleaves any 
disulphide bonds. Using a precast bis-tris gel of appropriate pore size, proteins migrate 
through a cross-linked polyacrylamide gel in response to an applied electrical field. The 
eletrophoretic mobility of SDS bound polypeptides will strictly depend on their 
molecular size, resulting in an effective separation with smaller molecules running 
faster than larger molecules. After separation by SDS-PAGE electrophoresis the 
migrated proteins are transferred from the gel matrix to a polyvinylidene fluoride 
(PVDF) membrane. During transfer, the proteins bind to this membrane, and are 
immobilised. For immuno-detection, protein-binding sites on the surface of the 
membrane are blocked by incubating with a protein-rich solution, in this case, fat-free 
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milk and the immobilised proteins are then readily accessible to a specific primary 
antibody. Primary antibody is then detected by a second antibody conjugated to 
horseradish peroxidase. A chemiluminescent substrate is then added, which allows the 
chemiluminescent reaction between the enzyme and the substrate to occur by emitting 
light. The emitted light is then detected using photographic film, followed by 
densitometric analysis. 
 
Western-blotting is often described as a semi-quantitative technique, with the amount of 
protein originally present in the samples proportional to the amount of peroxidase 
enzyme bound to the protein on the membrane, and so the amount of light generated 
and area together with intensity of the band present on the film. Routinely, western 
blotting samples were not protein assayed before loading, instead equivalent amounts of 
cells (based on equal coverage of tissue culture plastic) were lysed in equal amounts of 
buffer, and equal volumes were loaded. Usually, blotting with an antibody to 
glyceraldehyde 3-phosphate dehydrogenase (GAPDH), a house-keeping enzyme that 
catalyses the sixth step of glycolysis, was used to visually confirm comparable protein 
loading. 
 
2.3.2 Preparation of cell supernatants and lysates for western blotting 
 
Serum-deprived cells were washed twice with warm basal medium and incubated in a 
37°C, 5% CO2 incubator for the required time with and without growth factors (for 
SMC, these were 30ng/ml PDGF/BB, 30 ng/ml PDGF/AA and 30 ng/ml PDGF/BB and 
25 ng/ml basic FGF; for HUVECs 25 ng/ml VEGF was used). In some experiments, 
cells were preincubated for 30 mins with kinase inhibitors or STC-1 prior to growth 
factor treatment. 
 
After treatments, cells were washed twice with ice-cold phosphate-buffered saline 
(PBS) and immediately lysed in Cell Lysis Buffer (Cell Signaling Technology, Inc.) 
supplemented with 0.5 μl/ml   Protease   Inhibitor   Cocktail   and   Phosphatase   Inhibitor  
cocktails 1 & 2. Lysates were clarified by passage through a QIAshredder (Qiagen 
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Ltd.), and subsequently centrifuged (16 000 ×g, 4 °C, 10 min). Pellets were discarded 
and supernatants were stored at –80 °C until required for SDS PAGE. 
 
Cell culture supernatants were collected, and clarified by centrifugation (2860 ×g, 4 °C, 
10 min) to pellet the cell debris. Clarified supernatants were concentrated through an 
Amicon Ultra-4 Centrifugal Filter Device (Millipore Corp.). 
 
2.3.3 Deglycosylation 
 
STC-1 is N-glycosylated to varying degrees depending on the site of secretion. In 
certain experiments deglycosylation of STC-1 was performed to simplify the western 
blotting data. In these instances STC-1 was deglycosylated using 25500unit/µL Peptide-
N-Glycosidase F (PNGaseF) (New England Biolabs, Inc.) as previously described 
(Homes & Zachary 2008). 36 µl of concentrated supernatants were denatured with 1X 
Glycoprotein Denaturing Buffer at 100°C for 10 minutes. After the addition of 1% NP-
40 and G7 Reaction Buffer (50 mM sodium phosphate pH 7.5), two-fold dilutions of 
PNGase F were added and the reaction mix was incubated for 1 hour at 37°C.  
In other experiments, PNGase F was used in combination with chondoitinase ABC and 
heparinase to characterise in more detail the glycosylated forms produced by SMCs. 
Bacterially produced chondroitinase ABC (from Proteus vulgaris) and heparinase 
(Flavobacterium heparinum) are endolyases that catalyse the cleavage of 
glycosaminoglycan side chains from the proteoglycan core protein. Their primary 
substrates are chondroitin sulphate and heparan sulphate proteoglycan, respectively.  
 
Chondroitinase ABC (Sigma-Aldrich) was reconstituted in a buffer containing 0.01% 
w/v BSA and subsequently diluted into a buffer containing 50mM Tris, pH 8.0, with 60 
mM sodium acetate and 0.02% w/v BSA, and Heparinase I and III (heparitinase; Sigma) 
was prepared in a buffer containing 20 mM Tris-HCl, pH 7.5, containing 0.1mg/ml 
BSA and 4 mM CaCl2. The concentrated cell culture supernantants of the HCASMCs 
were treated with the enzymes by adding a final concentration of 1 unit per ml and then 
samples were incubated for 2 hours at 37°C. Samples were then analysed by SDS-
PAGE and immunoblotting.  
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Unit definition for chondroitinase: One unit will liberate 1.0 mmole of 2-acetamido-2-
deoxy-3-O-(b-D-gluc-4-enepyranosyluronic acid)-4-O-sulfo-D-galactose from 
chondroitin sulfate A or 1.0 mmole of 2-acetamido- 2-deoxy-3-O-(b-D-gluc-4-ene-
pyranosyluronic acid)-6-O-sulfo-D-galactose from chondroitin sulfate C per minute at 
pH 8.0 at 37 °C. 
 
2.3.4 SDS PAGE and Western blotting 
 
Proteins were separated by SDS–polyacrylamide gel electrophoresis in NuPAGE 4-12% 
Bis–Tris gels using MOPS running buffer systems (Life Technologies Ltd.). After 
electrophoresis,   proteins  were   then   transferred   to  0.45μm   Invitrolon  PVDF  membrane  
(Life Technologies Ltd.). Non-specific binding to the membrane was blocked by 
incubation in 5% w/v nonfat dried milk and 0.1% v/v Tween 20 in PBS with shaking at 
room temperature for one hour. Membranes were then incubated for either two hours at 
room temperature or overnight incubation at 4 °C with primary antibodies (see Table 
2.1) diluted in blocking solution. The membranes were washed three times each for 15 
mins with PBS-T and then incubated with the appropriate secondary antibody 
conjugated with horseradish peroxidase (at 1:10000 dilution). Immunodetection was 
visualised using chemiluminescent detection according to the manufacturers protocol 
(ECL Plus, GE Healthcare Plc). Blots were scanned and protein bands quantified by 
scanning densitometry of autoradiograms along with a calibration strip and analysed 
using ImageJ (National Institute of Health; http://rsbweb.nih.gov/ij/). Equal protein 
loading was assessed, with parallel samples with control antibodies to reference 
proteins, such as GAPDH and alpha Tubulin where appropriate. In addition, where 
protein phosphorylation was determined, the results are expressed as a ratio to the total 
(ie phosphorylated and unphosphorylated) protein for each sample.  
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Table 2.1 Antibodies used in this study 
Antibodies-
Target 
Host Dilutions Company 
STC-1 Goat 1:1000 R&D Systems 
STC-1 Chicken 1:800 Abcam Plc. 
Phospho-Akt 
(Ser 473) 
Rabbit 1:1000 Cell Signalling 
Technologies Inc. 
Akt Rabbit 1:1000 Cell Signalling 
Technologies Inc. 
Phospho-GSK-3α/β 
(Ser 21/9) 
Rabbit 1:1000 Cell Signalling 
Technologies Inc. 
p38 Mouse 1:1000 BD Transduction 
Labs. 
Phospho-p38 
(T180-Y182) 
Rabbit 1:1000 Cell Signalling 
Technologies Inc.. 
GAPDH 
V-18 
Goat 1:1000 Santa Cruz 
Biotechnology 
PDGFαR 
C-20 
Rabbit 1:1000 Santa Cruz 
Biotechnology 
Phospho-PDGFαR 
Tyr 745 
 
Goat 1:1000 Santa Cruz 
Biotechnology 
PDGFβR 
P-20 
Rabbit 1:1000 Santa Cruz 
Biotechnology 
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2.4 Small interfering RNA (siRNA) Transfection 
2.4.1  Principle of siRNA gene silencing 
RNA interference (RNAi) is a highly used technique applied to inhibit the expression or 
replication of specific mRNAs in a cell, therefore reducing the abundance of the protein, 
potentially blocking protein function. RNAi is a natural occurring cellular regulatory 
mechanism of controlling gene expression such as inhibiting the expression or 
replication of pathogenic double-stranded, dsRNA from certain viruses.  
In the RNAi response, an mRNA-targeted mechanism degrades mRNA using ds RNAs, 
which are processed into short, 21-23 nucleotide fragments, called small interfering 
RNAs (siRNAs) (Aagaard et al 2008). siRNAs are snipped from longer precursor 
dsRNA chains by an endonuclease called Dicer. The anti-sense strand of these siRNAs 
is then used by an RNA-induced silencing complex (RISC) through a base-pairing 
Phospho-PDGFβR 
Tyr 1021 
 
 
Rabbit 1:1000 Santa Cruz 
Biotechnology 
Phospho-PDGFαR  
(T849)/PDGFβR  
(T857) 
Rabbit 1:1000 Cell Signalling 
Technologies Inc. 
Alpha Tubulin Mouse 1:2000 Santa Cruz 
Biotechnology 
FAK Rabbit 1:500 Cell Signalling 
Technologies Inc. 
Phospho-FAK 
Tyr 407 
Rabbit 1:1000 Cell Signalling 
Technologies Inc. 
p130 Cas Mouse 1:1000 BD Transduction 
Labs. 
Phospho-p130 Cas 
(Tyr 410) 
Rabbit 1:1000 Cell Signalling 
Technologies Inc. 
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interaction, to guide mRNA cleavage, and promote mRNA degradation. For 
experimental purposes, this defence mechanism is deployed for the exogenous 
administration of synthetic dsRNAs, similar to Dicer products, which are engineered to 
precisely match the protein-encoding nucleotide sequence of the target mRNA.  
siRNAs do not readily cross the cellular membrane as result of their negative charge and 
size. Cellular delivery of siRNAs is usually achieved via complex formation with 
cationic liposome-like reagents such as oligofectamine or RNAiMAX, which are then 
released into the cytoplasm where they associate with RISC complex.   
 
2.4.2 Experimental details 
2.4.2.1 SMCs 
 
To explore what functional role STC-1 plays in SMC cells it was important to be able to 
effectively knock down STC-1 using targeted siRNAs. However, SMCs are relatively 
resistant to high efficiency transfection with siRNAs. Whilst nucleofection by 
eletroporation has been previously demonstrated to be an effective approach, which was 
previously used in this lab to investigate the role of critical genes such as Neuropilin 
1(NRP1) in SMCs (C. Pellet-Many, PhD Thesis 2010), obtaining a good STC-1 
knockdown in SMCs using this approach presented a difficult challenge.  
Initial experiments were performed using two different siRNAs as described below. 
Confluent cultures of HCASMCs were transfected using the Amaxa basic nuclefector 
kit for primary smooth muscle cells (Lonza). Briefly, the cells were plated at 
approximately 80% confluence and transfected on the following day using 100 nM final 
concentration of siRNA, non-target siRNA (# D-001810-01-05) and targeted STC-1-
specific siRNA (# J-006477-07) from Dharmacon, Silencer Pre-designed Neuropilin-1 
(NRP-1) siRNA (#4914), Silencer Negative Control #1 siRNA (Ambion Inc.) in 
nucleofection reagent solution provided with the kit. The cells were then incubated in 
SMC medium with 10% smooth muscle cell growth supplements for 24 h. Forty eight 
hours after transfection, cells were either harvested or rendered quiescent overnight 
prior to growth factor treatments. The major obstacle to using this approach was that for 
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STC-1 this method was able to achieve a reduction in STC-1 expression in some 
experiments, but other experiments produced inconsistent results. In addition, 
nucleofection also resulted in substantial levels of SMC cell death. 
Therefore, a new transfection reagent, siRNA duplex-Lipofectamine™   RNAiMAX  
(Life Technologies Ltd.) was tested and optimised for delivering STC-1 siRNA and the 
non-targetting control siRNA into SMCs. Optimisation consisted of using transfecting 
cells at low and high confluency and using two different RNAiMAX concentrations. 
Briefly, SMC cells were seeded in two 6-well plates and transfected when the cells 
reached   either   30%   or   80%   confluence,   according   to   the   manufacturer’s   protocol. 
siRNAs (20 μM)   were   diluted   in   250 μl   Opti-MEM I reduced serum medium (Opti-
MEM, Life Technologies Ltd) and mixed with either 2.5 or 5 μl  of  transfection  reagent  
pre-diluted in 250 μl   Opti-MEM. After 20 min incubation at room temperature, the 
complexes were added to the cells in a final volume of 2 ml medium. Cells were 
harvested after 48 hours.  
After 48 hours post transfection, the results showed that STC-1 expression was down-
regulated compared to the non-targeting control. Furthermore, the highest degree of 
STC-1 knockdown was achieved at the lower confluency (approx. 30%) and highest 
concentration of RNAiMAX. Thus, this optimized protocol, detailed below, was used in 
all subsequent experiments. 
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Figure 2.1: STC-1 gene knockdown mediated by two different applications 
A. HCASMC were transfected with STC-1 siRNA using nucleofection. Deglycosylated 
supernantant samples were analyzed by SDS-PAGE gels and western blots using chicken anti-
human STC-1 antibody. B. HCASMC at high and low confluences were transfected with siRNA 
using 2.5 and 5 µL Lipofectamine for up to 48 hr. Conditioned media from transfected cells 
were immunoblotted with goat anti-STC-1 antibody.  
 
 
 
 
 
 
B 
A 
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2.4.2.1.1 Procedure 
 
Target genes of interest were downregulated using pre-designed duplex siRNAs from 
Dharmacon or Ambion as detailed in Table 2.2. Non-targeting, negative control #1 
siRNA (Ambion) was used to control for the non-specific effects of siRNA transfection. 
 
siRNA transfection was performed using siRNA duplex-Lipofectamine™  
RNAiMAXand the cells were transfected at approximately 30% confluency. siRNA 
(20 μM)  were  diluted   in  250 μl  Opti-MEM I reduced serum medium  and mixed with 
5 μl  of  RNAiMAX  pre-diluted in 250 μl  Opti-MEM. After 20 min incubation at room 
temperature, the complexes were added to the cells in a final volume of 2 ml medium. 
Cells were harvested after 48 hr and the knockdowns were confirmed by western 
blotting, using appropriate antibodies.  
 
2.4.2.2 HUVECs 
Confluent HUVECs in 6-well plate were transfected using oligofectamine (Life 
Technologies Ltd). Briefly, siRNAs were diluted in warm Opti-MEM I, then incubated 
with 5% v/v oligofectamine for 25 mins to allow the siRNA/oligofectamine complex 
formation. Cells were washed with Opti-MEM and incubated for 4 hours with 
siRNA/oligofectamine/Opti-MEM   solution   (final   siRNA   concentration   200μM,  
1ml/well).  After 4 hr, the medium was adjusted to 10% v/v FBS and the following day 
changed to EGM. For functional studies, knockdown was assessed by lysing the 
fraction of unused parallel cultures of transfected cells in that particular experiment and 
analyzing these lysates via western blotting. 
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Table 2.2: Nucleotide catalogue number of siRNAs used in this study 
Target Catalogue Number Company 
Non-Target (NT) 1027281 Qiagen 
STC-1 J-006477-07 Dharmacon 
PDGFR 4392420 Ambion 
PDGFR 4390824 Ambion 
PKC AM51323 Ambion 
NRP1 4914 Ambion 
 
2.5 Polymerase Chain Reaction 
2.5.1 Principle of PCR  
Polymerase Chain Reaction (PCR) is an accurate, reliable molecular biology technique 
for the amplification of a single or a few copies of a piece of DNA across several orders 
of magnitude, generating many copies of an identical sequence of DNA. The starting 
material may be genomic DNA, RNA, cloned DNA or forensic samples.  
 
The technique uses a heat-stable DNA polymerase, such as Taq polymerase, an enzyme 
originally isolated from the bacterium Thermus aquaticus, to enzymatically synthesize a 
complementary DNA sequence from nucleotides, by using single-stranded DNA as a 
template, and primers. Primers are DNA oligonucleotides, which are required for 
initiation of DNA synthesis because they prime the DNA sample ready for the 
polymerase to bind and begin to copy. This enables the polymerase to selectively 
amplify the DNA sequence of interest.  
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During PCR, thermal cycling is employed with alternate and rapid heating and cooling 
of the PCR sample to a defined series of temperatures. These changes in temperature are 
used to control the activity of the polymerase and the binding of primers. Initiation of 
the PCR reaction occurs at high temperature such as 95°C where all double helix 
stranded  DNAs  are  “melted”  into  single  strands.  At  a  lower  temperature,  each  strand  is  
then allowed to hybridise with the complementary primers, followed by DNA 
enzymatic extension using DNA polymerase to selectively amplify the target DNA 
(called reverse transcription where RNA is used as the starting material). The selectivity 
of PCR results from the use of primers that are complementary to the DNA region 
targeted for amplification under specific thermal cycling conditions. Successive cycles 
will thus generate an exponentially increased number of DNA fragments, which can be 
visualized directly using agorose gel eletrophoresis followed by ethidium bromide 
staining. 
 
2.5.2 Principle of RT-PCR 
Quantitative real-time polymerase chain reaction (QRT-PCR or Q-PCR) is a modified 
form of the standard PCR technique that allows the monitoring of the accumulated PCR 
products in real time. Providing that the PCR reaction is proceeding exponentially (ie. 
neither the primers, nucleotides or Taq is limiting the rate of reaction) there is a 
quantitative relationship between amount of starting target sequence and amount of 
PCR product. The accumulation of PCR products is quantified by use of an integral 
fluorescent reporter molecule. The fluorescence emitted by the reporter molecule 
increases as the enzyme-catalysed DNA synthesis accumulates with each cycle of 
amplification.  
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Figure 2.2: Schematic presentation of the reverse transcription reaction 
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A commonly used reporter molecule is SYBR-Green, a dye that binds to the minor 
groove of double-stranded DNA but not to single-stranded DNA, and upon excitation 
emits light. Thus, as a PCR product accumulates, fluorescence also increases. SYBR 
Green has the advantage of being relatively inexpensive, easy to use, and sensitive.  
2.5.3  Experimental details 
Total RNA was purified from SMCs treated with 30ng/ml PDGF-BB or vehicle for 
indicated times and purified using the RNeasy mini kit (Qiagen) according to the 
manufacturer’s   instructions.   During   purification, RNA was digested with RNase-free 
DNase I (Qiagen) eradicating any residual genomic DNA. The DNase I was removed in 
a subsequent wash step, then, single-stranded complementary DNA (cDNA) was 
selectively synthesised from 2 μg  of   total  mRNA  with  oligo(dT)12–18 primer using the 
Superscript II first-strand synthesis system for RT-PCR (Life Technologies Ltd) 
according  to  manufacturer’s  instructions.   
The relative quantity of STC-1 and control gene GAPDH mRNA in each sample was 
determined using cDNA template with the Light Cycler-FastStart DNA Master SYBR 
Green   I   kit   (Roche   Diagnostics)   and   the   following   conditions:   2  min   incubation   at  
50  °C,  pre-denaturation  at  95  °C  for  10  min,  followed  by  40  cycles  of  95  °C,  15  s;;  and  
60  °C,  1  min.  The  primers  used  in this application are detailed in the Table 2.3. RT-PCR 
analyses were performed in duplicate for each sample using RNA preparations from at 
least three independent experiments.  
2.5.4  Agarose gel electrophoresis  
 
To confirm that the primers used in the QRT-PCR for stc and gapdh genes were specific 
and produced the PCR products of the correct size, the amplified PCR products were 
run on an agarose gel. PCR products were mixed with 6x loading buffer (Fermentas; 
final concentration 1x) and run at 120V on a 1% agarose gel containing 200ng/ml 
ethidium bromide, using TAE running buffer (40mM tris-acetate, pH 8.3, 1mM EDTA). 
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Table 2.3 Nucleotide sequences of STC-1 and GAPDH entry primers 
 
 
Gene 
 
Template 
Product length 
(PL) 
 
Oligo Name (length) 
 
Sequence  (5’3’) 
NM_003155.2 2008...........2028 
PL=236 
Forward STC-1 (21) GAGACAGGAAAAACC
AACAGG 
 2243...........2223 Reverce STC-1 (21) GATGAAAGGGGACGA
GTAAAG 
NM_002046.3 822...............841 
PL=251 
Forward GAPDH (20) GTCAGTGGTGGACCTG
ACCT 
 1072...........1053 Reverce GAPDH (20) CCCTGTTGCTGTAGCC
AAAT 
 
 
 
The sizes of PCR products were determined by comparison with a DNA molecular 
weight marker (100 bp ladder; Fermentas), which contains DNA fragments of known 
size, run on the gel alongside the PCR products. Following electrophoresis the gel was 
viewed and photographed under ultraviolet light. Figure 2.3 shows the size of the 
primers products obtained for the QRT-PCR reaction. Analysis of the gel and showed 
that both primers produced a single product corresponding to to their expected 
molecular weights, with the STC-1 cDNA product being around 236 bp and GAPDH at 
around 251 bp. No other non-specific bands were observed in the negative control lanes 
(lacking template cDNA). 
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Figure 2.3 Ethidium bromide-stained PCR products after agarose gel electrophoresis of the 
DNA fragments amplified from the cDNA of the samples used in RT-PCR reactions, using 
STC-1 and GAPDH primers. PCR products were analysed in 2% agarose TBE electrophoresis 
gels with negative control samples representing the PCR reaction carried out without cDNA 
template (–VE;). The gel also shows a DNA ladder and the DNA bands in the STC-1 and 
GAPDH lanes indicate successful amplification of the target DNA fragments of expected 
length. The gel shown is representative of the results obtained from two independent 
experiments. 
 
 
2.6 Enzyme-linked immunosorbent assay (ELISA) for STC-1 
2.6.1 Principle of ELISA 
Enzyme-linked immunosorbent assay (ELISA) is a plate-based assay designed for 
detecting and quantitatively evaluating the presence of substances such as peptides, 
proteins, antibodies and hormones. In an ELISA, an antigen is immobilized to a solid 
surface or a primary antibody coated on the surface and then complexed with an 
antibody that is linked to a reporter-enzyme. Detection is accomplished by assessing the 
conjugated enzyme activity via incubation with a substrate to produce a measurable 
product. The most crucial element of the detection strategy is a highly specific antibody-
antigen interaction. 
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2.6.2 Experimental details 
 
Quiescent HCASMCs were treated with or without 30ng/ml PDGF-BB, and cell culture 
supernatants were concentrated by filter centrifugation (as detailed in 2.3.2) prior to use 
of the duoset Elisa (R&D, Systems). For quantification of hSTC-1 in serum-free 
medium, 96-well microplates (C8 Maxisorp 445101, Nunc) were coated overnight at 
room temperature (RT) with 1.6 µg/ml capture antibody, goat anti-human STC-1 in 
PBS without carrier protein (R&D, Systems). The following day, each well was washed 
three times with washing buffer (0.05% v/v Tween 20, pH 7.2-7.4) and blocked with 
300 µl 1% v/v BSA in PBS (reagent diluent, pH 7.2-7.4) for 1 hour at RT. After 
washing  cells three times, 100 µl diluted supernantants were applied to duplicate wells 
after being diluted with reagent diluent. A standard curve was set up using 100 µl of the 
purified recombinant human STC-1 (0–4 ng/ml) in reagent diluent. The plates were 
incubated for 2 h at RT followed by washing three times and application of 100 µl of 
200ng/ml biotinylated detection goat anti-human STC-1 antibody (R&D, Systems) for 
2 h at RT. After washing three times, 100 µl of 1:200 diluted streptavidin conjugated to 
horseradish peroxidase was added, and further incubated for 20 minutes at RT. The 
Substrate solution (a 1:1 mixture of color reagent A, H2O2 and reagent B, containing 
tetramethylbenzidine; R&D Systems) was applied and plates were incubated at RT in 
the dark. The reaction was stopped after 15–20 min with 50 µl of 2 M H2SO4 and 
absorbance was immediately measured in a Tecan Magellan microplate reader at 
450 nm against a reference wavelength of 560 nm. 
2.7  Adenovirus Infection 
 
To examine the effect of STC-1 over-expression on smooth muscle and endothelial cell 
function, an adenovirus (Ad) expressing wild type STC-1 (Ad.STC-1) was used 
together with a control adenovirus, expressing lac Z (Ad.lacZ). The wild type STC-1 
and lac Z expressing adenoviruses were kindly provided from Dr David Holmes and 
some details of adenovirus production are given below. 
Adenoviruses are highly useful vehicles for delivering genes or DNA constructs to cells, 
permitting analysis of the signaling pathways and/or cell function involved in the 
 91 
 
overproduction of protein of choice on these cells. Adenoviruses are non-enveloped 
double-stranded DNA viruses whose capsid is mainly composed of pentons (penton 
base and fibre monomers) and hexons. The viral infection begins with the attachment of 
the fibre proteins to a cellular receptor named CAR (for coxsackievirus and adenovirus 
receptor) (Benihoud, Yeh, & Perricaudet, 1999), followed by the interaction of the 
penton base   with   αvβ3   and   αvβ5   proteins   belonging   to   the   Integrin   family.   After  
adenoviral internalisation through receptor-mediated endocytosis, the virus escapes 
from the early endosomal compartment and is transported into the nucleus where viral 
transcription and replication initiates. The adenovirus genome is extra-chromosomally 
expressed without integration into the host cell genome.  
Once inside the nucleus, adenoviral genes are expressed in two distinct phases, early 
and late, by viral DNA replication. The early phase is responsible for early (E1) genes 
expression coding for regulatory proteins required for replication of viral genome and 
later gene expression. Assembly of viral components followed by completion of the 
virus cycle subsequently triggers host cell death and the release of virion progeny 
(Russell, 2000). In this thesis, replication-defective adenoviral vectors are used, which 
are unable to produce additional viral particles to infect other cells since the E1 and E3  
genes have been deleted.  The expression level of the DNA sequence of interest in the 
adenovirus is under the control of host transcription machinery and initially increases 
over time before decreasing as the viral genome is diluted by cell division.  
2.7.1  Adenoviral Gateway® cloning systems and vectors 
 
Adenoviral systems are now popular platforms for reliable gene delivery and high-level 
transient expression in any mammalian cell type.  Adenoviral Gateway® Technology is 
a fast, easy, and accurate cloning strategy allowing a DNA fragment to be inserted into 
a universal entry vector (pENTR/D-TOPO) and then rapidly transferred into pre-
designed destination vectors (Fig. 2.4).  
 
Linear pENTR/D-TOPO vector has a four nucleotide overhang conjugated to a 
topoisomerase I from Vaccinia virus which allows the ligation and insertion of 5’  
CACC blunt-end PCR products (desired gene insert) into the plasmid. The vector also 
contains a kanamycin resistance gene for selection of positive transformants. Use of this 
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system allows the relocation of a sequence of interest at any destination vector via 
recombinational cloning between attL1/L2 sites in entry vector and the attLR1/R2 sites 
in the destination vector which are ampicillin selected. 
 
pAd/CMV/V5-DESTTM (36.7 kb) is a destination vector that can express high levels of 
the gene of interest in essentially any mammalian cell type, producing replication-
incompetent E1- and E3- deleted Ad5 adenoviral particles when transfected into the 
293A Cell Line. The 293A Cell Line facilitates the initial production, amplification, and 
titering of replication-incompetent adenoviruses. The 293A cells contain a stably 
integrated copy of the E1 gene that supplies the E1 proteins (E1a and E1b) required to 
generate recombinant adenovirus where the gene of interest is driven by immediate 
early human cytomegalovirus (CMV) promoter for high-level constitutive expression.  
The control plasmid, pAd/CMV/V5-GW/lacZ, is included for use as a positive 
expression control in the mammalian cell line of choice. 
 
 
 
 
 
 
 
 
 
Figure 2.4: Adenoviral Gateway® cloning vectors 
Schematic illustration of entry and destination vectors used in STC-1 adenoviral production 
from the Invitrogen Gateway® Technology manuals. 
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2.8  Cell migration assay 
2.8.1  Assay principle 
Transwell migration is commonly used to study migration of cells towards a 
chemoattractant. It was originally introduced for the analysis of leukocyte chemotaxis 
(Boyden 1962). The Transwell consists of two medium filled chambers separated by a 
microporous membrane. The upper chamber, a cylindrical cell culture insert, contains a 
polycarbonate membrane at the bottom with a defined pore size (in these experiments a 
pore size of 8 µm was used). Cells are seeded in the upper compartment in the serum-
free media, while chemoattractant are placed in the chamber below. Migratory cells 
therefore move through the pores toward the chemoattractant in the other chamber. The 
number of cells that have migrated to the lower side of the membrane is determined 
after removing non-migrated cells (on the upper surface of the membrane) by staining 
the membrane and then counting migrated cells under a microscope. 
 
2.8.2  Procedure 
 
Confluent HUVECs/HCASMCs were trypsinised and resuspended in serum-free media 
at 3x 105/3x 104 cells/ml respectively. In some experiments, prior to seeding, cells were 
incubated at this stage for 30 mins in the presence of 100ng/ml hrSTC-1 with agitation 
every 5-10 mins. 
 
Cells culture inserts (8m membrane pore size, 6.4mm diameter, Falcon Becton 
Dickinson) were inserted into a 24-well plate and in the lower chamber, 750 l serum-
free media with or without 25ng/ml VEGF/ 30ng/ml PDGF (for HUVECs/HCASMCs 
respectively) was added. Cell suspensions (500 µl) were added to the upper chamber 
and the Transwell was incubated at 37C for 4 hr.  Cells that have not migrated were 
scrapped from the upper side of the membrane using a cotton bud, and the cells on the 
lower side of the membrane were fixed and stained with the Reastain Quick Diff kit 
(Reagena). Nuclei of migrated cells were counted in four fields using an eyepiece 
indexed graticule at 100x magnification. The mean of four counts per insert was used as 
the count for each sample or insert. 
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2.9  Tubulogenesis co-culture assay 
 
In vitro angiogenesis was determined by using a co-culture tubulogenesis assay (Friis et 
al., 2003). Briefly, human dermal fibroblasts (HDF) were plated out in 24-well plates 
and grown until confluent in M106 medium. HUVECs were incubated for 48 h with 
adenovirus expressing either STC-1 of LacZ at a multiplicity of infection (MOI) of 20. 
HUVECs were then trypsinised and resuspended at 2 x 105 cells/ml in EBM plus 1% 
FBS. The M106 medium on the HDFs was replaced with 0.5 ml EBM plus 0.5% FBS 
and  25 ng/ml VEGF. Finally, 1x104 HUVECs (50 µl cell suspension) were added to 
each well. HUVECs and fibroblasts were propagated in co-culture for 7 days at 37°C 
and 5% CO2 incubator with the medium being changed after 3 days. After 1 week 
incubation, the medium was removed, clarified by centrifugation and stored at –20 °C 
for later analysis of STC-1 levels by Western blotting. Tube formation was visualised 
by staining for von Willebrand factor using the following method. All incubation steps 
were performed at room temperature and with gentle agitation. Cells were fixed in 
absolute ethanol for 2 hours, followed by washing twice with PBS-T and blocking with 
5% milk in PBS-T for 30 min. Cells were then incubated with an antibody to 
von Willebrand factor  (Abcam), diluted 1 in 1000 in PBS-Tween 20 with 5% milk for 1 
h. After washing with PBS-T, bound antibody was detected with a 
biotinylated secondary antibody (Chemicon,) diluted 1 in 2000 in PBS-T and incubated 
for 30 min. Avidin-Biotin complexes were formed using the ABC reagent 
(Vector Laboratories),   following   manufacturer’s   protocol   and   staining   was   finally  
visualized with diaminobenzidine (Sigma). Tube formation was imaged using a Leica 
stereomicroscope and four representative fields were captured for each well. Images 
were analyzed using the Angiosys software package (TCS Cellworks; 
http://www.tcscellworks.co.uk/pricing_ordering/product_detail.php?CI_ID=13) that 
measures average tube length, total tube length, number of tubes and the number of 
branch points.  
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2.10  Cell viability (XTT) assay 
2.10.1  Assay principle 
The XTT cell proliferation assay is an effective method to measure cell growth, viability 
and cytotoxicity. Tetrazolium salt, (XTT) a colourless or slightly yellow compound is 
reduced in metabolically active cells via mitochondrial dehydrogenase, to produce the 
bright orange coloured formazan dye. The formation of formazan can be quantified 
spectrophotometrically and the amount of dye produced directly correlates to the 
number of metabolically active cells present. Actively proliferating cells increase their 
metabolic activity while cells exposed to toxins such as hydrogen peroxide (H2O2) will 
have decreased activity. H2O2 is formed in the eukaryotic cell as a by-product of various 
oxidases and superoxide dismutases. Hydrogen peroxide accumulation in cells causes 
oxidative damage like oxidation of cellular targets such as DNA, proteins, and lipids 
leading to mutagenesis and cell death.  
2.10.2  Procedure 
 
HCASMCs (1.5 x103 cells/100 μl)  were  seeded  in  a  96-well plate and transfected with 
negative control, STC-1 siRNA or mock (no siRNA) using the Lipofectamine 
RNAiMax protocol (Section 2.4.2.1.1) for 48 hr and incubated 24hr in basal medium. 
The following day, cells were washed and treated with and without 30ng/ml PDGF-BB 
for 1hr and hydrogen peroxide for 24hr. Medium used for 24hr incubation were saved to 
assess STC-1   knockdown.   The   following   day,   50μl   of   XTT   reagent   (sodium   3'-[1-
(phenylaminocarbonyl)-3,4-tetrazolium]-bis(4-methoxy-6-nitro) benzene sulphonic acid 
hydrate) was added to each well/medium. The absorbance of the formazan product, 
reflecting cell viability, was measured at 490 nm. Each assay was performed in 
duplicate. A similar procedure was followed for the treatment of cells with recombinant 
STC-1 using the same reagents.  
 
2.11  Statistical analysis  
 
All results are reported as the means ± SEM of at least three independent experiments, 
unless otherwise indicated. Statistical analysis was performedusing Prism (GraphPad) 
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either by one or two-way  ANOVA  as   appropriate,  with  Bonferroni’s   test   for  multiple  
comparison of the differences between groups and the value of p < 0.05 was considered 
to be statistically significant. 
Each graph is presented data mean with error bars representing the standard error of the 
mean (SEM) unless otherwise stated on the text. 
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Chapter 3 
 
  
 
 
 
3 Results: Effect of STC-1 on Endothelial 
Cell function 
 
Genome-wide analysis of VEGF-induced gene expression in HUVECs led to 
identification of STC-1 as a VEGF-responsive gene (D. Liu et al., 2003). Further work 
in this laboratory explored in more detail STC-1 induction in endothelial cells and 
showed that VEGF and FGF synergistically upregulated STC-1 mRNA and protein 
expression. This was found to be mediated by the PKC and ERK pathways (Holmes & 
Zachary, 2008). This and other findings discussed in the introduction, led to the 
suggestion that regulation of this factor may be a key feature of the angiogenic response 
to VEGF and possibly other angiogenic cytokines. However the role of VEGF-induced 
STC-1 gene expression in the endothelium specifically or the vasculature in general is 
still not fully known. Before I began my PhD, limited pilot work had been performed 
examining the effects of recombinant STC-1 on endothelial cell proliferation and 
migration, and had not revealed any significant effects (unpublished results). However, 
since these were pilot experiments, at the start of my PhD, I examined effects of STC-1 
in endothelial cells in more detail using recombinant human STC-1 (rhSTC-1), and by 
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adenoviral overexpression of STC, and by targeted knockdown of STC-1. 
3.1 Induction of STC-1 by VEGF-A 
 
As previously identified, the angiogenic cytokine, VEGF, is able to induce STC-1 
expression. To confirm the STC-1 upregulation in response to VEGF treatment in 
HUVECs, concentrated media from HUVECs incubated with or without 25 ng/ml 
VEGF for 24 hours were prepared for immunoblotting. Analysis of western blots 
showed, as expected, a strong increase in expression of STC-1 protein migrating as a 
major band of ~35 kDa in HUVECs, in agreement with previously published data from 
this laboratory (Holmes and Zachary 2008). A representative blot obtained from these 
experiments is shown in Figure 3.1. 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: STC-1 upregulation by VEGF 
Confluent, serum-deprived HUVECs were treated with 25ng/ml VEGF (VE) or no addition (C) 
for 24 hours. The conditioned medium was clarified by centrifugation, concentrated and 
analysed by western blotting using antibodies to STC-1 and GAPDH. The blot shown is 
representative of three independent experiments yielding similar results. 
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3.2 Role of STC-1 in VEGF-stimulated cell migration 
 
Given the evidence suggesting a role for STC-1 in angiogenesis, I explored whether 
STC-1 could affect VEGF-mediated migration. The role of STC-1 in the migratory 
response of HUVECs towards VEGF was examined by the pre-treatment of cells for 30 
min with different concentrations of recombinant STC-1. Treatment with STC-1 alone 
for 4 hours at concentrations of 1 to 100 ng/ml showed no effect on migration of 
HUVECs (Fig.3.2). Stimulation of HUVECs with VEGF alone resulted in a near 6-fold 
increase in migration compared to the control (no VEGF) (Fig. 3.2). Pre-treatment of 
HUVECs with up to 50 ng/ml hrSTC-1 had no effect on VEGF-induced migration. In 
contrast however, pre-treatment with 100 ng/ml hrSTC-1 significantly decreased 
endothelial migration by approximately 40% compared to the effect of VEGF alone  
(Fig 3.2).  
 
3.3 Analysis of recombinant STC-1 on VEGF-induced signalling 
 
The inhibitory effect of 100ng/ml hrSTC-1 on VEGF-dependent migration, led me to 
examine the role of STC-1 on VEGF-stimulated signalling pathways.  HUVECS were 
pre-treated with two different concentrations of hrSTC-1 (50 and 100ng/ml) followed 
by stimulation for 10 minutes with VEGF (25 ng/ml) or no addition. Whole-cell lysates 
were prepared and immunoblotted to determine the activation states of several 
important signalling molecules involved in VEGF downstream signalling such as Akt, 
p38 kinase, FAK, p130 Cas and ERK1/2 (Fig 3.3).  
In several initial experiments, no apparent effect was observed in response to hrSTC-1 
treatment on different VEGF-induced downstream signalling pathways. It was noted 
that while VEGF increased activity of ERK1/2, Akt and p38kinase, I was unable to 
observe increases in p130Cas or FAK Y407 phosphorylation (Fig. 3.3). 
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Figure 3.2:  Effect of hrSTC-1 on HUVEC migration in response to VEGF-A165 
HUVEC cells were pre-incubated in suspension in serum free medium with hrSTC-1 for 30 
minutes at the indicated concentrations and then transferred into transwell migration assay 
chambers. Migration of the cells towards 25ng/ml VEGF (V) or no addition (serum free) was 
assessed after incubation at 37°C for 4 hours. The cells that had migrated were fixed, stained 
and counted. Photographs of representative transwell membranes are presented above. Results 
are shown as means ± SEM from three independent experiments (below), analysed by two-way 
ANOVA with Bonferroni’s test. ** P=0.001 compared to control (0), and * P=0.01 versus 
100ng/ml hrSTC-1 treatment. 
  ** 
hrSTC-1 (ng/ml) 
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Figure 3.3 Effect of STC-1 on VEGF stimulation of signalling pathways. 
Confluent, serum-deprived HUVECs were pretreated for 30 mins with the indicated 
concentrations (ng/ml) of hrSTC-1. Cells were then treated with 25 ng/ml VEGF (VE) or 
received no addition (C) for 10 mins followed by lysis and immunoblotting with the indicated 
antibodies. Results are representative of at least two independent experiments yielding similar 
results.
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3.4 Adenovirus mediated overexpression of STC-1 in HUVECs  
 
Incubating HUVECs with hrSTC-1 show how these cells respond to exogenous STC-1. 
However endothelial cells express significant amounts of STC-1 and I hypothesised that 
STC-1 may therefore have an autocrine effect, which cannot be mimicked by addition 
of exogenous STC-1. It is also possible that the hrSTC-1 used in my initial studies was 
not processed or post-translationally modified in ways that are important for its 
biological function. In order to investigate these possibilities, adenoviral infection of 
HUVECs was used to overexpress STC-1. To look at the levels of STC-1 in the cells 
and its secretion into the medium, two different multiplicities of infection (MOI) were 
used based on the viral titres. Confluent HUVECs were infected with adenoviruses 
expressing either STC-1 (Ad.STC-1) or the control gene, Lac Z (Ad.Lac Z), at MOIs of 
5 and 10. 48 hours after infection, the medium and cell lysates were immunoblotted for 
STC-1. The results, shown in Figure 3.4, show that STC-1 immunoreactive bands were 
strongly expressed in both the cells and the medium from Ad.STC-1-infected cells as 
compared with Ad.Lac Z-infected cells. The major bands sprecifically increased in 
medium from Ad.STC-1-infected cells were ~35, ~60 and ~80 kDa. The major 35kDa 
band is similar to that previously reported in this laboratory for endogenous STC-1 
(Holmes and Zachary 2008). It was decided that MOI of 10 would be used for further 
experiments.  
3.4.1 Effect of STC-1 overexpression on VEGF-stimulated migration and 
signalling 
I initially investigated whether STC-1 adenoviral overexpression could have any effect 
on endothelial cell migration. HUVECS were infected with either Ad.STC-1 or Ad.Lac 
Z at a MOI of 10 for 48 hours, and their migration towards VEGF was assessed in a 
transwell assay. Infection of endothelial cells with Ad.STC-1 adenovirus at MOI of 10 
significantly increased the STC-1 levels secreted in media a compared to control cells 
infected with Ad.Lac Z (data not shown) but did not significantly alter VEGF-induced 
HUVEC migration (Fig 3.5). It was also noted that adenoviral infection in itself had a 
slight effect on the basal level of HUVECs migration in the absence of VEGF 
stimulation (Fig 3.5).  
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Figure 3.4 Effect of adenovirus-mediated overexpression of STC-1 in HUVEC 
HUVECs were infected with the indicated adenovirus for 48hr at MOI of 5 and 10. Serum-
starved cells were then incubated for 4hr. Concentrated supernantant medium and lysed cells 
samples of uninfected (UI) and infected cells with indicated adenoviruses were immunoblotted 
with STC-1 antibodies. 
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Figure 3.5: Effect of adenovirus-mediated overexpression of STC-1 on migration 
HUVECs were either uninfected (SF), or infected with Ad.Lac Z (LZ) or Ad.STC-1 for 48 hr 
at an MOI of 10. Migration was then assessed in a transwell assay towards 25ng/mL VEGF  
(V) or no addition (C) after 4 hr treatment, after which the migrated cells were fixed, stained 
and counted. Results are means ± SEM from three independent experiments and were 
analysed by two-way  ANOVA,  with  Bonferroni’s  test  for  multiple  pair-wise comparisons. No 
significant differences were observed between Ad.Lac Z and Ad.STC-1 infected cells in 
response to VEGF treatment. 
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Despite the lack of effect on migration, I next investigated the role of adenovirus-
mediated STC-1 overexpression on VEGF stimulated signalling. HUVECs were 
infected with Ad.STC-1 or Ad.Lac Z for 48 hrs. Cells were then serum starved 
overnight and treated with and without VEGF for 10 mins. Cells were lysed and western 
blot analysis was performed.  As expected, VEGF treatment resulted in increased 
phosphorylation of P38 MAP kinase and ERK1/2 (Fig. 3.6). Akt phosphorylation was 
increased by VEGF in the absence of adenovirus, but it was noted that both Ad.LacZ 
and Ad.STC-1 both enhanced Akt phsophorylation regardless of VEGF stimulation. 
This is likely to represent a non-specific effect of viral infection on HUVECs and 
similar results have been obtained by other colleagues in the lab. Curiously, p130Cas 
and FAK phosphorylation levels were largely unaffected by VEGF stimulation even in 
the absence of viral infection, although basal levels of phsophorylation were relatively 
high. Most importantly, there was no indication that STC-1 overexpression had any 
effect on either the VEGF-stimulated or basal levels of phosphorylation of any of the 
proteins examined (Fig. 3.6). 
 
3.4.2 Effect of STC-1 overexpression in VEGF-stimulated tubulogenesis 
 
The co-culture tubulogenesis assay is used as an in vitro model of angiogenesis. A 
monolayer of fibroblasts together with stimulation by VEGF provides a model of 
interactions between endothelial cells and stromal cells that at least partially mimicks 
the microenvironment in which sprouting angiogenesis occurs in vivo. This assay was 
used to determine whether overexpression of STC-1, using Ad.STC-1 infection, had any 
effect on the abilty of HUVECs to form tube like structures. Both uninfected HUVECs, 
and cells infected with Ad.STC-1 virus showed an extended network of endothelial cell 
tubules after 7- to 10-days culture in the presence of VEGF, whereas cells cultured 
without VEGF showed little or no tubulogenesis (Fig. 3.7A, B). It was confirmed that 
infection with Ad.STC-1 resulted in a sustained increase in secreted STC-1 throughout 
the assay period from 1 to 7 days, and that VEGF also increased STC-1 protein 
expression after 7 days adenoviral infection in ininfected, Ad.LacZ-infected and 
Ad.STC-1-infected cells (Fig 3.7C). It was difficult to see VEGF-stimulated STC-1 
expression in day 1 cultures, because of the difficulty in exposing the gel long enough  
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Figure 3.6: Effect of adenovirus-mediated overexpression of STC-1 on phosphorylation of 
VEGF- induced signalling 
HUVECs were infected with the indicated adenovirus for 48hr at MOI of 10. Serum-starved 
cells were then treated with (+) or without (-) 25 ng/ml VEGF for 10 mins followed by lysis and 
immunoblotting with the indicated antibodies. Results are representative of at least two 
independent experiments. 
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due to very high STC-1 expression in Ad.STC-1-infected cells (Fig. 3.7C). There was a 
trend for VEGF treatment of Ad.STC-1-infected cells to have increased numbers of 
branch points and total tube length compared to uninfected and Ad.Lac Z infected cells, 
however this was not statistically significant. Furthermore, cells infected with Ad.Lac Z 
exhibited generally elevated and variable basal levels of tube formation in the absence 
of VEGF. Thus the mean number of branch points and total tube length in Ad.LacZ-
infected cells was similar with or without VEGF treatment and similar to that found in 
non-infected cells after VEGF stimulation. This made it difficult to interpret the effect 
of Ad.STC-1 overexpression in this assay. The reason for the high level of tube 
formation in the Ad.Lac Z treated cells in the absence of growth factor is unknown, but 
it is unlikely to be an effect of virus infection since Ad.STC-1 treated cells behaved in a 
similar manner to uninfected cells without VEGF.  
 
3.5 STC-1 knockdown and endothelial migration  
 
The results from experiments using Ad.STC-1 overexpression indicated that adenovirus 
mediated STC-1 expression had no significant effect on VEGF-stimulated migration 
when compared to that observed with Ad.Lac Z control. This may indicate that 
endogenous levels of STC-1 are sufficient to maximally drive endothelial migration. 
We therefore determined whether reducing endogenous STC-1 production by siRNA 
mediated knockdown could have any effect on endothelial cell migration. 
Representative blots demonstrating effective knockdown of STC-1 are shown in Figure 
3.8A. A trend was observed for knockdown of STC-1 to modestly reduce VEGF-
stimulated HUVEC migration, but this effect did not reach statistical significance (Fig 
3.8B).  
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Figure 3.7: Effect of adenovirus overexpression of STC-1 in a VEGF-mediated angiogenic 
coculture assay                                                                   
                                                                                                                      continued  over…….. 
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Figure 3.7: Effect of adenovirus overexpression of STC-1 in a VEGF-mediated angiogenic 
coculture assay  
Human dermal fibroblasts were grown in 24-well plates to confluence. HUVECs were infected 
with either Ad.Lac Z or Ad.STC-1 at MOIs of 10 or no virus (UI) for 48 hr. Trypsinised 
HUVECs were then seeded (10,000 cells per well) on top of the fibroblast cell layer. Cell co-
cultures were then maintained for 7 days in the presence of EBM plus 0.5% serum alone (C) or 
EBM plus 0.5% serum and 25ng/ ml VEGF (VE). During the period of the assay, the medium 
was removed every 3 days and replaced with fresh EBM plus 0.5% FBS  VEGF. The removed 
medium was clarified by centrifugation and used to assess secreted STC-1 levels by 
immunoblotting. Endothelial cells were then visualized by immunostaining for von Willebrand 
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factor  (vWF). (A) VEGF induces tube formation in co-culture. Representative results are 
presented showing that VEGF (25 ng/ml) induces extensive tube formation in the co-culture 
model using non-infected endothelial cells (right hand panel) compared to cells cultured in the 
absence of VEGF (left hand panel). (B) Representative pictures of vWF-stained HUVECS after 
7 days in co-culture. The top two panels show non-infected HUVECs in the absence (left hand 
panel) or presence (right hand panel) of 25 ng/ml VEGF. The middle two panels show Ad.Lac Z 
infected HUVECs in the absence (left hand panel) or presence (right hand panel) of 25 ng/ml 
VEGF. The lower two panels show Ad.STC-1 infected HUVECs in the absence (left hand 
panel) or presence (right hand panel) of 25 ng/ml VEGF. (C) Ad.STC-1 results in increased 
STC-1 expression in the medium throughout the period of the assay. Media was collected 
during the periodic media changes, clarified by centrifugation and immunoblotted for STC-1. 
The figure is representative of media from three different assays. (D) Quantitation of coculture 
assays. After immunostaining with vWF antibody, tube formation was digitised and quantified 
using Angiosys software. The bar graph represents the mean ± SEM number of branch points 
(left hand graph) or total tubule length (right hand graph) counted in three independent 
experiments. Statistical analysis by two-way  ANOVA,  with  Bonferroni’s  test  for  multiple  pair-
wise comparisons indicated *P < 0.05 for C vs VE in UI and STC-1 groups for both branch 
points and total tube length. 
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Figure 3.8: Effect of siRNA-mediated STC-1 knockdown on VEGF-induced migration 
A. Representative blot indicating the degree of knockdown caused by siRNA-mediated 
transfection. Supernantant media from siRNA-transfected cells were collected and prepared for 
immunoblotting and probed with an antibody to STC-1. B. HUVECs were pre-treated for 48 hr 
with STC-1 siRNA and a non-targeting control siRNA (NT) or no treatment, untreated (UT). 
Cells were trypsinised and migration assay was assessed in a transwell assay using 25ng/ml 
VEGF (V) or no addition (C) as the chemoatttractant. Data are from three independent 
experiments. Analysis of VEGF- stimulated migration by two-way ANOVA indicated no 
significant effect achieved by STC-1 siRNA treated cells compared to the control NT siRNA, 
(p>0.05).  
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3.6 Discussion 
 
In cardiovascular biology, VEGF is a critical cytokine exhibiting multiple diverse 
biological functions in endothelial cells. For example, VEGF signalling induces the 
migration and survival of endothelial cells. Gene expression profiling studies in 
endothelial cells and in models of sprouting angiogenesis or capillary formation have 
suggested a possible role of STC-1 in angiogenesis and/or its potential importance in the 
modulation of neovascular diseases (Gerritsen et al., 2002; Holmes & Zachary, 2008; 
Kahn et al., 2000; D. Liu et al., 2003; S. Yang et al., 2002). Currently however, 
relatively little is known about how expression of STC-1 affects endothelial angiogenic 
responses. In this chapter I aimed to identify possible functional roles of STC-1 in 
VEGF- mediated endothelial cell responses.  
Since VEGF plays an important role in a number of processes required for angiogenesis 
in endothelial cells, including migration, I initially confirmed that VEGF does 
upregulate STC-1 expression (Fig. 3.1). I next investigated the role of STC-1 in VEGF-
stimulated cell migration, using recombinant STC-1. In these studies, 100 ng/ml STC-1 
resulted in an approximately 40% reduction in VEGF-induced migration whereas STC-
1 at up to 50 ng/ml had no effect on VEGF-mediated migration (Fig. 3.2). This was 
somewhat unexpected since the finding that STC-1 was upregulated in response to 
VEGF might suggest a pro-angiogenic role for this factor. However, it also possible that 
STC-1 might be required for modulating responses to VEGF by limiting angiogenic 
processes at higher concentrations of STC-1. Indeed, (Zlot et al., 2003) showed that 
STC-1 acted as a selective autocrine negative modulator of HGF-induced endothelial 
migration and morphogenesis (cord formation) on Matrigel. Although the expression of 
both HGF and its receptor c-Met are known to be up-regulated in both physiological 
and pathological angiogenesis, HGF is not considered to be an endothelial-selective 
mitogen and morphogen. In contrast to the data presented in this thesis however, (Zlot 
et al., 2003) did not see an effect of STC-1 on VEGF-induced migration, even when 1 
µg/ml STC-1 was used. In addition they also failed to show VEGF-induced 
upregulation of STC-1 expression in a HUVEC monolayer, although an increase was 
noted in a 3D culture. The reasons for these discrepant results are unknown; however, it 
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should be noted that (Zlot et al., 2003) used a supraphysiological dose of VEGF (400 
ng/ml) to induce STC-1 expression which may result in endothelial cells becoming non 
responsive due to VEGF receptor downregulation. In addition, the migration assay used 
by (Zlot et al., 2003) lasted 18 h compared to 4 h in my migration assays; therefore it is 
possible that the inhibitory effect of STC-1 on VEGF-induced endothelial migration 
observed in this thesis may be transient. In addition the recombinant STC-1 used by 
(Zlot et al., 2003) was from a different source to the one used in this thesis and this may 
also partly account for the discrepancies. 
Analysis of VEGF-stimulated signalling revealed that STC-1 had no effect on any of the 
VEGF-stimulated signalling pathways investigated (Fig. 3.3). An important pathway 
involved in VEGF-induced signalling is phosphorylation of the nonreceptor tyrosine 
kinase FAK, which act as a mediator between extracellular matrix and cytoskeleton 
(Abu-Ghazaleh, Kabir, Jia, Lobo, & Zachary, 2001). Recent findings suggested that 
STC-1 reduced HGF-induced FAK phosphorylation (Zlot et al., 2003). In contrast, 
STC-1 pre-incubation had no effect on VEGF-induced FAK phosphorylation in the 
studies presented here. I was also not able to observe any change in VEGF-induced 
FAK phosphorylation. In addition, VEGF mediated phosphorylation of another protein 
important in cell migration p130Cas (Crk-associated substrate) was also not 
significantly increased. This was unexpected since other colleagues in this and other 
laboratories have shown that VEGF inducesphosphorylation of Y407 FAK and Y410 
p130Cas in HUVECs (Evans et al., 2011; Herzog, Pellet-Many, Britton, Hartzoulakis, 
& Zachary, 2011). It is difficult to explain this difference, but it is possible that the 
batches or passages of HUVECs used for this set of experiments were less responsive or 
possibly less quiescent than usual, resulting in weaker signalling responses.  Overall, I 
was unable to attribute the inhibitory effect of 100 ng/ml STC-1 on VEGF–induced 
migration to changes in any of the signalling pathways I investigated. Given that both 
FAK and p130Cas are phosphorylated at multiple sites, in further work it would be 
desirable to have examined effects of STC-1 on VEGF-induced phosphorylation of 
FAK and p130Cas at different tyrosine residues, eg FAKY397 or FAKY861, which are 
also known to be regulated by VEGF. In addition, VEGF also regulates cell migration 
via multiple other pathways, eg the small GTPase, Rac. Further work should undertake 
a more comprehensive study of effects of STC-1 on VEGF-induced chemotactic 
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signalling. 
Additionally, it should be noted, that the inhibitory effect of hrSTC-1 on VEGF-induced 
migration was observed at only a single concentration of STC-1 (100ng/ml), and it is 
unclear that this concentration is physiologically relevant. There is limited information 
available on in vivo levels of circulating STC-1 in mammals, making it difficult to 
evaluate the physiological relevance of 100ng/ml STC-1. However, it is also possible 
that in pathophysiological situations, STC-1 may be strongly over-expressed locally, 
similar to the strong over-expression of VEGF observed in many cancers or neovascular 
eye diseases. It should also be noted that since endothelial cells produce and secrete 
endogenous STC-1, they therefore may not necessarily be particularly responsive to 
exogenously administered STC-1. To address this, further experiments could be 
performed in which exogenous STC-1 is used in cells in which endogenous STC-1 
expression is inhibited using targeted siRNA-mediated knockdown. 
Other concerns about experiments involving exogenously added hrSTC-1 are that STC-
1 may function in an autocrine fashion and that its post-translational processing may be 
important for its function, aspects that may not be mimicked by treatment with hrSTC-
1. To address this, experiments were performed using an adenovirus to overexpress 
STC-1 in endothelial cells. Adenoviral overexpression of STC-1 had no effect on 
HUVEC migration towards VEGF, in contrast to the inhibitory effect seen with 
recombinant STC-1 (Fig. 3.5); Ad.STC-1 also caused no apparent changes in the 
phosphorylation of any of the VEGF-induced signalling proteins examined (Fig. 3.6). 
These negative findings may indicate that endogenously produced STC-1 in Ad.STC-1-
infected endothelial cells does not accumulate sufficiently to reproduce the inhibitory 
effect caused by 100 ng/ml hrSTC-1. It was observed that there was a slight alteration in 
Akt phosphorylation in response to VEGF treatment in the presence of adenovirus 
overexpressed STC-1 in comparison to Lac Z infected cells. I also noticed that basal 
levels of Akt activity was altered in infected Lac Z cells as well, although VEGF- 
stimulated Akt phosphorylation was greater in the presence of STC-1. This made the 
interpretation of these results difficult since it was difficult to know whether enhanced 
Akt phosphorylation was due simply to adenoviral infection or to STC-1 over-
expression. This question could be partly addressed using a different control vector, eg 
Ad.GFP, or by lowering the MOI of infection to reduce the viral load.  
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Overall, I was unable to find any evidence by which either endogenous or exogenously 
administered STC-1 could influence VEGF signalling. It may be that STC-1 acts by 
influencing the activity of other growth factors/cytokines, HGF for example. In 
addition, Chen et al. 2008 described a critical role for STC-1 in regulating endothelial 
cell function under normal or inflammatory conditions by inhibiting TNF--induced 
monolayer permeability in endothelial cells. TNF--stimulated expression of the 
junction molecules, ZO-1 and claudin-1, was downregulated by STC-1 at both the 
mRNA and protein levels, suggesting a new role for STC-1. However, this study found 
that STC-1 failed to block the VEGF-induced increase in cell permeability, indicating 
that the negative effect of STC-1 could be specific to TNF-. 
In a fibroblast/endothelial cell coculture model of angiogenesis, the formation of new 
capillary-like structures composed of endothelial cells, adenoviral STC-1 
overexpression also did not significantly either positively or negatively modulate 
tubulogenesis, though  (Figs. 3.7). However, the interpretation of these results was 
complicated by a stimulatory effect on tubulogenesis of Ad.LacZ infection alone. The 
reason for this is unknown but may be related to the increased basal Akt 
phosphorylation also observed after viral infection (Fig. 3.6), although this is unlikely 
since Ad.STC-1 produced no similar increase in tubulogenesis in the absence of VEGF.  
Knockdown of STC-1 in HUVECS resulted in a trend for lower VEGF-stimulated 
migration in comparison of non-target siRNA, but this was not significant (Fig. 3.8) . It 
is possible that a more substantial knockdown of STC-1 expression may be required to 
significantly affect VEGF-induced migration and this needs further investigation. Taken 
together with the other migration assay data, it could be hypothesised that endogenous 
and exogenously administered STC-1 have different effects. Endogenous STC-1 may be 
required, at a low level, for optimal endothelial motility and increasing STC-1 
somewhat above this level using adenoviral over-expression has no additional effect. In 
contrast, high levels of exogenous STC-1 may be inhibitory. Obviously much more data 
is required to support this hypothesis, nonetheless it does fit with the idea put forward 
by other groups that STC-1 may act as a stabilising signal during angiogenesis, 
promoting the maturation of new blood vessels rather than further growth (Zlot et al 
2003). 
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Given the largely negative data presented here it could be concluded that STC-1 has 
little or no effect on endothelial cells. Nevertheless, there is considerable evidence that 
STC-1 does influence endothelial function. For example STC-1 increases intracellular 
Ca2+ levels in quiescent HUVECs (Chakraborty et al., 2007). The mechanism involved 
was not explored, however a similar effect was observed in epithelial tumour cell lines 
and STC-1 in these cells was found to act via modulation of purinergic signaling (Block 
et al 2010). 
As already discussed, Chen et al 2008 reported that STC-1 inhibited TNF- induced 
endothelial permeability and this is in broad agreement with the findings by 
Chakraborty et al who showed that STC-1 inhibited monocyte transmigration through a 
HUVEC monolayer (Chakraborty et al., 2007). Indeed it seems that STC-1 may have a 
more general role in inhibiting macrophage and leucocyte migration (C. Chen, 
Jamaluddin, Yan, Sheikh-Hamad, & Yao, 2008; Kanellis et al., 2004). 
Further evidence of a role for STC-1 in endothelial biology comes from microarray data 
which demonstrates that STC-1 exerts both short-term (2 h) and long-term (24 h) effects 
on gene expression in cultured HUVECs, regulating a number of genes that are 
important to cell growth and differentiation such as growth factors and regulators of cell 
cycle and apoptosis in endothelial cells (Chakraborty et al., 2007). Once again, 
however, the mechanism behind these transcriptional effects was not explored. 
Overall therefore it can be concluded that although VEGF regulates endothelial STC-1 
expression, STC-1 regulates endothelial function largely through non-VEGF mediated 
pathways, or else regulates other VEGF functions not examined in this chapter. 
However, the data presented here indicates that STC-1 is not a pro-angiogenic signal 
but may instead act to maintain newly formed vessels or in the functions of mature 
vascular endothelium, or endothelial functions under conditions of stress. More work is 
required to test these hypotheses and investigate in more detail the mechanisms by 
which STC-1 exerts its effects on endothelial cell biology. 
 
. 
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Chapter 4 
 
 
 
 
 
4 PDGF regulation of STC-1 expression 
 
Various studies have suggested that STC-1 may have a role in wound healing, 
angiogenesis and cancer (Law et al., 2010). In the previous Chapter, though I confirmed 
that VEGF-A165 upregulates STC-1 protein expression (Holmes & Zachary, 2008; D. Liu 
et al., 2003{Holmes, 2008 #1048), I was however, unable to find definitive evidence for 
a role for STC-1 in VEGF-mediated endothelial function. Given that STC-1 is a 
secreted protein, it is possible that the main effects of endothelial derived STC-1 may 
actually be paracrine in nature, possibly acting on vascular smooth muscle cells (SMC). 
Indeed by secretion of various factors, such as endothelial derived-PDGF, endothelial 
cells can modulate the cellular responses of SMC and pericytes (mural cells involved in 
stabilizing capillaries) including proliferation, migration and vessel stability (Hellstrom, 
Kalen, Lindahl, Abramsson, & Betsholtz, 1999). In addition, it was also of interest to 
examine whether VSMC could themselves express STC-1. At the beginning of this 
thesis, STC-1 was not known to be expressed in SMC or to regulate SMC function. 
Firstly, therefore, I investigated whether STC-1 is expressed in SMC and whether 
PDGF signaling could affect STC-1 expression. Several approaches are described below 
which aim to generate an overall picture of STC-1 upregulation in response to the 
PDGF-BB isoform in SMCs. 
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4.1 PDGF-BB stimulated STC-1 gene expression 
 
The possibility that PDGF might regulate the effect of STC-1 expression was initially 
investigated in two different human primary SMCs, Aortic (Ao) SMCs and Coronary 
artery (CA) SMCs. Analysis of PDGF-BB-induced STC-1 expression was performed by 
real-time, quantitative RT-PCR using gene-specific STC-1 primers and GAPDH as a 
reference gene. Treatment of a confluent monolayer of human CASMCs with 30ng/ml 
PDGF-BB for different times, showed that PDGF-BB treatment induced expression of 
STC-1 mRNA significantly after 45 minutes, with a maximum increase of 
approximately 14-fold at 90 minutes (p<0.001), thereafter expression declined to just 
above basal level after 24 hours (Fig. 4.1).   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Regulation of STC-1 gene expression by PDGF-BB 
Confluent, serum–starved CASMCs were treated with 30 ng/ml PDGF for the indicated times 
before mRNA extraction. STC-1 mRNA levels were determined by real-time quantitative RT-
PCR and normalised to GAPDH mRNA levels. The results are expressed as mean fold 
increases ± SEM from three independent experiments, * p<0.001 versus 0 hr time point.  
 * 
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Figure 4.2: Analysis of intracellular and secreted STC-1 protein induction  
A. Confluent, serum-starved HAoSMCs were treated with or without 30ng/ml PDGF-BB for 24 
hours. Conditioned media were concentrated then deglycosylated with PNGase F enzyme and 
immunoblotted and probed with indicated antibodies. B. HCASMCs were treated with either 
different concentrations of PDGF-BB as indicated or no addition (C) for 24 hours. Conditioned 
media and whole cell extracts were prepared for SDS-PAGE, immunoblotted and probed with 
chicken anti-human STC-1 antibody from Abcam Plc. 
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4.2 Analysis of PDGF regulation of STC-1 protein secretion 
 
Having established that PDGF BB upregulates STC-1 mRNA expression I used 
Western blot analysis to confirm that STC-1 protein expression is also increased. 
Because STC-1 is generally secreted from cells imunoblotting was performed on 
concentrated cell media supernatants as well as whole cell lysates. Supernantants and 
whole-cell lysates were prepared from serum-starved cells after treatment with different 
PDGF-BB concentrations for 24 hours.  
In an initial experiment when the concentrated supernantants were not deglycosylated, 
the antibody used could not detect the secreted STC-1 in the supernatant. However, as 
previously reported, STC-1 is a glycosylated protein in different systems (Holmes & 
Zachary, 2008). Therefore, secreted proteins in the cell supernantants were concentrated 
and deglycosylated and run in parallel with whole-cell lysates. The western blot analysis 
showed a clear detection of secreted protein after PDGF treatment. However, a 
consistent problem was that STC-1 protein levels in the cell lysates were very faint 
compared to the supernantants (Fig. 4.2). This was exacerbated by the use of a relatively 
ineffective antibody (raised in chicken to human STC-1), which was the best one 
available at the time. It was then decided to perform western blots only use concentrated 
supernantant from cell cultures in all subsequent experiments. Better antibodies with 
greater sensitivity were also identified. In particular, blots were performed using 
different antibodies from R&D Systems. 
 
4.2.1  STC-1 is N-glycosylated in SMCs 
 
Western blotting of supernantants prepared from SMCs revealed that STC-1 was 
expressed as a single band in SMCs approximately 35-kDa molecular size (Fig. 4.3). A 
similar molecular weight band of STC-1 is also expressed in endothelial cells and 
several cancers (see chapter 3 and (Holmes & Zachary, 2008). As previously shown, 
STC derived from corpuscles of Stannius (CS) has a carbohydrate moiety attached at a 
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single consensus N-linked glycosylation site at the consensus site, Asn29-Ser30-Thr31 of 
the mature protein core. It has been shown that the glycosylation patterns of CS and 
ovarian STC differ in the size of this posttranslational modification. Fish ovarian STC is 
substantially more highly glycosylated than the CS-derived hormone. To assess if STC-
1 secreted protein in SMC contains a similar N-linked glycosylation as in fish species, 
PNGase F digestion was performed on SMCs concentrated supernantants. PNGase F is 
an amidase, which cleaves between the innermost GlcNAc and asparagine residues of 
high mannose, hybrid and complex oligosaccharides from N-linked glycoproteins. 
Treatment of supernatants from SMCs with PNGase F enzyme resulted in a shift in 
STC-1 molecular weight by approximately 5-8 kDa as compared to untreated samples, 
to a band with a molecular weight of 28 kDa (Fig. 4.3). In contrast, treatment with 
enzymes, which specifically remove O-linked glycosylated moieties, namely either 
chondroitinase (which removes chondroitin sulphate chains), or with heparitinase 
(which removes heparan sulphate-rich chains) had little or no effect on STC-1 
molecular weight. It was noted that chondroitinase and heparatinase particularly in 
combination, did reduce the level of immunoreactive STC-1, but conversion of 
glycosylated STC-1 to other species by these enzymes was not detected. Furthermore, 
combinations of PNGase with chondroitinase and heparatinase made no further 
difference to the level of STC-1 compared with PNGase alone. This result indicates that 
secreted STC-1 in SMCs is an N-linked glycosylated protein. 
4.2.2  PDGF-induced STC-1 expression is restricted to the BB isoform 
 
Having shown that PDGF-BB upregulates STC-1 expression in SMCs, I determined 
whether other growth factors, including the PDGF isoform AA could also induce STC-1 
expression. The results showed, as before, that treatment with 30ng/ml PDGF-BB 
significantly increased STC-1 protein release in conditioned culture medium, whereas 
PDGF-AA had no effect (Fig. 4.4). This suggests that STC-1 stimulation could be 
regulated via PDGFR as PDGF-BB binds to  and  receptors with high affinity while 
PDGF-AA acts only through  receptors. 
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Figure 4.3: Glycosylation of STC-1 in SMCs 
Conditioned medium from CASMCs was concentrated then treated with and without PNGase F, 
chondroitinase (Ch.ABC) and heparitinase III (Hep) or in combination as indicated. 
Supernantants were immunoblotted and probed with goat STC-1 antibody from R&D Systems. 
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As expected, treatment with VEGF-A165 had no effect in SMCs and additionally, FGF-2, 
a known mitogen for SMCs, also had no effect on STC-1. It should also be noted that a 
combination of PDGF-BB and FGF did not have a synergistic effect on STC-1 
expression, in contrast to the effect of VEGF and FGF combined in HUVECs (Holmes 
& Zachary, 2008). Similar data showing STC-1 upregulation specifically by PDGF-BB 
was also observed in AoSMCs (Fig. 4.2A).  
 
4.2.3 Time and dose response of PDGF-stimulated STC-1 secretion 
 
Following the initial analysis of upregulation of STC-1 by PDGF-BB in SMCs I 
performed further characterization of this response. A time course experiment was 
carried out over a period of 24 hours. Cell culture supernatants from PDGF-BB-treated 
cells were collected at 0, 1.5, 3, 6 and 24 h and assayed for secreted STC-1. Western 
blot data (Fig. 4.5) showed that PDGF-BB caused a significant time–dependent increase 
in the stimulation of STC-1, which was detectable as early as three hours and 
significantly different from basal conditions at 24 h. Nevertheless, there was also a 
time-dependent increase in STC-1 secretion over 24 h in the absence of PDGF-BB 
stimulation and this may reflect a response of the cells to prolonged serum starvation. 
Since the 24 hr time point resulted in the strongest STC-1 upregulation, this was used in 
subsequent PDGF-BB experiments, unless otherwise stated. 
PDGF-BB-stimulated STC-1 expression was additionally examined using ELISA to 
quantify time-dependent STC-1 expression in PDGF-treated and untreated cells (Fig. 
4.6). Concentrated supernatants from three independent experiments were subsequently 
used in a sandwich ELISA kit designed to measure STC-1 protein in cell culture 
supernatants. In agreement to the Western blot data, increasing STC-1 expression in 
conditioned culture medium was observed in PDGF-stimulated samples. However, there 
was also a time-dependent stimulation of STC-1 in SMCs in basal conditions over a 
time of 24 h, such that PDGF-induced STC-1 expression was not statistically significant   
compared with untreated SMCs using this method, despite PDGF-BB-stimulated STC-1 
being considerably greater than STC-1 expression after 24 h incubation in serum-free 
medium. This may be due to the increased variability seen with this assay. 
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The influence of different concentrations of PDGF-BB on STC-1 stimulation was also 
further examined using the goat anti-STC-1 antibody. In response to different PDGF-
BB concentrations, STC-1 protein levels were increased after 24 hours treatment as seen 
in Figure. 4.7A. Western blotting of supernantants indicated a significant increase in 
STC-1 in cells was obtained with 60 and 120ng/ml PDGF-BB treatments compared to 
unstimulated cells (p<0.05).  
Together, these results indicated that the expression of STC-1 was upregulated in a time 
and concentration-dependent manner by PDGF-BB, whereas PDGF-AA and FGF had 
no effect in SMCs.   
 
4.3 PDGF-stimulated upregulation of STC-1 is mediated via PDGFRs 
 
PDGF-BB is a major initiator of angiogenesis and its biological effects are mediated via 
two major protein tyrosine kinase receptors, PDGFR and PDGFR, acting both as a 
chemoattractant and a proliferating reagent, and is responsible for the migration of the 
SMC and the formation of the neointima (Levitzki, 2004). The involvement of PDGF 
receptors in mediation of PDGF mitogenic activation of SMCs was examined using 
time and dose-dependent activation.  
 
4.3.1 Effect of PDGF-BB on PDGF receptors  
 
Initial experiments were performed to characterise PDGF-induced  and  receptor 
phosphorylation. Immunoblotting of lysates prepared from CASMCs treated with 30 
ng/mL PDGF-BB for different times with specific antibodies to PDGFR and 
PDGFRß, indicated that PDGF-BB was able to induce rapid phosphorylation of both  
and -receptors in SMCs detectable after 2.5 mins, reaching a maximum at 2.5-10 and 
2.5-5 minutes for  and -receptors respectively, and thereafter declining (Fig. 4.8). 
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Figure 4.4: Specificity of PDGF-BB in STC-1 upregulation  
 A. Conditioned medium from quiescent cultures of HCASMCs treated for 24 hours with 
30ng/ml PDGF-BB, 30ng/ml PDGF-AA, 25ng/ml VEGF-A165, 25ng/ml FGF-2, or no treatment 
(CNT) were concentrated and then analyzed by SDS-PAGE gels and Western blotting with goat 
antibodies to human STC-1. Cell lysates were separately prepared and blotted with anti-
GAPDH antibody. B. Quantified data of densitometry of immunoblots for the PDGF-BB-
induced STC-1 protein levels. Results are representative of three independent experiments 
n=3,with error bars ± SEM, * P<0.01. 
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Figure 4.5: Analysis of time course of PDGF-BB simulation of STC-1 secretion in SMCs 
by Western blotting 
A, Quiescent SMCs were stimulated with and without 30ng/ml PDGF-BB for the indicated 
times (0, 1.5, 3, 6, 24 hours) and concentrated media samples were separated by SDS-PAGE 
electrophoresis. Western blot analysis was performed with a goat polyclonal STC-1 antibody. 
The cell lysates were run in a separate gel and blotted for GAPDH as controls. Representative 
Western blotting results are shown. B, Bar graph showing the densitometric quantification of 
STC-1 expression normalized to GAPDH levels from three independent experiments. Data are 
means +/-SEM, * P<0.05 for 24 hours PDGF-BB versus 24 hours without PDGF-BB (SF). 
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Figure 4.6: Time course of PDGF-BB induced change of STC-1 protein level in HCASMC 
analysed by ELISA 
Cells were incubated with and without 30ng/ml PDFG-BB for indicated times and STC-1 
protein released into cell culture media was measured by ELISA in three independent 
experiments (means +/- SEM),  P  0.01 PDGF-BB (24) hr versus PDGF-BB (0).   
 
  
 
 * 
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Figure  4.7: Effects of increasing PDGF-BB concentration on STC-1 induction 
A. Concentration-dependent response of STC-1 expression to PDGF-BB. Confluent HCASMCs 
were cultured in serum-free conditions for 24 hours and then incubated with no addition (0) or 
with various concentrations of PDGF-BB ranging from 7.5 ng/ml-1 to 120 ng/ml-1 for a further 
24 hours. The level of deglycosylated STC-1 protein was detected by immunoblot analysis 
using a chicken anti-STC-1 antibody. B. Quantification of the effect of various PDGF-BB 
concentrations on upregulation of STC-1. Data from three independent experiments are 
represented by densitometric normalized values to GAPDH using ImageJ.  Results were 
assessed by one-way   Anova   with   differences   located   by   Borferroni’s   test   for   multiple  
comparison tests. Results are means +/-SEM, * P<0.05 compared versus control (0). 
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 The phosphorylation of PDGFR isotypes in SMCs was directly evaluated by 
immunoblot analysis of cell extracts in comparison to untreated controls. Western blot 
analysis showed that activation of the PDGFR persists for longer than PDGFR, since 
 receptor phosphorylation level does not decrease until 30 min whereas -receptor 
phosphorylation becomes attenuated by 10 mins (Fig. 4.8).  This may reflect a 
difference in the rates of endocytotic receptor internalization, or possibly receptor-
specific regulation of phosphorylation by, for example, tyrosine phosphatases.  
 
4.3.2 PDGF-stimulated downstream signalling 
 
PDGF, via activation of its receptor tyrosine kinases (RTK) is known to increase 
tyrosine phosphorylation and activation of a number of cellular components such as 
MAPKs, PI3K, and phospholipase C-, which are known to be involved in multiple 
cellular and developmental responses. Initial experiments were performed to 
characterize PDGF-BB downstream signaling pathways.  
Using antibodies directed specifically to the various phosphorylation sites of different 
signaling proteins involved in different PDGF signaling pathways, it was determined 
that PDGF-BB induces a marked phosphorylation of p38 MAPK, ERK1/2 and Akt 
kinases. Time and dose dependent treatments of confluent serum-starved SMC cultures 
with PDGF-BB, indicated that maximal kinase activation was obtained at 10-20 mins 
after PDGF-BB addition within a range of 10-50 ng/ml PDGF-BB (Fig. 4.9). 
PDGF treatment reproducibly induced downstream signaling as determined by 
immunoblots. However there were differences observed in the duration of activation. 
For example, the Akt activation persisted for up to 60 mins. In contrast, p38 kinase 
seemed to be more transiently phsophorylated with a return to basal levels by 20 mins, 
while ERk1/2 kinase remained phosphorylated for up to 20 mins. 
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Figure 4.8: PDGF-B stimulates phosphorylation of PDGFR and PDGFR in CASMC  
Confluent, serum deprived CASMC were stimulated with 30ng/ml PDGF-BB for the indicated 
times before lysis. Samples were then Western blotted with phospho-specific antibodies to both 
PDGFRs or the reference protein GAPDH. The results show the rapid autophosphorylation of 
PDGF Receptor  (Tyr1021) and PDGF Receptor  (Tyr754). Results are representative of 
three independent experiments yielding similar results. 
 
 132 
 
 
 
 
 
 
 
 
 
Figure. 4.9: Effect of time and dose responses of PDGF-BB for phosphorylation of p38 
MAPK, ERK1/2, and Akt    
A. Confluent, serum-deprived CASMCs were treated with 30ng/ml PDGF-BB for the indicated 
times before harvesting the cells for immunoblot analysis. Samples were then probed with the 
indicated antibodies. Control (C) means sample in SFM with no PDGF-BB treatment.  
B. Serum-deprived, CASMCs were stimulated for 10 min with either different concentrations of 
PDGF-BB or no addition (C). Cell lysates were then prepared and immunoblotted with the 
indicated antibodies. Data in both A & B are representative of at least three independent 
experiments. 
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4.3.3  Effect of Knockdown of PDGFRs on STC-1 upregulation 
 
In order to establish that the PDGF-BB upregulation of STC-1 was mediated via its 
receptors in SMCs two approaches were used: pharmacological inhibition of PDGFRs, 
and siRNA-mediated knockdown of both receptors. 
The role of PDGFRs was initially examined using siRNA knockdown targeting PDGF 
receptors. The effective knockdown of both PDGF receptors is shown in figure 4.10. 
These data show that siRNA targeted to PDGFR specifically and markedly reduced 
expression of PDGFR with little effect on PDGFR expression while PDGFR–
specific siRNA reduced PDGFR expression with little effect on PDGFR level. 
The involvement of PDGFR and PDGFR on STC-1 expression was initially 
examined using siRNA knockdown of each receptor individually (Fig. 4.11). In this 
same experiment STC-1 siRNA was used to confirm the identity of the major STC-1 
protein band. Unexpectedly, siRNA directed against PDGFR appeared to increase 
STC-1 protein secretion, whereas PDGFR knockdown showed a trend for reduced 
PDGF-BB-stimulated STC-1 upregulation compared to either non-targeted control 
siRNA or the effect of PDGFR–targeted siRNA, although this effect was not 
statistically significant (Fig.4.11A, B). Thus, these data indicate that homodimeric 
PDGFR does not appear to be responsible for PDGF-BB induced STC-1 upregulation, 
but suggest a role in part for PDGFR. Since PDGF-BB binds to and activates both 
receptors and also binds to heterodimers, it was possible that PDGF-BB-induced STC-1 
expression might be mediated through homodimeric PDGFR activation and/or by 
PDGFR- heterodimers. Nevertheless, the fact that PDGFR knockdown alone was 
not sufficient to significantly reduce PDGF-BB induced STC-1 expression suggests 
either there is some compensatory role played by PDGFR, or it may simply be that the 
level of knockdown was not enough to completely prevent signalling through this 
receptor. It is also important to note that due to the need to treat with PDGF-BB for 24 h 
to obtain robust STC-1 protein upregulation, PDGFR immunoreactivity is markedly 
decreased due mainly to ligand-induced receptor-mediated endocytosis, receptor 
degradation and down-regulation following activation.   
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Figure   4.10:   Effects   of   siRNAs   directed   against   PDGRαR   and   PDGFβR   on   PDGR  
expression  
CASMC   were   transfected   with   25nM   siRNA   targeting   PDGRαR,   PDGFβR,   STC-1 and NT 
(non-targeting siRNA) using lipofectamine RNAiMAX, or untransfected and untreated sample 
Control (C) and transfected and PDGF-BB treated sample, (+PDGF-BB).  After 72 hours, 
serum-starved cells were treated for 10 mins treatment with 30ng/ml PDGF-BB. Cell extracts 
were immunoblotted and probed with the indicated antibodies. In this experiment total Akt was 
used as a loading control. 
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Figure 4.11: Effect of PDGFR and PDGFR siRNAs on STC-1 stimulation 
A. Serum- deprived HCASMCs were transfected with 25nM siRNA targeting PDGFR, 
PDGFR, STC-1 and NT (non-targeting siRNA) using lipofectamine RNAiMAX reagent. After 
72 hr serum-starved cells were treated for further 24 hr with 30ng/ml PDGF-BB. Lysates and 
supernantants were immunoblotted and probed with indicated antibodies. Results are 
representative of three independent experiments. B. Quantification of results from part A. 
Results were analysed by two-way   ANOVA   using   Bonferroni’s   test   for   multiple   pair-wise 
comparisons. 
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Figure 4.12: Effect of double PDGFR knockdown on downstream signalling 
SMCs were incubated with or without (Control) 25nM siRNA of PDGF receptors and non-
specific siRNA (NT). Cells were then treated with for 10 mins with 30ng/ml PDGF-BB (+) or 
no addition (-) and harvested. Cell extracts were immunoblotted and probed with the indicated 
antibodies. 
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4.3.3.1 Double  knockdown  of  PDGFαR  and  PDGFβR 
 
Taken together, the results from experiments using siRNA targeting either homodimeric 
PDGFR or PDGFR indicated that knockdown of either receptor alone failed to have 
a dramatic effect on STC-1 induction. It seemed likely from these results that there was 
some functional redundancy involved in PDGF-stimulated STC-1 by these receptors. To 
address this, double siRNA knockdowns targeting both PDGFRs in SMCs were 
performed.  
Initially, I determined whether double PDGFR and PDGFR knockdown was 
effective in inhibiting PDGF-BB stimulation of receptor activation and downstream 
signaling. As shown in Fig. 4.12, double knockdown of PDGFR and PDGFR 
strongly inhibited activation of both receptors and activation of ERK and p38 kinase in 
response to PDGF-BB. In addition, PDGF-BB-induced Akt activation was also 
inhibited, though these siRNAs were insufficient for complete inhibition of Akt 
activation, despite strong inhibition of PDGFR and PDGFR phosphorylation and of 
other signaling pathways examined (Fig. 4.12). 
 
To assess whether PDGFR and PDGFR play redundant and compensatory roles in 
STC-1 upregulation, expression of both PDGF receptors was reduced in SMCs using 
double siRNA knockdown as before, and cells were treated for 24 hours with or without 
PDGF-BB to induce STC-1 expression. Results from experiments using double siRNA 
targeting both PDGFR and PDGFR indicated that receptors levels were substantially 
reduced. As expected 24 hours treatment with PDGF-BB caused a marked decrease in 
expression of both receptors, more striking for than PDGFR than PDGFR, and a 
marked increase in STC-1 protein expression. However, although there was a noticeable 
trend for reduced PDGF-stimulated STC-1 protein levels, this was not statistically 
significant in three independent experiments (Fig. 4.13). It was also noted in these 
experiments that non-targeted control siRNA also decreased PDGFR expression 
compared with untransfected control cells, most likely reflecting an effect of 
transfection conditions on receptor expression. 
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4.3.3.2  NRP1  and  PKCα  knockdown 
 
It has previously been reported that STC-1 expression is mediated via NRP1 and PKC-
dependent pathways in response to VEGF treatment in endothelial cells (Holmes & 
Zachary, 2008; Sazonova et al., 2008). Initially, the role of NRP1, a co-receptor for 
PDGFR and  (Pellet-Many et al., 2011), was examined using a specific siRNA. A 
representative blot of the effect of NRP1 knockdown on PDGF-induced STC-1 protein 
expression is shown in Fig. 4.14A. NRP1 knockdown did not significantly affect 
PDGF-BB-stimulated STC-1 expression compared to the non-targeted control siRNA.  
 
 
 
 
 
 
 
 
 
 
 
Figure 4.13: Effect of double PDGF receptor knockdown on PDGF-stimulated STC-1 
expression 
A. SMCs were treated with 25nM of the indicated siRNA or without any siRNA (C). After 72 hours, cells 
were then treated for 24hr with 30ng/ml PDGF-BB (+) or with no addition (-) and then lysed. Cell 
extracts were immunoblotted and probed with the indicated antibodies. B. Quantification of the effect of 
PDGFR and PDGFR siRNAs on STC-1 induction. Results are mean ± SEM STC-1 levels normalised 
to GAPDH, from three independent experiments. Differences between siRNAs were analysed by one-way 
ANOVA  using  Bonferroni’s  test  for  multiple  pair-wise comparisons. 
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Initial attempts were made to examine the role of specific signaling pathways in PDGF-
BB-induced STC-1 expression using inhibitors of signaling pathways, eg of PKC, 
MAPK and PI3K pathways. However, due to the need to treat for 24 hours with PDGF-
BB to induce robust STC-1 expression, it was found that such a longer-term treatment 
with pharmacological inhibitors, eg GF109203X or wortmannin, had severe effects on 
cell viability, making interpretation of these data very difficult. Since PKC was 
implicated in mediating STC-1 expression (Holmes & Zachary, 2008; Sazonova et al., 
2008), and PKC is a major PKC isoform in cultured human CASMC (Yasunari, 
Maeda, Minami, & Yoshikawa, 2001), I instead examined the effect of PKC-targeted 
siRNA. A representative blot of the effect of PKC knockdown on PDGF-induced 
STC-1 protein expression is shown in Fig. 4.14B. PKC knockdown did not 
significantly reduce, and in fact somewhat enhanced, PDGF-BB-stimulated STC-1 
expression compared to the non-targeted control siRNA (Fig. 4.14B). 
4.3.4 Pharmacological inhibition of PDGF Receptors 
 
Two problems encountered using siRNA are incomplete knockdown and off-target 
effects. An alternative approach, which may address at least the first of these drawbacks 
is to use pharmacological membrane-permeable inhibitors. Therefore, the role of 
PDGFR signalling was examined using the PDGFR kinase inhibitor AG 1296. 
Quinoxaline AG 1296, an ATP-competitive blocker, is a highly potent and selective 
inhibitor of PDGFR and its family members Kit and FIt3.  
To examine the effect of AG1296 on the PDGF receptors, SMCs were pretreated with 
10M AG1296 followed by PDGF-BB treatment. As expected, after 10 min PDGF 
treatment, AG 1296 at 10M completely blocked PDGF- stimulated phosphorylation of 
both - and -receptors at Tyrosine 849 and 857 respectively (Fig. 4.15), in agreement 
with previously published data (Kovalenko et al., 1997). This region of the - and -
receptors is 90% structurally similar and is located in the bi-partite receptor kinase 
domain.  -Receptor phosphorylation of tyrosine 1021, a PLC binding site (Morrison, 
Kaplan, Rhee, & Williams, 1990), was also reduced, albeit not completely inhibited. It 
should also be noted that the decrease in PDGFR immunoreactivity usually seen with 
PDGF-BB stimulation was completely absent in the AG1296 treated cells.  
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Figure 4.14: Effect of NRP1 knockdown on PDGF-stimulated STC-1 
A. CASMC were transfected with 25nM siRNA targeting NRP1 and NT (non-targeting siRNA) 
using lipofectamine RNAiMAX, or untransfected (C). After 72 hr, serum-starved cells were 
treated for further 24 hr with 30ng/ml PDGF-BB. Cell lysates were immunoblotted and probed 
with the indicated antibodies. Supernantants were concentrated and immunoblotted and probed 
for STC-1. B. CASMC were transfected with 25nM siRNA targeting   PKCα   and   NT using 
lipofectamine RNAiMAX, or untransfected (C).  After 72 hr, serum-starved cells were treated 
for further 24 hr with 30ng/ml PDGF-BB. Cell lysates were immunoblotted and probed with the 
indicated antibodies. Supernantants were concentrated and immunoblotted and probed for STC-
1. 
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PDGF- induced phosphorylation of the downstream signaling molecules, p38 MAPK 
and ERK1/2, was fully inhibited, and Akt phosphorylation was markedly reduced in 
AG1296-treated cells (Fig. 4.15). The effect of AG1296 on PDGF-stimulated STC-1 
regulation and phosphorylation of Akt was also examined after 24 hr PDGF-BB 
treatment. AG1296 strongly reduced the activation of Akt, and also prevented the 
attenuation of PDGFR expression as indicated by the lack of decrease in its 
immunoreactivity following PDGF-BB stimulation. In contrast the reduction in 
PDGFR level was unaffected by AG1296, suggesting that the inhibitor may prevent 
PDGFR internalization but has little effect on PDGFR internalization and 
degradation. Surprisingly, STC-1 induction was not affected by the inhibitor, perhaps 
suggesting that residual PDGFRs signalling, resistant to the inhibitor, may be sufficient 
to drive STC-1 upregulation.  Other possible explanations for the lack of effect of the 
PDGFRs inhibitor are discussed below. 
 
4.4 Discussion  
 
STC-1 gene expression is widely seen in tissues like heart, liver, lung, adrenal glands, 
kidney, prostate and ovary. The expression of STC-1 is induced by various stimuli, such 
as VEGF, hypoxia/oxidative stress and inflammation. However, at the start of this 
thesis, there were no reports regarding PDGF-mediated STC-1 expression in SMCs, or 
effects of PDGFs on STC expression.  
The possible effect of PDGF in STC-1 expression was examined in human CASMCs 
and AoSMCs. A major finding of this chapter is that PDGF induced expression of STC-
1 mRNAs indicated by quantitative PCR. Further experiments indicated that PDGF-BB 
stimulated STC-1 protein expression in a time and dose-dependent manner in CASMCs. 
Interestingly, while STC-1 expression was strongly upregulated by PDGF-BB, PDGF-
AA, another potent SMC mitogen that acts through the activation of PDGFR only, had 
no effect on PDGF-stimulated STC-1 expression.  
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Figure 4.15: Tyrphostin AG1296 does not completely inhibit PDGF-stimulated 
downstream signaling  
Confluent, serum-starved HCASMCs were pre-incubated with or without (Control) 10M of 
AG1296 or solvent alone (0.1% DMSO) for 30 mins followed by 10 mins treatment with 
30ng/ml PDGF-BB (+) or no addition (-). Cells were then lysed and immunoblotted using the 
indicated antibodies. These data are representative of at least two independent experiments. 
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Since PDGF-BB binds and specifically activates both PDGF transmembrane receptors, 
 and , whereas PDGF-AA binds specifically to PDGFR, the selectivity of PDGF-
BB for STC-1 upregulation strongly suggested that STC-1 expression would be 
mediated via PDGFR. However siRNA-mediated receptor knockdowns of either 
PDGFR or PDGFR suggested that PDGFR or possibly PDGFR/ heterodimers 
might be the primary receptor(s) responsible for STC-1 upregulation. In contrast, 
PDGFR siRNA knockdown had no effect on PDGF-stimulated STC-1 expression. 
However, it was also evident that knockdown of either PDGFR or PDGFR or of 
both PDGFR and PDGFR only partially reduced PDGF-BB-induced STC-1 
expression. The most likely explanation is that STC-1 induction by PDGF-BB only 
requires a low level of receptor activation and the knockdown was insufficient to 
completely prevent this. This would also explain the reduced but significant Akt 
activation seen after double receptor knockdown (Fig. 4.12). This explanation implies 
that very low levels of PDGFR activity or only a fraction of the total cellular pool is 
required for downstream PDGF functional signalling necessary for STC-1 upregulation, 
while a larger PDGFR pool is required for activation of some signaling pathways, eg 
ERK1/2 and p38 MAPK. 
It is unclear why PDGF-BB might induce STC-1 upregulation via PDGFR, while 
PDGF-AA had no effect, but this might reflect distinct conformational changes in 
PDGFR upon binding of these two ligands that may elicit divergent intracellular 
signalling through the same receptor. There is at least one reported example of 
differential regulation of PDGF-BB–induced activation as opposed to PDGF-BB-
induced activity (Rolny, Spillmann, Lindahl, & Claesson-Welsh, 2002). The results 
presented here appear to represent another instance of differential PDGFR signalling 
by PDGF-AA and BB. Further work is required to confirm this hypothesis, for example 
investigation of STC-1 expression in cells specifically expressing PDGFR or PDGFR 
and mutant PDGFRs. As an alternative to PDGF receptor knockdowns, I also used the 
PDGF receptor inhibitor AG1296. This compound should, in theory, completely block 
all PDGFR mediated signalling. However despite blocking PDGF-BB-induced PDGFR 
tyrosine phosphorylation, p38 and ERK1/2 phosphorylation and strongly reducing Akt 
activation, this inhibitor had little effect on STC-1 induction.  
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Figure 4.16: Tyrphostin AG1296 has little effect on PDGF-stimulated STC-1 expression   
 Confluent, serum-starved HCASMCs were pre-incubated with or without (Control) 10M of 
inhibitor or solvent alone (0.1% DMSO) for 30 mins followed by 24 hours treatment with 
30ng/ml PDGF-BB (+) and no addition (-). Cells were then lysed and immunoblotted using the 
indicated antibodies. These data are representative of at least two independent experiments. 
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This was a surprising result, which is difficult to explain. It is possible that metabolism 
of the drug over a 24 h treatment might be sufficient to reduce effective concentrations 
of the drug to allow some PDGFR signaling sufficient to allow STC-1 expression to 
recover. I also noted that while AG1296 prevented downregulation of PDGFR it had 
no effect on downregulation of PDGFR. Since receptor downregulation is a 
consequence of receptor activation and subsequent ligand-induced endocytosis and 
degradation, one interpretation of my results is that, though AG1296 transiently 
inhibited both PDGFRs, it had a more sustained inhibitory effect on PDGFR, allowing 
longer-term PDGFR activity to compensate for inhibition of PDGFR. This possibility 
warrants further study, perhaps by examination of effects of AG1296 on PDGFR and 
PDGFR kinase activity at different times. 
VEGF- stimulated STC-1 upregulation in endothelial cells had been reported to occur 
via PKC and NRP1-dependent pathways (Holmes & Zachary, 2008). NRP1 is thought 
to be important for VEGF-stimulated STC-1 expression through the ability of NRP1 to 
potentially stabilise VEGFR2/KDR activity, suggesting that STC-1 expression is 
regulated by NRP1/KDR signalling. However, NRP1 knockdown was not able to 
reduce PDGF-stimulated STC-1 expression in SMCs, in contrast to VEGF-stimulated 
STC-1 expression in endothelial cells  (Holmes & Zachary 2008), suggesting that NRP1 
may be important in VEGF-stimulated STC-1 expression in HUVECs, but not in SMCs. 
It was also found that VEGF-induced STC-1 mRNA expression was blocked by a broad 
spectrum inhibitor of PKC (GF109203X), suggesting that in endothelial cells STC-1 
expression is mediated through PKC activation (Holmes & Zachary, 2008). I did not use 
PKC inhibitors in this chapter, because the 24 hour treatment required to strongly 
upregulate STC-1 protein, would result in toxicity and a large loss of cell viability 
(unpublished observations). However, in the current study, siRNA-mediated 
dowregulation of PKC appeared to increase rather than decrease PDGF-stimulated 
STC-1 expression levels. This finding is in agreement with a recent study that showed 
PKC knockdown strongly upregulated STC-1 levels in a breast cancer cell line 
(Cornmark, Lonne, Jogi, & Larsson, 2011). In further work I would need to examine 
the signaling pathways mediating PDGF-BB-induced STC-1 expression more fully, by 
investigating effects of shorter-term treatments with signaling pathway inhibitors on 
STC-1 mRNA expression, and using knockdowns to other PKC isoforms expressed in 
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SMC. 
Given the partial effects of PDGFR knockdown and the lack of effect of a non-selective 
PDGFR inhibitor on STC-1 expression, other possible mechanisms for PDGF-BB-
induced STC-1 expression need to be considered. Another possible explanation for my 
data is that a novel mechanism not mediated solely or partly by known PDGFRs is 
responsible for PDGF-BB-induced STC-1 expression. There is however no strong 
evidence in the literature for such a mechanism. A non-PDGFR receptor, LRP1 (low 
density lipoprotein receptor-related protein 1) has been shown to modulate PDGF 
signalling but this occurs via interaction with PDGFR (Muratoglu, Mikhailenko, 
Newton, Migliorini, & Strickland, 2010). However, it is possible that STC-1 expression 
may be enhanced by interaction of PDGF-BB with other cell-surface molecules such as 
heparan sulphate or chondroitin sulphate glycosaminoglycans (HSPGs, CSPGs), such as 
perlecan or syndecans, which are strongly expressed in SMC. PDGF-B chains bind to 
HSPG and CSPG, and these interactions regulate biological functions of PDGF-B in 
development (Garcia-Olivas, Vilaro, Reina, & Castel, 2007; Lindblom et al., 2003); 
(Abramsson et al., 2007). This is a possibility, which could be tested initially by 
examining effects of targeted knockdown of known proteoglycans in SMC on PDGF-
BB-induced STC-1 expression. I also found that STC-1 was constitutively expressed in 
SMC in the absence of serum or PDGF treatment, and that this constitutive expression 
was considerable. It is therefore possible that PDGF-B may sequester some extracellular 
or cell surface component that negatively regulates basal STC-1 expression, and can 
thereby enhance constitutive STC-1 expression. 
In summary, the results in this chapter show that PDGF-BB stimulates STC-1 mRNA 
and protein expression in arterial SMC, and also that STC-1 is constitutively expressed 
in these cells. PDGF-BB-induced expressed is at least partially mediated via PDGFR 
and possibly PDGFR/ heterodimers, but there appears to be compensation between 
the two receptors. However, the partial inhibition of STC-1 expression by knockdown 
of both PDGFRs raises the possibility that an unconventional pathway is also involved 
not mediated by known PDGFRs, or by a non-RTK pathway. 
 
 
 147 
 
 
 
 
Chapter 5 
 
 
 
5 Effects of STC-1 on vascular smooth 
muscle cell function 
 
In the cardiovascular system, PDGF has been implicated in a variety of physiological 
and pathophysiological processes, including recruitment and proliferation of vascular 
mural cells during development, and pathophysiological SMC accumulation in vascular 
pathologies such as atherosclerosis and restenosis. PDGF-BB-induced chemotactic 
migration of SMC is thought to play a particularly important role in these processes. 
Having demonstrated that PDGF-BB induces STC-1 expression in primary cultures of 
SMC in Chapter 4, I decided to investigate the role of STC-1 protein expression in 
PDGF-BB mediated SMC functions, focusing particularly on PDGF-BB functional 
signaling and on PDGF-BB-induced cell migration.  
5.1 Effects of rhSTC-1 on PDGF-BB signalling  
 
PDGF-BB, via PDGFRs, activates several intracellular signaling pathways, including 
the ERK1/2 cascade, PLC- leading to activation of PKC, and the PI3K pathway 
leading to activation of Akt. One of the major downstream targets of PDGF-BB 
signalling is the serine/threonine kinase, Akt. There is strong evidence in the literature 
that Akt is a crucial downstream target of PI3K and it is likely to be responsible for 
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many of the biological consequences of PI3K activation in SMC. For example, SMC 
survival is dependent on Akt signalling (Allard, Figg, Bennett, & Littlewood, 2008).  
To assess whether SMC signal transduction could be altered by PDGF-BB induced 
STC-1 expression, CASMCs were pre-treated with recombinant human STC-1 (hrSTC-
1) protein for 30 min, followed by a further 10 min PDGF-BB treatment (Fig. 5.1A). As 
expected, immunoblotting using phosphorylation-specific antibodies demonstrated a 
robust increase in Akt phosphorylation (Ser 473) 10 min after PDGF-BB stimulation 
when compared with untreated cells. Interestingly, the immunoblotting analysis also 
revealed a synergistic effect of STC-1 on PDGF-induced Akt activation compared with 
the effect of PDGF alone. Quantification of Akt phosphorylation in several experiments 
showed that synergistic enhancement of PDGF-BB-induced Akt activity by STC-1 was 
consistent and statistically significant, while STC-1 alone had no detectable effect on 
Akt activity (Fig. 5.1B).  
The involvement of STC-1 in PDGF-induced Akt phosphorylation was further 
examined after different times of PDGF-BB treatment.  SMCs were pre-incubated with 
100ng/ml hrSTC-1 for 30 min followed by stimulation with PDGF-BB or vehicle over a 
period of two hours. The levels of Akt phosphorylation were examined as well as other 
PDGF-induced downstream pathways in SMCs. The synergistic augmentation of Akt 
phosphorylation was found to occur for up to 2 hours treatment with STC-1 and PDGF, 
whereas ERK1/2 phosphorylation was not affected (Fig. 5.2). In contrast, PDGF-BB 
induced p38 phosphorylation appeared to be decreased at 10 min treatment after STC-1 
preincubation compared to PDGF-BB alone.  
The influence of different concentrations of hrSTC-1 on PDGF-stimulated Akt 
phosphorylation was also examined. Pre-treatment of SMCs with various concentrations 
of STC-1 for 30 mins resulted in the enhancement of PDGF-induced Akt 
phosphorylation, an effect that was evident at all the STC-1 concentrations used from 
25-600 ng/ml (Fig. 5.3). It was noted that the same STC-1 concentrations alone in the 
absence of PDGF-BB, had no effect on Akt activity. Both the time and concentration 
experiments results indicated that STC-1 significantly enhances PDGF-stimulated Akt 
phosphorylation. 
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Figure 5.1: Synergistic effect of hr STC-1 and PDGF-BB on Akt activation 
A. HCASMCs were pre-treated with or without human recombinant STC-1 for 30 mins at 
100ng/ml, and then treated for 10 minutes with or without PDGF-BB at 30 ng/ml. Cell lysates 
were then prepared and immunoblotted with antibodies to Akt phosphorylated at Ser473, or 
total Akt. B. Western blot data for phosphorylated Akt was quantified from three independent 
experiments and are presented as means +/- SEM normalized to total Akt levels. PDGF-
BB+STC-1 treatment resulted in a significant increase in Akt activity after 10 min of treatment 
compared with PDGF-BB alone (*p < 0.001). 
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Figure 5.2: STC-1 is involved in enhancement of Akt activation but attenuates p38 
phosphorylation  
Confluent serum-starved HCASMC were treated with or without addition of 100ng/ml hrSTC-
1, and subsequently treated with or either no addition (0) or with 30 ng/ml PDGF-BB for the 
indicated times. Cells were then lysed and immunoblotted with the indicated antibodies. Results 
are representative of two independent experiments. 
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5.2  The effect of STC-1 on downstream targets of the Akt pathway 
 
Activation of Akt has been reported to phosphorylate multiple downstream effectors, 
such as glycogen synthase kinase 3 (GSK3). GSK3 is a key regulator of many cell 
functions, including the control of cell division, apoptosis, microtubule organization and 
the specification of cell fates during embryonic development. GSK3 is a highly 
conserved serine/threonine protein kinase that is negatively regulated by Akt. GSK3 
activity is inhibited by phosphorylation of two known isoforms, GSK3 at ser 21, and 
GSK3 at ser 9. To further investigate the effect of STC-1 on SMCs, Akt downstream 
signaling was examined.  
5.2.1  Effect of STC-1 on PDGF-BB-induced GSK3 phosphorylation 
 
To determine whether PDGF-stimulated Akt enhanced activation by STC-1 could also 
enhance downstream target proteins of the Akt pathway, the effect of STC-1 on 
GSK3/ phosphorylation at Ser 21 was examined using recombinant STC-1 protein. 
Representative blots demonstrated that STC-1 strongly enhanced PDGF-stimulated 
GSK3/ phosphorylation at Ser 21 for the - isoform and Ser 9 for the -isoform, 
whereas p38 kinase phosphorylation was attenuated (Fig. 5.4). As expected, 
phosphorylation of Akt was enhanced. 
 
5.2.2  Effect of STC-1 knockdown on PDGF-BB-induced Akt signalling   
 
To further examine the importance of STC-1 in regulating PDGF-induced Akt 
phosphorylation in SMCs, STC-1 was knocked down using targeted siRNAs. 
Representative blots of the effect of STC-1 knockdown on PDGF-stimulated Akt 
phosphorylation are shown in Figure 5.5A, with the quantified effect on Akt 
phosphorylation present in Figure 5.5B. 
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Figure. 5.3: Effects of different hrSTC-1concentrations on Akt phosphorylation 
Serum–starved, confluent HCASMCs were pre-treated with various concentrations of hrSTC-1 
as indicated for 30mins and then treated for 10 minutes with or without PDGF-BB at 30 ng/ml. 
Cell lysates were then prepared and immunoblotted for the indicated antibodies. This result is 
representative of two independent experiments. 
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Figure 5.4: Effects of STC-1 on PDGF-BB-induced GSK3 phosphorylation  
A. Confluent, serum-starved CASMCs were pre-incubated for 30 mins with 100ng/ml hrSTC-1, 
followed by 10 mins treatment with or either no addition (C) or 30ng/ml PDGF-BB (BB). Cells 
were then lysed, blotted and probed with the indicated antibodies. These blots are representative 
of 3 independent experiments yielding similar results. B. Quantification of the effect of STC-1 
on PDGF-mediated GSK3 phosphorylation. Results are from three independent experiments and 
are presented as means +/- SEM normalized to total GSK3 levels without reaching any 
statistical significance (p0.05). 
A B 
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STC-1 knockdown appeared to reduce PDGF-induced Akt phosphorylation, although 
this was not statistically significant. There was no effect of STC-1 knockdown on 
ERK1/2 phosphorylation. It was also observed that the levels of Akt and ERK1/2 
phosphorylation in transfected samples (both NT and STC-1 siRNAs) were increased in 
the absence of ligand, suggesting a non-specific effect of transfection and further 
complicates interpretation of data with these siRNAs.  
 
5.3 Adenovirus overexpression of wild-type STC-1 protein in SMCs 
 
To complement the results using hrSTC-1 and to further validate the synergistic effect 
of STC-1 in PDGF-stimulated Akt phosphorylation, adenovirus overexpression of STC-
1 in SMCs was used. SMCs were infected with adenoviruses overexpressing STC-1 
(Ad.STC-1) or -galactosidase (Ad.Lac Z) as a control. 
I first assessed the effect of viral infection on STC-1 protein overexpression in 
CASMCs in a time and MOI-dependent manner compared to the control infection with 
Ad.Lac Z. A range of MOIs were used to infect cells for 48 hours, from 5 to 100 
infectious units per cell. Infection with Ad.STC-1 caused a MOI-dependent increase in 
STC-1 expression in contrast to Ad.Lac Z-infected cells which showed no increase in 
basal STC-1 expression. Immunoblots revealed a gradual and stable increase of STC-1 
with a readily detectable level of overexpression that lies between MOI of 10 and 100 
(Fig. 5.6).  
Similarly, a time course experiment using an MOI of 10 showed that STC-1 expression 
in the medium of Ad.STC-1 infected cells increased with time over a period of up to 4 h 
after cells had been transferred to fresh medium, indicating that adenovirally-expressed 
STC-1 is secreted rapidly from SMC. There was no increase in STC-1 expression in 
Ad.Lac Z infected cells over this time period (Fig. 5.7). 
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Figure 5.5: Effect of STC-1 knockdown on PDGF-stimulated  signalling 
A. HCASMC were transfected with 25nM targeting STC-1 or NT (non-targeting) siRNA using 
lipofectamine RNAiMAX, or untransfected (C). After 72 hr, serum-starved cells were treated 
for 10 mins with 30ng/ml PDGF-BB or without addition (-). Cell lysates were immunoblotted 
and probed with the indicated antibodies. Supernantants were concentrated and immunoblotted 
and probed for STC-1. Data presented are from four independent experiments. The dashed line 
indicates that the blots are derived from different regions of the same blot. B. Quantification of 
results for Akt phosphorylation in panel A, (n = 4) are presented normalised to total Akt levels. 
Analysis by two-way   ANOVA   with   Bonferroni’s   test   for   multiple   comparisons   showed   no  
significant difference. 
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Figure 5.6: Overexpression of STC-1 using adenoviruses 
HCASMCs were incubated with adenovirus encoding wild-type STC-1 and contol Lac Z at the 
indicated multiplicity of infection (MOI) for 48h. Cells were then lysed and supernantant were 
collected and prepared for immunoblotting. Position of STC-1 is indicated by the arrow based 
on it molecular weight around 40 kDa, whereas the upper band could be unspecific interaction 
due to the viral expression. Data are from a single experiment.  
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Figure 5.7: Time dependent overexpression of STC-1  
CASMCs were incubated with adenovirus encoding STC-1 or Lac Z at an MOI of 10 for 48h. 
Serum- deprived cells were washed two times with serum free medium and supernantant 
samples were collected at the indicated times and immunoblotted and probed with anti-STC-1 
antibody. Data are representative from two independent experiments. 
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To determine the involvement of overexpression of STC-1 in PDGF-induced Akt 
pathway, I initially investigated whether adenovirus infection would have a non-specific 
effect on Akt phosphorylation in SMCs. This preliminary experiment was performed 
because I had seen that adenoviral infection had increased basal Akt phosphorylation in 
endothelial cells (Chapter 3, Fig. 3.5). I observed that both Ad.Lac Z and Ad.STC-1 
infection resulted in a MOI-dependent effect on Akt phosphorylation in the absence of 
ligand stimulation. It could be argued that Ad.STC-1 had a slightly greater effect than 
Ad.LacZ at lower MOIs, perhaps indicating that STC-1 does enhance Akt signalling. 
 However the increase in basal Akt phosphorylation upon viral infection made it 
difficult to assess the effect of STC-1 overexpression on PDGF-stimulated Akt 
phosphorylation. Therefore adenovirus-mediated expression of STC-1 was not further 
used as an approach to examine the role of STC-1 in PDGF-stimulated Akt 
phosphorylation enhancement. It should be noted that this particular observation has 
been observed previously in this laboratory in work with other adenoviruses generated 
by the same methodology as the ones used in this study. 
 
5.4 Role of STC-1 in PDGF-stimulated cell migration 
 
After observing the synergistic effect of STC-1 in PDGF-mediated Akt pathway 
activation, I decided to study the effect of STC-1 in PDGF-stimulated SMC migration 
which is considered an important process in the abnormal accumulation of SMC 
associated with atherosclerosis, restenosis, graft stenosis and other vessel wall 
pathologies.  
5.4.1  Effect of hrSTC-1 on PDGF-induced cell migration  
 
Initially, the involvement of STC-1 in SMC migration was examined with different 
concentrations of hrSTC-1. Since STC-1 was consitituitvely produced by SMC, I 
hypothesized that STC-1 was unlikely to act as a chemotactic factor by itself, but may 
have a regulatory role in SMC chemotaxis. Therefore I examined initially whether 
addition of STC-1 alone to SMC could affect SMC migration. These initial studies 
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showed that STC-1 by itself was not able to cause any effect on SMC migration (Fig 
5.9). In contrast, PDGF-BB stimulation resulted in a significant activation of SMC 
migration by nearly 6 fold (Fig. 5.9).  
To assess the role of STC-1 in PDGF-stimulated migration, CASMCs were pre-treated 
with different concentrations of hrSTC-1 and then allowed to migrate towards PDGF-
BB or vehicle in transwell assays (Fig. 5.10).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.8: Adenoviral overexpression of STC-1 and lac Z increases the phosphorylation 
of Akt kinase in CASMCs 
CASMC were infected with Ad.STC-1 or Ad.Lac Z using different MOI as indicated. 48 hours 
after infection, cells were harvested and immunoblotted and probed with the indicated 
antibodies. Supernantants were concentrated and blotted for STC-1. The results are 
representative of at least 3 independent experiments yielding similar results. 
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Figure 5.9: CASMC migration in response to PDGF-BB and STC-1 
CASMC cells were trypsinised and treated for 30 minutes with hrSTC-1 at the indicated 
concentrations and then seeded into a transwell migration assay chamber and allowed to migrate 
at 37°C for 4 hours. In parallel, other cells were allowed to migrate towards 30ng/ml PDGF-BB 
or no addition (serum free) in the lower chamber and the cells were allowed to migrate at 37°C 
for 4 hours. Then the cells that migrated were fixed, stained and assessed by counting. The 
results are means +/- SEM obtained from three independent experiments.  
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Figure 5.10:  hrSTC-1 reduces CASMC migration in response to PDGF-BB 
CASMC cells were pre-incubated in suspension with hrSTC-1 at the indicated concentrations 
and then transferred into transwell migration assay chamber. Migration of the cells was assessed 
towards 30ng/ml PDGF-BB or no addition (SF) at 37°C for 4 hours. Then the cells that 
migrated were fixed, stained and counted. Data are from four independent experiments. 
Analysis of PDGF-BB-stimulated migration by two-way ANOVA indicated a significant 
reduction by 100ng/ml hrSTC-1 treated cells compare to the PDGF-BB only treated cells, 
PDGF-BB vs 100ng/ml hrSTC-1, * P=0.01 and SF vs PDGF-BB, ** P=0.001. 
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The data showed that hrSTC-1 concentrations ranging between 1-50ng/ml had little 
effect on PDGF-induced CASMCs migration, but the higher dose of 100ng/ml resulted 
in a significant reduction in the number of cells that migrated towards a 30ng/ml PDGF 
gradient compared to cells that were not pretreated with STC-1 (Fig. 5.10). It should 
also be noted that this is strikingly similar to the effect of 100ng/ml STC-1 on VEGF-
mediated migration in endothelial cells (Chapter 3; Fig. 3.2). 
5.4.2 Effect of STC-1 knockdown on PDGF-stimulated SMC migration 
 
A role for STC-1 in PDGF-stimulated cell migration was also examined by depleting 
STC-1 in CASMCs with siRNA and assessing the migratory response towards the 
chemoattractant, PDGF-BB. Transfection of cells with siRNAs targeted to STC-1 
caused a large reduction in the amount of STC-1 secretion by these cells (Fig. 5.11A). 
STC-1 knockdown also caused a trend towards reduced migration of SMCs to PDGF 
but this was not statistically significant  (Fig. 5.11 B). 
To check the consistency of the results of siRNA transfection experiments on PDGF-
mediated migration, a second siRNA was used. STC-1 knockdown using the second 
STC-1 siRNA showed a similar effect to the first STC-1 siRNA, with a small trend 
towards decreased migration, but no significant effect on PDGF-stimulated migration of 
STC-1 compared with non-targeted siRNA (Fig. 5.12). 
5.4.3  Effects of adenoviral overexpression of STC-1 on migration 
The role of STC-1 in PDGF-stimulated cell migration was further examined by 
infection of CASMCs with adenoviruses to overexpress STC-1 or the control, Ad.Lac 
Z. Adenovirus-mediated overexpression of STC-1 had no effect on the migratory 
response of SMCs in the presence or absence of PDGF chemoattractant, compared to 
Lac Z virus-infected cells (Fig. 5.13).  
5.5 Involvement of STC-1 in SMC survival 
 
Another key biological role for Akt is in pro-survival or anti-apoptitic cell signaling. 
The role of STC-1 in SMC survival was assessed by pre-treatment with hrSTC-1 
followed by PDGF-BB or no treattment. 
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Figure 5.11: Effect of STC-1 knockdown on PDGF-BB-mediated cell migration  
A. CASMC cells were transfected with STC-1 siRNA or a non-targeting control siRNA (NT) or 
no treatment (Control). After 48 h, cells were trypsinised and SMC migration was assessed in a 
transwell assay using 30ng/ml PDGF-BB or no addition (-) as the chemoatttractant. Data are 
from three independent experiments. Analysis of PDGF-BB- stimulated migration by one-way 
ANOVA indicated no significant effect achieved by STC-1 siRNA treated cells compared to the 
control siRNA. B. Representative blot showing STC-1 knockdown achieved by STC-1 siRNA 
transfection. Concentrated supernantants from the media were immunoblotted with antibodies 
against STC-1. 
 
 164 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.12: Effect of STC-1 knockdown by using a second siRNA on PDGF-BB-mediated 
cell migration  
CASMC cells were transfected with a second STC-1 siRNA or a non-targeting control (NT) or 
no treatment (SF & BB). After 48 h, cells were trypsinised and migration was assessed in a 
transwell assay using 30ng/ml PDGF-BB or no addition (SF) as the chemoatttractant. Data are 
from three independent experiments. Analysis of PDGF-BB-stimulated migration by one-way 
ANOVA indicated no significant effect achieved by STC-1 siRNA treated cells compared to the 
control siRNA. 
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Apoptosis was induced by treatment with 1 mM hydrogen peroxide (H2O2) and the 
number of viable cells was assessed using the XTT (sodium   3  ́- [1- 
(phenylaminocarbonyl)- 3,4- tetrazolium]-bis (4-methoxy- 6-nitro) benzene sulfonic 
acid hydrate) viability assay. 
H2O2 decreased the number of viable SMC, an effect that was not altered in the presence 
of PDGF-BB (Fig. 5.14). Treatment with STC-1 produced a modest trend towards a 
reduction in cell viability, while a combination of STC-1 and PDGF-BB, although this 
was not statistically significant. In addition treatment with a combination of STC and 
PDGF-BB produced a more prominent increase in cell viability following H2O2 
treatment.  
 
5.6 Discussion 
 
The data reported in Chapter 4 indicated that PDGF stimulates STC-1 expression in 
SMCs via a possible PDGFR-mediated pathway. In this Chapter, the role of STC-1 in 
PDGF- stimulated downstream signalling cascades and associated biological functions 
were examined, to further understand the biological relevance of PDGF-stimulated 
STC-1 upregulation in SMC. 
Human recombinant (hr) STC-1 protein was used to explore whether STC-1, as a 
secreted factor following PDGF stimulation in SMC, has an impact on PDGF-induced 
downstream signaling. The major finding of this chapter is that treatment of SMCs with 
hrSTC-1 significantly increased PDGF-BB stimulated Akt phosphorylation in a time 
and concentration-dependent manner. Since STC-1 had no detectable effect on the level 
of Akt activity, these findings indicate a synergistic activation of Akt in the presence of 
STC-1 and PDGF in SMCs. 
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Figure 5.13: Effect of adenovirus-mediated overexpression of STC-1 on cell migration  
CASMC were infected with either Ad.STC-1 or Ad.lac Z for 48 hr at MOI of 10. Uninfected, 
serum starved cells were trypsinised and added to the upper chamber of a transwell migration 
assay chamber. The supernantants of infected cells were collected and were added to the lower 
chamber with or without the addition of 30ng/ml PDGF-BB as the chemoattractant. After 4 
hours, cells that migrated were fixed, stained and the number of migrated cells was assessed by 
counting. Data presented are mean +/- SEM numbers of migrated cells from three independent 
experiments. 
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Figure 5.14: Effects of STC-1 on PDGF-induced survival 
HCASMC were pre-treated with or without addition of 100ng/ml STC-1 for 30 mins followed 
by stimulation with or without 30ng/ml PDGF-BB for a further 60 mins. Cells were then 
incubated overnight in the presence (+) or absence (-) of 1mM H2O2 to induce apoptosis. Cells 
were then stained with XTT reagent. The absorbance of the formazan product, reflecting cell 
viability, was measured at 595 nm. Results are mean +/- SEM obtained from three independent 
experiments. 
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Akt, a serine-threonine protein kinase, is the most crucial downstream mediator of the 
RTK-PI3K complex. The family of Akts has been found to have key regulatory roles in 
many cellular processes in SMC including normal cell growth, cell cycle progression, 
and cell survival (Allard et al., 2008; Shiojima & Walsh, 2002). PDGF-dependent 
activation of PI3K/Akt pathway has also been reported to regulate cell motility 
(Millette, Rauch, Kenagy, Daum, & Clowes, 2006). Constitutive activation of the 
PI3K/Akt pathway has been shown to inhibit apoptosis in various cell types and blocks 
programmed cell death induced by a variety of apoptotic stimuli (Shiojima & Walsh, 
2002). The mechanism by which Akt protects cells from apoptosis is complex, since 
Akt once activated, directly phosphorylates several components of the cell-death 
machinery such as Bad, caspase 9, GSK3 and members of the FoxO family (Allard et 
al., 2008). For example, one consequence of Akt activity is phosphorylation of Bad, a 
pro-apoptotic member of the Bcl-2 family of proteins, which dissociates the 
heterodimeric complex formed with the survival factor Bcl-xl thereby restoring the anti-
apoptotic function of Bcl-xl. Allard et al. (2008) demonstrated that vascular SMC 
survival in response to a physiological death stimulus is dependent on Akt signalling. 
Akt-mediated phosphorylation of GSK-3 at serines 21 or 9 causes inhibition of GSK3, 
and this can therefore prevent the promotion of apoptosis by GSK3-mediated activation 
of p53 or inactivation of survival factors. However, it is important to recognise that 
GSK3 may both promote and inhibit apoptosis, and its role in this process is 
controversial (Beurel & Jope, 2006). The effect of STC-1 on PDGF-BB-induced Akt 
activation prompted me to further investigate whether this effect extended to 
downstream effectors such as GSK3. Results presented in this chapter show that STC-1 
also enhanced the stimulation of GSK3 phosphorylation by PDGF. These results 
suggest that the synergistic effect of STC-1 on PDGF-stimulated Akt phosphorylation 
may also enhance GSK3 inhibitory loop activation by Akt. In contrast to effects on the 
Akt pathway, there was some indication in my data that the phosphorylation levels of 
p38 in response to PDGF-BB were attenuated as result of STC-1 pre-treatment. 
However, this observation requires more work to verify that this was a statistically 
significant effect. Nevertheless, it is of interest that there are several examples in the 
literature of crosstalk between the p38 and Akt pathways (Berra, Diaz-Meco, & Moscat, 
1998; Gratton et al., 2001). 
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Knockdown of STC-1 via siRNA had no significant effect on PDGF-stimulated Akt 
phosphorylation, although a noticeable trend towards inhibition was seen compared to 
the control non-targeted siRNA. The lack of a significant effect after STC-1 knockdown 
may be due to a number of reasons. Firstly, if endogenous STC-1 production is to some 
degree involved in mediating PDGF-bb-induced Akt activation, the degree of 
knockdown may not have been sufficient to affect PDGF-stimulated Akt activation. 
Alternatively, STC-1 may simply not be required at all for activation of Akt by PDGF-
BB alone, but can only enhance activity.  
High STC-1 expression in the tumor vasculature and under hypoxic conditions may 
have protective and regulatory roles in cell survival (Lal et al., 2001; H. Y. Yeung et al., 
2005). Overexpression of STC-1 protein has also been associated with several cancers 
including ovarian cancer, but no essential function has been pinpointed (G. Liu et al., 
2010). In addition, the effects of STC-1 on metabolic rate and uncoupling of oxidative 
stress suggest that STC-1 may be involved in delaying the onset of hypoxia-induced 
apoptosis in human neuronal cells (Zhang et al., 2000). Greater cellular phosphate 
uptake by neuronal cells could reduce the rise in intracellular calcium caused by 
hypoxia, with an anti-apoptotic effect. In light of these data, it is possible that effects of 
STC-1 on respiration and mitochondrial calcium accumulation could be part of a pro-
survival pathway in metabolically active, mitochondria-rich cells (Ellard et al., 2007; 
Zhang et al., 2000). Recent data shows that overexpression of STC-1 is associated with 
increased expression of the anti-apoptotic proteins Bcl-2 and Bcl-xl, which leads to the 
inhibition of cleavage of procaspase-3, -8 and -9 (G. Liu et al., 2010). However, my 
results suggest that in SMCs, STC-1 is involved in the enhancement of phosphorylation 
of Akt and the Akt effector, GSK3, by PDGF. However, more work is required to 
validate this conclusion. It would be interesting, for example to examine effects of STC-
1 on PDGF-BB-induced Akt activation in other cell types. I would also like to examine 
effects of STC-1 on a wider range of Akt substrates. Furthermore, the mechanism 
through which STC-1 regulates PDGF-BB-induced Akt activation is unclear. My 
working hypothesis is that STC-1 binds to a specific cell surface receptor in SMC, 
which is able to mediate a synergistic interaction with PDGF-BB to enhance Akt 
signaling at some point proximal to Akt in the signaling cascade. One possibility is that 
STC-1 might enhance PDK-mediated phosphorylation of ser 473. Another possibility is 
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that STC-1 acts synergistically at the level of PI3K activation. It would be important to 
test these possibilities. The PDK responsible for phosphorylation of Akt ser 473 is 
unknown, but it would be possible to examine whether STC-1 can enhance 
phosphorylation of the p85 subunit of PI3K. At present a receptor for STC-1 has not 
been molecularly identified in any organism and this will be discussed in Chapter 6. 
However, a possible alternative to a mechanism mediated via a specific STC-1 receptor 
is that STC-1 might interact with PDGF-BB and/or with PDGFRs to enhance PDGF-BB 
interaction with its receptor in a way that can selectively enhance Akt activation. It is 
not clear how this might occur, however. 
 
Synergistic enhancement of Akt activity by STC-1 could shift the balance between 
antiapoptotic and proapoptotic signalling in favour of decreased cell death. Though I 
was unable to show a statistically significant effect of STC-1 on SMC viability, a trend 
towards a synergistic effect of STC-1 in combination with PDGF-BB was observed. 
These data would need to be confirmed using different assays of apoptosis, eg using 
other markers of apoptosis such as caspase activation, or FAK cleavage, TUNEL 
staining, or FACS analysis of annexin V staining. One problem I encountered in this 
aspect of the work is that cultured SMC are quite resistant to apoptosis. For example, 
while serum withdrawal is a strong stimulus for apoptosis in HUVECs, it has little 
effect on SMC death. On the other hand, pharmacological inducers of cell death using, 
for example, staurosporine, etoposide, or anisomycin, would have such powerful effects 
that it might be difficult to show a survival effect of STC-1. 
Broadly in support of my data, several reports in the literature have shown a significant 
role for STC-1 in survival or protection against supeoxide generation through induction 
of mitochondrial uncoupling proteins (Huang et al., 2012; Y. Wang et al., 2009). Liu et 
al. (2010) examined the association of STC-1 expression in ovarian cancer cells and 
apoptosis using annexin V fluorescence apoptosis assay. Retroviral-mediated 
overexpression of STC-1 appeared to lower the percentage of apoptotic cells rather than 
in corresponding control cells, suggesting that STC-1 may have anti-apoptotic activity. 
Whilst, in ovarian xenograft model in nude mice, siRNA-linked STC-1vectors caused 
nearly twice the percentage increase in apoptosis than in tumors derived from 
corresponding control cells (G. Liu et al., 2010). Other cell types such as mesenchymal 
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stem cells, secrete STC-1, and studies have demonstrated that the secretion of STC-1 
from these cells reduces ROS- or UV irradiation - stimulated cell death in a co-culture 
system (Block et al., 2008; Ohkouchi et al., 2012). Furthermore, the addition of STC-1 
recombinant protein into A549 cells exposed to 100 mol/l H2O2 resulted in the 
restoration of ROS to control levels by increasing anaerobic glycolysis together with 
UCP2 expression, while siRNA-mediated STC-1 knockdown inhibited cytoprotection of 
H2O2-injured cells (Ohkouchi et al., 2012). However, the underlying mechanism by 
which STC-1 enhances excessive anaerobic glycolysis and protection during the 
oxidative response it is still unclear (Ohkouchi et al., 2012). Other studies suggest that 
the molecular mechanism of ROS protection provided by STC-1 is a result of induced 
UCP2 expression and decreased protein carbonyl and nitrotyrosine levels which are 
generated by ROS (Roddy et al., 2012; Y. Wang et al., 2009). Additionally, STC-1 has 
been reported to be neuro- and renal-protective (Huang et al., 2009; Zhang et al., 2000), 
and upregulated in ischemic preconditioning (Westberg et al., 2007), observations that 
may or may not be explained by its multiple effects in lowering ROS generation. 
Recently, UCP2 has been implicated as a regulator of phagocytic engulfment of 
apoptotic cells, and data have shown an essential role for UCP2 in apoptotic cells 
clearance in vivo (D. Park et al., 2011). However, it is not yet known if STC-1 is 
involved in phagocytosis of apoptotic cells. It is also unknown whether STC-1 regulates 
UCPs in SMC. I examined this question during the course of my thesis, but did not see 
any effect of STC-1 on UCP2 expression in SMC cultures (Fig. 5.2). I also tried to 
examine the effect of UCP2-targeted siRNA on the response of SMC to STC-1, but was 
unable to obtain effective UCP2 knockdown (results not shown). Therefore, I did not 
pursue the role of UCP2 further. 
In contrast to the idea that STC-1 might have an anti-apoptotic effect, there are data 
indicating that STC-1 has a negative effect on pro-survival signalling pathways and/or 
has a positive effect on cell death signalling. For example, (Nguyen et al., 2009) 
demonstrated that treatment of wild type mouse embryo fibroblasts with H2O2 induced 
STC-1 expression 40-fold and reduced their survival much more than did a similar 
treatment of STC-1-/-cells. Moreover, their data showed a role for STC-1 in the 
oxidative stress response suggesting that STC-1 functions in a negative feedback loop to 
regulate MEK and ERK1/2. However, the precise mechanism by which STC-1 inhibits 
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MEK activation and mediates apoptosis is not known and requires further investigation 
(Nguyen et al., 2009). In addition, V5-tagged pLenti6.3/ V5-DEST overexpression of 
exogenous STC-1 was found to sensitize histone deacetylase inhibitor, (Dox)-induced 
cellular apoptosis induced by doxorubicin, an important class of anticancer agent, also 
suggesting a pro-apoptotic role of STC-1 in human nasopharyngeal carcinoma cell line 
CNE2 (Ching, Yeung, & Wong, 2012). 
I would like to have complemented studies of effects of recombinant STC-1 on Akt 
activity with results from adenovirus-mediated STC-1 overexpression. However, this 
was not practical because both Ad.Lac Z and Ad.STC-1 consistently increased Akt 
phosphorylation, indicating that increased Akt activity is a possible consequence of 
adenovirus transduction in these cells. The basis of increased Akt phosphorylation in 
adenovirally infected cells is unclear, but might involve the triggering of intracellular 
protective machinery, which consequently alters cellular behaviour.  
Results in this chapter also showed that treatment of SMCs with 100ng/ml hrSTC-1 
significantly decreased PDGF-stimulated SMCs migration. As previously observed in 
Chapter 3, 100 ng/ml of STC-1 also partially inhibited HUVEC migration in the 
presence of VEGF, suggesting a common mechanism of action for STC-1 regulation of 
migration in these different cell types. However, adenovirus-mediated overexpression of 
wild type STC-1 did not significantly alter PDGF-induced SMCs migration when 
compared to control Lac Z adenovirus. Again, this is similar to the results observed in 
HUVECs and may indicate that the cells are not responsive to intracellular STC-1, or 
that adenoviral ATC-1 overexpression does not produce sufficient concentrations of 
STC-1 to have an effect. Studies with two different siRNAs showed that STC-1 
knockdown had no significant effect on PDGF-stimulated migration, although a 
detectable trend towards inhibition was seen with both siRNAs examined. 
The importance of STC-1 in PDGF-stimulated migration is not clear, but other results 
also suggest a regulatory role of STC-1 in cell migration. Using the human keratinocyte 
model HaCa T cells, (B. Yeung & Wong, 2011) showed that STC-1 knockdown was 
found to significantly inhibit cell migration, while V5-tagged STC-1 overexpression 
significantly enhanced migration towards staurosporine, a non-specific kinase inhibitor. 
However, it is widely know that staurosporine is used as an apoptotic agent, and its 
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effect on dephosphorylation of a key migratory kinase, FAK, could contribute to the 
overall results (Kabir, Lobo, & Zachary, 2002). Furthermore, STC-1 overexpression in 
the unstimulated cells failed to induce cell migration.  
The reasons behind the lack of statistically significant results, obtained with STC-1 
knockdown and STC-1 overexpression in PDGF-induced migration, could be the result 
of a low number of repeated experiments. A higher number of experiments might have 
produced more convincing results that could have confirmed a functional distinction 
between control cells and cells treated with recombinant STC-1 or with STC-1 
knockdown or over-expression. Other data reported in this chapter, such as increased 
GSK3 phosphorylation as result of a synergistic effect of STC-1 and PDGF-BB 
treatment, showed a trend for an increase in phoshorylation at Ser 21 for alpha and Ser 9 
for beta isoforms. A greater statistically significant effect could have been obtained if 
more experiments had been performed in order to address variation between 
experiments due to other factors like differences between cell batches and culture 
conditions. 
Overall, the results obtained in this chapter indicate that STC-1 can enhance PDGF-BB-
stimulated Akt activity via an unknown mechanism, an effect which other data 
produced in this chapter suggests but does not prove, may mediate cytoprotection after a 
H2O2-induced insult. Other data in this chapter shows that STC-1 at 100 ng/ml also 
partially inhibits PDGF-BB-induced chemotaxis.  
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Chapter 6 
 
 
6 Discussion 
 
 
 
 
After its initial discovery as a major hormone produced by the corpuscles of Stannius 
(CS) in bony fish, STC-1 was identified in humans by mRNA differential display of 
genes involved in the control of cellular proliferation and by a random sequencing 
screen of a human fetal lung cDNA library (Chang et al., 1995; Olsen et al., 1996). It is 
well-established that STC-1 acts as an anti-hypercalcaemic hormone in teleost fish and 
it was anticipated that the mammalian homologue might similarly play a role in calcium 
and/or phosphate homeostasis. Indeed, STC-1 can regulate Ca2+ fluxes in mammalian 
cells. However, there appears to be no physiological role of STC-1 in mammalian 
growth or calcium or phosphate homeostasis because STC-1 deficient mice have no 
overt phenotype and display no alteration in serum calcium and phosphate (Chang et al 
2005). STC-2-deficient mice display a 10-15% increase in body weight compared with 
littermate controls, but this was independent of pituitary function or effects on the 
growth hormone/IGF-I axis, and was not associated with changes in serum calcium or 
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phosphate, or changes in bone development (Chang et al., 2008). Therefore the function 
of STCs in mammals remains an enigma. Furthermore, human STC-1 is implicated in 
several physiological and pathological processes in mammals including angiogenesis, 
and responses to ischemia and stress (Chang et al., 2003). The precise involvement of 
STC-1 in these systems is still unclear and remains to be further studied. However, 
work by our group and others have indentified STC-1 as an immediate-early VEGF- 
regulated gene in endothelial cells (Bell et al., 2001; Holmes & Zachary, 2008; D. Liu et 
al., 2003; Zlot et al., 2003). It was also demonstrated that FGF-2 synergistically 
enhanced STC-1 mRNA and protein expression induced by VEGF-A165 (Holmes & Zachary, 
2008). These findings highlighted the possible role of STC-1 upregulation in 
pathophysiological neovasculation and/or as an important regulatory factor in the 
angiogenic milieu.  
The studies presented in Chapter 3 were designed to examine the possibility that STC-1 
could regulate endothelial functions of the key angiogenic cytokine, VEGF, centrally 
involved in angiogenic responses such as cell migration and tubulogenesis, and major 
VEGF signaling pathways. The results obtained indicated little effect of modulating 
STC-1 levels in assays of migration, cell signaling and tubulogenesis using recombinant 
STC-1, adenoviral over-expression or targeted siRNA-mediated knockdown. The one 
exception was an inhibitory effect on VEGF-induced migration at 100ng/ml (discussed 
in Chapter 3.6). Given the largely negative data presented here it could be concluded 
that STC-1 has little or no effect on endothelial cells. Nevertheless, there is considerable 
evidence that STC-1 does influence endothelial function. For example STC-1 increases 
intracellular Ca2+ levels in quiescent HUVECs (Chakraborty et al., 2007). The 
mechanism involved was not explored, however a similar effect was observed in 
epithelial tumour cell lines and STC-1 in these cells was found to act via modulation of 
purinergic signaling (Block, DiMattia, & Prockop, 2010). As already discussed, Chen et 
al 2008 reported that STC-1 inhibited TNF- induced endothelial permeability, 
suggesting a new role for STC-1 in maintaining an anti-inflammatory endothelial 
barrier, and this finding is in broad agreement with the findings of Chakraborty et al., 
2007 who showed that STC-1 inhibited monocyte transmigration through a HUVEC 
monolayer (Chakraborty et al., 2007). Indeed it seems that STC-1 may have a more 
general role in inhibiting macrophage and leucocyte migration (C. Chen et al., 2008; 
Kanellis et al., 2004). Furthermore, despite the redundancy of STC-1 in mouse 
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development, surprisingly little work has been performed on the role of STC-1 in 
zebrafish development. One study tried to investigate the effect of STC-1 in zebrafish 
using STC-1 morpholino-mediated knockdown, and demonstrated that zebrafish STC-1 
regulates Ca2+ transport via negatively effecting the expression of gill epithelial Ca 
channels to reduce Ca2+ uptake in zebrafish embryos (Tseng et al., 2009). However, it 
would also be interesting to examine the effects of STC-1 and/or STC-2 morpholino 
knockdown on zebrafish embryonic vascular development using the fli-GFP fish line, in 
which jellyfish green fluorescent protein (GFP) expression is under the control of the 
endothelial cell-specific fli promoter. It is also possible that STC-1 may have a more 
specific role in mammalian angiogenesis in disease-related situations such as cancer. 
For example, high expression of STC-1 in the tumour vasculature and under hypoxic 
conditions has been suggested to have protective and regulatory roles in cell survival 
(Lal et al., 2001; H. Y. Yeung et al., 2005). 
 
Overall however, my data suggest that although VEGF regulates endothelial STC-1 
expression, STC-1 regulates endothelial function largely through non-VEGF mediated 
pathways, or else regulates other VEGF functions not examined in this chapter. 
However, the data presented here indicates that STC-1 is not a pro-angiogenic signal 
but may instead act to maintain newly formed vessels or in the functions of mature 
vascular endothelium, or endothelial functions under conditions of stress. More work is 
required to test these hypotheses and investigate in more detail the mechanisms by 
which STC-1 exerts its effects on endothelial cell biology. 
 
A major novel finding of this thesis is that STC-1 mRNA and protein expression is also 
induced by PDGF-BB in human arterial SMC, an effect mediated at least partly via 
PDGFR. STC-1 protein is also expressed constitutively in SMC at a significant level. I 
also showed that STC-1 secreted by SMC is post-translationally modified by N-linked 
glyosylation. These findings add significantly to existing knowledge about the 
regulation of STC-1 expression, and have potential novel implications for the regulation 
of SMC function. However, a weakness of this part of the thesis is that I was unable to 
show strong inhibition of the effect of PDGF-BB on STC-1 protein expression by 
knockdown or pharmacological inhibition of PDGFRs, possible reasons for which were 
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discussed in Chapter 4. An alternative approach to examining the role of PDGFRs in 
STC-1 regulation would be to use mouse SMC from mice deficient in  either  PDGFRα  
or  PDGFRβ, such as those generated by (French, Creemers, & Tallquist, 2008). 
 
One possibility that I explored is that STC-1 could regulate functions mediated by 
PDGF-BB in SMC. PDGF-BB is a potent chemoattractant for SMC, and PDGF-BB 
expression is increased in endothelial tip cells. This chemotactic activity is thought to 
play an important role in biological functions of PDGF-BB such as recruitment of 
pericytes to newly sprouting capillaries, or of SMC in arteriogenesis, and in 
pathological processes such as atherosclerosis and restenosis after angioplasty which are 
charcaterised by abnormal accumulation of SMC in the neointima of affected arteries. 
The finding that STC-1 could significantly inhibit PDGF-BB-induced SMC migration is 
therefore potentially of interest as a regulatory mechanism in biological functions of 
PDGF-BB. It is unlikely that STC-1 plays a critical role in SMC recruitment to new 
blood vessels in development, given that STC-1 deficient mice have no noticeable 
phenotype. However, it was found that mice overexpressing STC-1 exhibit a 30-50% 
reduction in post-natal growth as well as reduced litter sizes that appear to be 
independent of any effect on pituitary function or production of Growth Hormone or 
IGF-I (Varghese et al., 2002). The cause of this effect of STC-1 over-expression in mice 
is unknown, but it is interesting to speculate whether it could be due to a negative 
regulatory effect of high levels of STC-1 on angiogenesis consistent with my 
observation. This idea is also supported by a previous study showing that STC-1 
negatively regulates HGF-induced endothelial cell migration (Zlot et al., 2003). 
However, another recent study examined metastatic growth of colorectal carcinoma cell 
lines co-injected with either wild-type of STC-1-deficient fibroblasts derived from STC-
1-/- mice. This paper showed that tumours grown together with STC-1-deficient 
fibroblasts exhibited fewer metastases compared with tumours grown with wild-type 
fibroblasts (Pena et al., 2013). Furthermore, these fibroblasts are responsive to PDGF-
BB, and PDGF-BB induced STC-1 mRNA expression in them. These findings are more 
suggestive of a role of fibroblast-derived STC-1 in promoting tumour cell migration 
involved in metastatic spread, than a negative regulatory role. The role of STC-1 in 
regulating chemotactic effects of PDGF-BB in cells of mesenchymal origin (eg SMC, 
pericytes, fibroblasts) is a question that would need to be examined in further work 
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using animal models of angiogenesis and SMC migration, or of stromal cell interactions 
with tumour cells, and investigating the effects of STC-1 overexpression locally (using 
adenoviral over-expression) or in transgenically over-expressing mice. The functional 
role of STC-1 glycosylation is also unknown, but may be important for its secretion. 
This could be examined by identifying the main sites of N-linked glycosylation, and 
analysing their importance by over-expressing mutated forms of STC-1. 
 
A key unanswered question is whether STC-1 acts via a cell-surface or other cellular 
receptor. There is strong evidence through analysis of ligand-receptor binding assays 
revealing the presence of STC-1 receptors on mitochondria and plasma membranes with 
ligand sequestration appearing to occur in a mitochondrial compartment in fish as well 
as in mammals (McCudden et al., 2002; Richards et al., 2012). It has not been 
explained, however, how extracellular STC-1 is able to enter the cell in order to bind 
mitochondrial receptors. Presumably some mechanism would need to exist to allow for 
STC-1 to enter the cell and cross the plasma membrane, but at present this is unclear. 
Furthermore, despite the accumulating evidence of a possible STC-1 receptor, which 
could serve as the transducer by which STC-1 could influence intracellular signalling 
and thus exert physiological responses, the STC-1 receptor has not yet been purified or 
molecularly characterized. Furthermore, the downstream signalling pathways regulated 
by STC-1 are essentially unclear. It remains attractive to suggest that STC-1 effects are 
mediated by specific cellular receptors. Technologies have been developed which could 
be useful in identifying STC-1 receptors, such as the ligand-based, receptor-capture 
(LRC) technology employing a trio-functionality reagent TRICEPTS for the subsequent 
capture of glycoprotein receptors on living cells and tissues (Frei et al., 2012). A 
simpler approach to identification of STC-1 receptors might be covalent cross-linking of 
radiolabelled STC-1 to binding components available at the cell surface. Such an 
approach was successful in initially identifying a novel cell surface binding component 
for VEGF, later found to be Neuropilin-1 using a combination of Con A Sepharose and 
VEGF-Sepharose affinity chromatography (Soker et al., 1998). It was not within the 
scope of this thesis to molecularly define the STC-1 receptor in endothelial cells or 
SMC, but this should be a major goal of future STC-1 research. It is of course possible 
that STC-1 acts in an entirely different way and lacks a specific high-affinity cell 
surface receptor. For example STC-1 might function in mammals as a circulating 
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protein, which might bind to plasma proteins, and is involved in protein transport in the 
circulation, or possibly lacks a defined function.  
 
Another unanswered question is how STC-1 is able to alter specific intracellular 
signalling pathways. There is very little known about regulation of intracellular 
signalling by STC-1. Since PDGF-BB induced STC-1 expression in SMC, I asked 
whether this could regulate PDGF-BB-dependent signalling in SMC. My results showed 
that though STC-1 was not able to promote signalling through several major signalling 
cascades, it did significantly enhance PDGF-BB-induced Akt activation as determined 
by Akt phosphorylation at serine 473, and also enhanced PDGF-BB-induced 
phosphorylation of the Akt substrate, GSK3. My data also suggested that STC-1 might 
inhibit PDGF-BB-induced p38 kinase activity, though these data are ore preliminary. As 
discussed in chapter 5, how STC-1 might enhance PDGF-BB signalling through the Akt 
pathway is unclear, though I speculate that this is most likely due to some receptor-
mediated effect of STC-1 which is able to synergise with PDGF-BB signalling upstream 
of Akt as depicted in Figure 6.1. The fact that STC-1 did not cause a general 
enhancement of PDGF-BB signalling, argues against this being a non-specific effect of 
STC-1, though this cannot be ruled out. 
 
Positive regulation of Akt signalling by STC-1 suggests that STC-1 should also enhance 
cellular functions regulated by Akt, such as cell survival. In support of this possibility I 
was able show evidence for a synergistic survival effect of STC-1 and PDGF-BB in the 
increased SMC cell death induced by hydrogen peroxide, though this effect was not 
statistically significant. However, Akt is also implicated in cell migration, and STC-1 
did not enhance PDGF-BB-induced cell migration. Further work should examine more 
fully the effect of STC-1 on the apoptosis/survival of SMC using a variety of assays and 
in response to a variety of apoptotic stimuli. In support of a role of STC-1 in promoting 
cell survival, and as mentioned above, high expression of STC-1 in some tumours, eg 
ovarian cancer, and under hypoxic conditions has been suggested to have protective and 
regulatory roles in cell survival (Lal et al., 2001; H. Y. Yeung et al., 2005). 
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Figure 6.1: Proposed model for STC-1 function in smooth muscle cells 
Schematic diagram of STC-1 signalling pathway highlights some aspects of extracellular 
secreted STC-1 role in SMCs. We hypothesis that STC-1 might bind to a specific cell surface 
receptors initiating intracellular signaling cascades that might lead to various cellular responses, 
and the unknown effects are indicated with a question mark. Embedded in this model are the 
STC-1 functional effects observed in the present study. 
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In addition, the effects of STC-1 on metabolic rate and uncoupling of oxidative stress 
suggest STC-1 involvement in delaying the onset of hypoxia-induced apoptosis in 
human neuronal cells (Zhang et al., 2000). Enhanced cellular phosphate uptake by 
neuronal cells (caused by STC-1), might diminish the hypoxia-induced rise in 
intracellular calcium, thereby delaying apoptosis. In light of these data, it is possible 
that cyto-protective effects of STC-1 on respiration and mitochondrial calcium 
accumulation could be part of a novel anti-apoptotic pathway, operative in 
metabolically active, mitochondria-rich cells (Ellard et al., 2007; Zhang et al., 2000). 
Recent data shows that overexpression of STC-1 is associated with increased expression 
of the anti-apoptotic proteins Bcl-2 and Bcl-xl, which leads to the inhibition of cleavage 
of procaspase-3, -8 and -9 (G. Liu et al., 2010). Another future challenge will be the 
identification of how the STC-1 and PDGF-mediated PI3K pathways converge to 
mediate Akt phosphorylation in SMC, and to address whether this effect can also be 
identified in other PDGF-responsive cell types.  
 
The observed accumulation of secreted STC-1 expressed from both vascular endothelial 
cells and SMCs might indicate that STC-1 could be a critical modulator for cell-cell 
regulatory interactions and/or exchange of signals between these cell types. However 
the cellular consequences of such modulation as well as the primary stimulatory cells 
responsible for excessive secretion of STC-1 could vary depending on numerous 
physiological parameters regulated by proteins under the control of different primary 
and/or secondary messengers molecules. In terms of the role of STC-1 in endothelium-
SMCs interaction, co-culture ex vivo angiogenesis-related assays such as polymer 
matrices assay, Matrigel or aortic ring assays may be useful. 
 
There is strong evidence from studies in fish and in some mammalian cells that STC-1 
has a role in regulating Ca2+ fluxes and homeostasis. Furthermore, numerous studies 
have indicated that the intracellular Ca2+-associated signaling in vascular cells, 
particularly in SMCs, is primarily controlled by the influx of extracellular Ca2+ and 
IP3-dependent Ca2+ release from intracellular stores such as endoplasmic/sarcoplasmic 
reticulum (ER/SR) through Ca2+-induced Ca2+ release (CICR). Moreover, this 
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extracellular Ca2+ ions mobility is so tightly regulated that innumerable cellular 
processes such as motility, adhesion, metabolism, proliferation and apoptosis are 
initiated as results of it. Consequently, vascular calcium modulation of vasodilator 
responses play a critical role in the peripheral vascular resistance and establishment of 
vascular tone, thereby serve to maintain the homeostasis of blood circulation. However 
it is unclear how STC-1 secreted in subintimal region between endothelium and SMCs 
could possibly modulate or inhibit Ca2+ sparks and consequently induce membrane 
depolarization that might be importantly involved in the control of vascular tone and 
vasomotor responses.  
In comparison to STC-1, its homologue STC-2 has a direct role in Ca2+ cellular 
regulation acting as a negative regulator of Ca2+ influx through plasma membrane-
localized store-operated Ca2+ channels, (SOCs) (Zeiger et al., 2011). This study 
identified a potential role for STC-2 in the cellular stress responses by limiting the ER 
Ca2+ sensor STIM1-mediated activation of Ca2+ influx, thus increasing stress- induced 
cellular viability. Although in this study, I was unable to determine whether STC-1 
plays a role in cell survival, and I did not examine STC-1 regulation of Ca2+ signalling 
in SMC due to lack of access to facilities for these studies, and to lack of time, it would 
important to examine if STC-1 acts as a regulator of intracellular SMC Ca2+ 
homeostasis, using the fluorescent imaging of STC-1−/− mouse embryonic fibroblasts 
loaded with the ratiometric dye Fura-2 as in Zieger et al (2011).  
 
Given that STC-1 is implicated in regulating mitochondrial functions, it is possible that 
STC-1 complexation with its putative membrane-spanning receptor might target 
mitochondrial functions, possibly involving enhanced oxygen consumption rate and 
uncoupling of oxidative phosphorylation (Ellard et al., 2007). However, the exact 
mechanism involved needs to be elucidated. Whether STC-1/receptor complex is able to 
associate with intracellular mitochondrial proteins or recruit other intracellular binding 
partners remains unclear.  
 
Another clue to a possible function of STC-1 has come from sequence analysis studies, 
which identified a consensus protein kinase ATP-binding domain in human STC-1 near 
the N-terminus of the protein, and studies showing that ATP is able to bind to STC-1 
thereby antagonising STC-1 binding to its mitochondrial receptors (Ellard et al., 2007). 
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It is also believed that secreted STC-1 contains one or more unidentified serine residues 
that may be substrates for extracellular phosphorylation by ecto-PKC during or soon 
after secretion from the cell (Jellinek et al., 2000). While the addition of phosphates to 
STC-1 may cause conformational changes, it may subsequently help regulate protein 
processing, structure and its biological activity. Apart from these findings, STC-1 so far 
lacks a clear domain structure that might provide insights into its function. 
 
 
In conclusion, this investigation is the first description of regulation of STC-1 
expression in SMC, its induction by PDGF-BB, and of a role for STC-1 in regulating 
PDGF-BB-dependent Akt signalling and SMC migration. However, investigation of 
STC-1 presents a number of significant challenges, particularly the lack of 
unambiguous identification of its receptor, and mechanism of action or biological 
function in mammals. Understanding and determining the underlying mechanisms of 
STC-1-mediated effects on SMCs and in the vasculature more generally will require 
much further work. 
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